 
 
 
 
 
 
Cover Page  
NF PROTOCOL 105 
A Phase II Study of Cabozantinib (XL184) for Plexiform Neurofibromas in 
Subjec ts with Neurofibromatosis Type 1  in Children and Adults  
NCT: 02101736  
 
Document Date d: May 1, 2019   
 
 
 
 
 
 
 
 
 
This page submitted: 2/3/2023  
NF Protocol #105   Version 2.1 
05/01/2019 
 
 
 
 
 
 
Neurofibromatosis (NF) Consortium  
 
NF PROTOCOL 105 
A Phase II Study of Cabozantinib (XL184) for Plexiform Neurofibromas 
in Subjec ts with Neurofibromatosis Type 1  in Children and Adults 
 
 
 
Sponsored by: 
 
Department of Defense  
USAMRMC 
And the  
Office of the Congressionally Directed Medical Research Programs  (CDMRP)  
 
 
IND # 118308  
 
Protocol Chairs  
Michael Fisher , MD, Chair 
Jaishri Blakeley, MD, Co-Chair 
Amy Armstrong, MD, Co -Chair 
 
Medical Monitor 
Alyssa Reddy , MD

NF Protocol #105   Version 2.1 
05/01/2019 
2 
 Protocol Roster  
 
Study Chair  
Michael Fisher, MD  
Children’s Hospital of Philadelphia  
3501 Civic Center Boulevard 
Philadelphia, PA 19096 Phone:  215-590-2800 
fisherm@email.chop.edu
 
 
Study Co -Chairs  
Jaishri Blakely, MD 
Johns Hopkins University 1550 Orleans Street Suite 1M16  
Baltimore, Maryland 21231 Phone:  410-955-8837 
Fax:  410-614-9335 
Jblakel3@jhmi.edu
 
 
Amy Armstrong , MD  
Riley Hospital for Children  
705 Riley Hospital Dr.  
RI 4340 Indianapolis, IN  46202 Phone:  317-948-8568 
Fax:  317- 944-3107 
 amyearms@iu .edu
 
 
Study Committee  
Kent Robertson, MD, PhD  
705 Riley Hospital Dr.  
RI 4340 
Indianapolis, IN  46220 
Phone:  417-944-8784 
krobert@iu.edu  
 Brigitte Widemann, MD 
National Institutes of Health – NCI  
10 Center Drive  
Building 10 -CRC: Room 1 -5750 MSC 
Bethesda, MD  20892 Phone: 240-760-6203 
Widemanb@mail.nih.gov
 
 
Bruce Korf, MD, PhD  
University of Alabama at Birmingham  
1720 2nd Avenue South - 230 KAUL  
Birmingham, Alabama  35294-0024 
Phone:  205-934-9411 
Fax: 205- 934-9488 
bkorf@uab mc.edu  Medical Monitor  
Alyssa Reddy, MD 
University of California, San Francisco 
550 16th Street 
UC Box 0137 San Francisco, CA 94758 
Phone: 415-353-2657 
Alyssa.Reddy@ucsf.edu 
 
Study Statistician  
Gary Cutter, PhD 
Department of Biostatistics  
University  of Alabama at Birm ingham  
1667 Univ ersity  Blvd - Ryals 410 
Birmingham AL  35243 Phone:  205-975-5048 
Fax:  295-975-2531 
cutterg@uab.edu
 
 
Study Statistician/NFCTC Co -PI (Data)  
Lloyd Edwards, PhD  
Department of Biostatistics  
U. of Alabama  at Birmingham  
1665 Univ Blvd - Ryals 327D 
Birmingham AL  35243 
205-975- 0687 Phone  
ljedward@uab.edu  
 
Clinical Nurse Manager  
Lynn Merritt, RN  
U. of Alabama at Birmingham 
1530 3rd Avenue South – Kaul 230 Birmingham, AL  35294-0024 
Phone 205-934-5376 
jlynnrn@uab.edu  
 
Program Director 
Karen A. Cole -Plourde, BS  
University of Alabama at Birmingham  
1720 2nd Avenue South – 230 KAUL  
Birmingham, AL 35294-0025 
Phone:  205-934-5150 
Fax : 205-975-3543 
kcole@uab.edu  
 
 
 
 
 
NF Protocol #105   Version 2.1 
05/01/2019 
3 
  
Central  Biomarkers  
Cytokine anal ysis 
Khadijeh Bijangi -Vishehsaraei, MS, PhD  
Children’s Clinical Research     
Center/Translational Research and    
Integrated Biology, Indiana University 
705 Riley Hospital Drive, Room 2641 
Indianapolis, Indiana 46202  
Phone: 317-278-3050 khbijang@iupui.edu  
   
Endothelial Progenitor Cells  
Karen Pollok, PhD  
Angio BioCore , Indiana University  
Contact: Emily Sims, Core Manager                                
980 W. Walnut St., R3 -343 
Indianapolis, IN 46202 
Phone:  317-278-7232 
ecwillar@iupui.edu  
 
Central Imaging  
Eva Dombi, MD  
National Cancer Institute  
10 Center Drive  
Bldg 10 -CRC,  Rm 1 -5750 
Bethesda, MD 20892 
Phone:  240-858-3852 
Fax:  301-402-1734 
dombie@mail.nih.gov  
 
Central Quality o f Life 
Pam Wolters, PhD 
Pediatric Oncology Branch  
Bethesda, MD  20892-8200 Phone:  301-496-0562 
Fax:  301-402-1734 
woltersp@mail.nih.gov
 
 
 
 
 
  
Research Compliance Manager 
Juliette Southworth, BS, CCRP  
The University of Alabama at Birmingham – 
Kaul 230 
Birmingham, AL 35294-0024 205-975- 4075 Phone  
jsouthworth@uab.edu  
 
Department of Defense  
Kimberly Boelte Pope, PhD  
Science Officer (General Dynamics IT) 
Congressionally Directed Medical Research 
Programs  
1053 Patchel Street  
Frederick, MD 21702 
Phone:  301-619-4006 
Fax:  301- 619-7796 
kimberly.b.pope2.ctr@mail.mil   
 
  
NF Protocol #105   Version 2.1 
05/01/2019 
4 
 Participating Sites  
 
Bruce Korf, MD, PhD  
University of Alabama at Birmingham  
1720 2nd Ave So uth -  KAUL 230 
Birmingham, Alabama  35294-0024 
Phone:  205-934-9411/Fax: 205-934-9488 bkorf@uabmc.edu
 
 James Tonsgard, MD  
University of Chicago 5841 South Maryland Avenue, MC 3055 Chicago, IL  60637 Phone:  773-702-6488 tonsgard@midway.uchicago.edu
 
Michael Fisher, MD  
Children’s Hospital of Philadelphia 3501 Civic Center Boulevard Philadelphia, PA 19096 Phone:  215-590-2800 fisherm@email.chop.edu
 
 David Viskochil, MD, PhD  
University of Utah  
50 North Medical Drive – 2C412 SOM Salt Lake City, UT  84132 Phone:  801-581-8943 dave.viskochil@hsc.utah.edu
 
Roger Packer, MD  
Children’s National Medical Center  
111 Michigan Avenue, NW  
Washington, DC  20010 Phone:  202-884-2120 rpacker@cnmc.org
 
 David Gutmann, MD, PhD  
Washington University School of Medicine 660 South Euclid Avenue – Box 811 St. Louis, MO  63110 Phone: 314-362-7379  gutmannd@neuro.wustl.edu
 
Wade Clapp, MD  
Indiana University  1044 West Walnut Street  Cancer Center, Room 402A  Indianapolis, IN  46202 Phone: 317-278-9290 dclapp@iu.edu
 Jeffrey Allen, MD  
New York Univ. Pediatrics 160 E. 32
nd Street – 2nd Floor 
Hassenfeld Children’s Center  
New York, NY 10016 Phone: 212-263-9907 Jeffrey.Allen@nyumc.org
  
 
Tena Rosser, MD 
Children’s Hospital Los Angeles  
300 Medical Plaza Box 696824 
Los Angeles, CA  90095 
Phone: 323-361-2471 trosser@chla.usc.edu
 Nicole Ullrich,  MD, PhD  
Children’s Hospital Boston – Dept. of Neurology 
300 Longwood Avenue – Fegan 11 
Boston, MA  02115 
Phone: 617-355-2066 Nicole.Ullrich@childrens.harvard.edu
 
 
Elizabeth Schorry, MD  
Cincinna ti Children’s Hospital Medical 
Center  
3333 Burnet Avenue - ML 4006 Cincinnati, OH  45229 Phone:  513-636-4760 
elizabeth.schorry@cchmc.org  Brigitte Widemann, MD  
National Institutes of Health – NCI  
10 Center Drive; Building 10- CRC: Room 1 -
5750 MSC Bethesda, MD  20 892 
Phone: 301-496-7387 
widemanb@mail.nih.gov   
NF Protocol #105   Version 2.1 
05/01/2019 
5 
 Laura Klesse, MD, PhD  
Childrens Medical Center of Dallas  
University of Texas Southwestern Medical 
Center  
5323 Harry Hines Blvd. 
Dallas, Texas 75390-9063 Phone:  214-456-3727 Fax:  214-648-3122     
  
 
Affiliate sites   
Massachusetts General Hospital (Ullrich; Plotkin)  
Dana Farber Cancer Institute (Ullrich; Kieran)  
UCLA (Rosser; Silva)  
Johns Hopkins (Packer; Blakeley)  
Ohio State University (Schorry) Lurie Children's Hospital of Chicago (Tonsgard; Listernick and Goldman)   
NF Protocol #105   Version 2.1 
05/01/2019 
6 
 Roles and Responsibility of Study Personnel:  
 
Michael Fisher , MD :  Study PI, Protocol Chair.  Steering Committee Chair of NF Consortium 
Jaishri Blakeley, MD:  Protocol Co- Chair  
Amy Armstrong , MD :  Protocol Co- Chair  
 Kent Robertson, MD :  Study Committee  
Brigitte Widemann, MD:  Study Committee   
Bruce Korf, MD , PhD:  NF Consortium PI, Study Committee , IND Holder  
Gary Cutter PhD : Study S tatistician .  Biostatistician & Deputy Director of NF Operations Center  
Lloyd Edwards, PhD: Biostatistician & Co -PI NF Operations Center  
Alyssa Reddy , MD  Medical Monitor 
Eva Dombi, MD : Volumetric MRI analysis of plexiform neurofibromas on protocol 
Pam Wolters, PhD: Quality of life and pain surveys 
Khadijeh Bijangi- Vishehsaraei, MS, PhD : Cytokine B iomarkers   
Karen Pollok, PhD : Endothelial Progenitor Cell Biomarkers  
Lynn Merritt , RN, : Clinical Coordinator – NF Operations Center  
Karen Cole-Plourde: Program Director  – NF Operations Center  
Juliette Southworth, BS, CCRP : Research Compliance Manager  – NF Operations Center  
NF Protocol #105   Version 2.1 
05/01/2019 
7 
 TABLE OF CONTENTS  
 PAGE  
ABSTRACT/SCHEMA ............................................................................................................................................... 9 
EXPERIMENTAL DESIGN SCHEMA  .................................................................................................................. 12 
1.0 GOALS AND OBJECTIVES  (SCIENTIFIC AIMS)  ................................................................................ 14 
2.0 BACKGROUND AND RATIO NALE  ........................................................................................................ 14 
2.1  CABOZANTINIB TABLETS  ........................................................................................................................... 22 
2.2  CABOZANTINIB NONCLINICAL TOXICOLOGY  .......................................................................................... 23 
2.3  CLINICAL EXPERIENCE  ............................................................................................................................. 24 
3.0 SCREENING AND STUDY ENROLLMENT PROCEDURES  .............................................................. 31 
3.1 INFORMED CONSENT /ASSENT  ................................................................................................................... 31 
3.2 SCREENING PROCEDURES  ......................................................................................................................... 32 
3.3 STUDY ENROLLMENT  ................................................................................................................................ 32 
4.0 SUBJECT ELIGIBILITY  ............................................................................................................................ 32 
4.1 INCLUSION CRITERIA FOR ALL SUBJ ECTS : ............................................................................................... 32 
4.2  EXCLUSION CRITERIA  ............................................................................................................................... 35 
5.0 REQUIRED DATA  ...................................................................................................................................... 38 
5.1 TESTS AND OBSERVATIONS  ....................................................................................................................... 40 
5.2 RECORDS TO BE KEPT ................................................................................................................................ 40 
5.3 ROLE OF DATA MANAGEMENT  ................................................................................................................. 40 
6.0 TREATMENT PROGRAM  ........................................................................................................................ 41 
6.1 TREATMENT OVERVIEW  ........................................................................................................................... 41 
6.2   RATIONALE FOR CABOZANTINIB DOSE SELECTION  ................................................................................. 41 
6.3 ADMINISTRATION , DOSE, SCHEDULE AND ROUTE  ................................................................................... 42 
6.4  CRITERIA FOR STARTING  SUBSEQUENT CYCLES  ...................................................................................... 44 
6.5  DOSE ESCALATION SCHEMA  ..................................................................................................................... 44 
6.6  AGENT INFORMATION  ............................................................................................................................... 45 
7.0  MODIFICATIONS FOR ADVERSE EVENTS  .............................................................................................. 46 
7.1 GENERAL GUIDELINES FOR TREATMENT DELAY , DOSE REDUCTION , OR STUDY DRUG ....................... 46 
DISCONTINUATION FOR TOXICITY  ........................................................................................................................ 46 
7.2   DEFINITION OF DOSE-LIMITING TOXICITY (DLT)  .................................................................................. 46 
7.3   DOSE MODIFICATIONS FOR ADVERSE EVENTS  ........................................................................................ 47 
8.0   SUPPORTIVE CARE AND OTHER CONCOMITANT TH ERAPY  ..................................................... 52 
9.0 EVALUATIONS/MATERIAL  AND  DATA  TO BE ACCESSIONED  .................................................... 54 
9.1 REQUIRED CLINICAL , LABORATORY AND DISEASE EVALUATION  .......................................................... 54 
9.2 HISTORY AND PHYSICAL EXAMINATION AND VITAL SIGNS  ...................................................................... 54 
9.3 PHONE CALL.............................................................................................................................................. 54 
9.4 LABORATORY TESTING  ............................................................................................................................. 54 
9.5 EKG  ........................................................................................................................................................... 55 
9.6 MRI  FOR VOLUMETRIC ANALYSIS OF PLEXIFORM NE UROFIBROMA  ....................................................... 55 
9.7 QUALITY OF LIFE AND PAIN EVALUATIONS (REQUIRED ) ........................................................................ 55 
9.8 BIOMARKER STUDIES  ................................................................................................................................ 58 
9.9 BIOLOGICAL SPECIMENS FOR BANKING  (APPENDIX XV) ........................................................................ 58 
10.0 ADVERSE REPORTING REQUIREMENTS  .......................................................................................... 59 
10.1 DEFINITIONS  .............................................................................................................................................. 59 
NF Protocol #105   Version 2.1 
05/01/2019 
8 
 10.2 GRADING OF ADVERSE EVENTS USING COMMON TERMINOLOGY CRITERIA (CTCAE)  ....................... 60 
10.3 ATTRIBUTION : DEFINITIONS OF RELATI ONSHIP TO STUDY MEDICATION ARE AS FOLLOW S: ................. 60 
10.4 REPORTING PROCEDURES FOR ALL ADVERSE EVENTS  ........................................................................... 61 
10.5 EXPEDITED REPORTING GUIDELINES  ...................................................................................................... 61 
10.6 REPORTING OF PROTOCOL VIOLATIONS /DEVIATIONS AND UNANTICIPATED PROBLEMS  ..................... 62 
11.0 CRITERIA FOR REMOVAL  FROM PROTOCOL THERA PY AND OFF STUDY CRI TERIA  ...... 63 
11.1 CRITERIA FOR REMOVAL FROM PROTOCOL THERAPY  ........................................................................... 63 
11.2   OFF STUDY CRITERIA  ............................................................................................................................... 63 
12.0 STATISTICAL AND  ETHICAL CONSIDERATIONS  ........................................................................... 64 
12.1 SUBJECT ACCRUAL .................................................................................................................................... 64 
12.2 STATISTICS AND FEASIBILITY  ................................................................................................................... 64 
12.3 STATISTICAL ANALYSIS PLAN .................................................................................................................. 66 
12.4 DEFINITIONS OF EVALUABLE  .................................................................................................................... 68 
13.0 RESPONSE CRITERIA  .............................................................................................................................. 68 
14.0 HUMAN SUBJECTS PROTECTION & DATA SAFETY MONITORING PLAN  .............................. 76 
15.0 PUBLICATION OF DATA AND PROTECTION OF TRADE SECRETS  ........................................... 78 
16.0 REFERENCES  ............................................................................................................................................. 79 
APPENDIX I:  SCHEDUL E OF EVALUATIONS  ................................................................................................ 80 
APPENDIX II: PERFORMANCE STATUS SCALES/S CORES  ......................................................................... 82 
APPENDIX III: PARTICIPANT DOSE DIARY  ................................................................................................... 83 
APPENDIX IV:  PROTOCOL FOR REQUIRED PRE -STUDY AND ON- STUDY M RI STUDIES  ............... 84 
APPENDIX V:  BIOMARK ER STUDIES  .............................................................................................................. 87 
APPENDIX VI:  PHARMA COKINETIC STUDIES  ............................................................................................. 89 
APPENDIX VII:  CONSORTIUM QOL AND PAIN M EASURES  ..................................................................... 97 
APPENDIX VIII: BLOOD PRESSURE NORMS  ................................................................................................ 139 
APPENDIX IX: MRI ELI GIBILITY FORM  ....................................................................................................... 142 
APPENDIX X: SUGGESTED PROPHYLAXIS AND TREATMENT FOR PALMAR -PLANTAR 
ERYTHODYSESTHESIA SY NDROME (PPE)  ................................................................................................... 143 
APPENDIX XI: CABOZAN TINIB DOSING NOMOGRA M ............................................................................. 144 
APPENDIX XII: PLEXIF ORM NEUROFIBROMA SYM PTOM CHECKLIST  ............................................ 146 
APPENDIX XIII: PN LOCATION AND ASSOCIATE D MORBIDITIES  ....................................................... 149 
APPENDIX XIV:  PLEXIFORM NEUROFIBRO MA CLINICIAN MORBIDI TY ASSESSMENT  ............. 151 
APPENDIX XV:  BIOLOGICAL SPECIMEN FOR BANKING  – COLLECTION AND SHIPPING .......... 153 
  
NF Protocol #105   Version 2.1 
05/01/2019 
9 
 ABSTRACT/SCHEMA  
 
Background 
 
Neurofibromatosis type 1 (NF1) is one of the most common inherited disorders in the general 
population, affecting approximately 1 in 3500 people with an estimated 100,000 individuals 
afflicted in the United States alone.  NF1 is an autosomal dominant disorder caused by mutations in the NF1 tumor suppressor gene resulting in a deficiency in a protein called neurofibromin.  
Deficiency in neurofibromin allows activation of the Ras oncoprotein with resultant cutaneous and 
plexiform neurofibromas (a complex of Schwann cells, fibroblasts, endothelial cells, and mast 
cells), which may be disfiguring, painful and life threatening.  These tumors are refractory to most therapeutic approaches including chemotherapy, radiation, and surgery.  These tumors can result in significant morbidity if located near vital structures, including nerves, blood vessels, and the 
airway.  Thus, in this group of patients, the development of novel treatment interventions is needed.  
Receptor tyrosine kinase inhibitors are an emerging class of drugs in the treatment of malignancies.  
C-kit, in particular, is a tyrosine kinase that has been shown to be essential in the development of 
plexiform neurofibromas.  Preclinical investigation has elucidated the role of c- kit in the activation 
of mast cells, one of the components of plexiform neurofibromas and a limited number of clinical 
trials targeting c -kit are underway.  Targeting of multiple RTKs may increase efficacy either by 
synergy or b locking tumor escape pathways.  Subsequent screening of clinically relevant c-kit and 
multiple RTK inhibitors in an in vivo  model of NF1  plexiform neurofibroma has identified 
cabozantinib (XL184) as an excellent candidate for clinical testing.  Cabozantini b is a small-
molecule RTK inhibitor that blocks phosphorylation of c- Met, RET, c -kit and VEGFR2 at 
nanomolar or subnanomo lar concentrations.  C- MET and VEGFR2 are  strong regulators of tumor 
angiogenesis.  Plexiform neurofibromas are highly vascular tumors and it is postulated that this may be a key mechanism in tumor development and growth.  In small animal NF1 models, 
cabozantinib shows strong biological activity and results in decreased tumor size, number and biologic activity .  Preliminary data shows tha t this molecule may be even more effective than 
agents currently undergoing clinical evaluation.  In preclinical trials, cabozantinib reduced mast cell concentration by greater than 50%.  Transgenic mice with plexiform neurofibromas treated 
with cabozantinib had a 70% reduction in tumor numbers as compared to vehicle controls and 50% 
reduction in tumor size for residual tumors.  Using FDG- PET, tumors in treated mice had 
significant reduction in metabolic activity.  Based on these striking results,  we propose 
cabozantinib for human clinical trials  for plexiform neurofibromas. 
  
NF Protocol #105   Version 2.1 
05/01/2019 
10 
  
Primary Objectives  
 
1. Primary Aim:   To estimate the objective response rate (ORR) as defined by 20% volumetric 
MRI response of the target lesion  to cabozantinib at 12  months in children  and adults with 
NF1 plexiform neurofibromas by volumetric MRI imaging.  
2. Secondary Aims : 
1. To assess the tolerability and toxicity of cabozantinib in subject s with NF1.  
3. Exploratory Aims: 
1. To estimate the ORR  of up to 2 non-target plexiform neurofibromas to cabozantinib by 
MRI.  
2. To assess quality of life and pain in subject s with NF1 and plexiform neurofibromas on 
cabozantinib  
3. To assess the  PedsQL NF1 QOL Module, a disease specific QOL scale,  and the pain 
scales  for use in this patient population 
4. To assess activity of cabozantinib on mast cell activity by FACS  
5. To describe changes by flow cytometry in peripheral blood monocyte counts, 
circulating endothelial cells, and plasma angiogenic factors  during treatment with 
cabozantinib (see laboratory correlates section  13.0 C) 
6. To describe the baseline and change in circulating cytokine factors related to proliferating cells (see laboratory correlates section  13.0 C) 
7. To characterize the pharmacokinetic profile of cabozantinib in this population  
8. To determine whether patients who respond (≥20% objective radiographic response of target lesion by 12 cycles ) to cabozantinib will maintain that response for 1 year off 
therapy  
9. To compare the volumetric assessment of plexiform neurofibroma response to therapy performed by two independent analysts using different volumetric analysis methods.    
 
Eligibility  
1.  Subject ≥ 3 years of age who meet clinical diagnostic criteria of neurofibromatosis type 
1 (NF1) o r have known pathogenetic NF1  mutation AND  
2. Subject s must have plexiform neurofibroma(s) with a target lesion that has  evidence of 
progression by serial imaging OR  known significant morbidity, such as (but not limited 
to) head and neck lesions that could c ompromise the airway or great vessels, brachial or 
lumbar plexus lesions that could cause nerve compression and loss of function, lesions that could result in major deformity (e.g., orbital lesions) or are significantly disfiguring , lesions of the extremity that cause limb hypertrophy or loss of function, and 
painful lesions.  Subject s with paraspinal plexiform neurofibromas will be eligible for 
this trial. Histologic confirmation of tumor is not necessary in the presence of consist ent 
clinical and radiographic findings, but should be considered if malignant degeneration of a plexiform neurofibroma is clinically suspected . 
    
NF Protocol #105   Version 2.1 
05/01/2019 
11 
 Design  
• Cabozantinib will be administered orally daily on a continuous dosing schedule (28 days = 1 
treatment  cycle ).  
• Disease status will be evaluated using volumetric MRI analysis at regular intervals .  
• Pain reduction and quality of life outcomes will also be assessed . 
• Toxicity of chronic cabozantinib administration will be evaluated using physical and laboratory evaluations and adverse event reporting by patients. 
NF Protocol #105   Version 2.1 
05/01/2019 
12 
 EXPERIMENTAL DESIGN SCHEMA  
  
 
 
 
      
Un  
               
 
 
Cycle 3-12 (60 
mg) Cycle  1-2 (40 mg 
starting dose) De-
escalation 
of dose 
Dose 
escalation  
Response 
evaluation at 
4,8,12, (18, 24) 
months  Study Entry  
See dosing schema for rules 
for de -escalation of dose 
secondary to toxicity  
Tumor response will be done by MRI volumetrics at 4, 8, and 12 months 
(prior to cycle 5, 9 and end of study). Subjects may remain on drug for up to 12 additional cycles  and will have MRI done subsequently at 6 
months intervals.  Subjects who do not achieve at least 15% reduction in volume of the target tumor at the 8 month interval will be considered 
treatment failure and taken off study.  Unacceptable Toxicity  
Off Study  Unacceptable toxicity despite 
dose de- escalation or 
progressive disease  Study Enrollment: Cohort A (age ≥16 years)  
NF Protocol #105   Version 2.1 
05/01/2019 
13 
 Study Enrollment: Cohort B  (age 3 -15 years ) 
 
  
 
 
 
  
 
 
 
 
 
  
 
 
 
  
 
 
 
  
 
 
 
  
 
 
 
 
 
  
 
 
  
  Cycle 1 -2 
(30 mg/m2) 
Response evaluation 
at 4,8,12, (18, 24) 
months  Cycle 3 -12 
(40 mg/m2) Dose 
reduction  
(23 mg/m2) 
Off Study 
Tumor response will be done by MRI volumetrics at 4, 8, and 12 months 
(prior to cycle 5, 9 and end of study). Subjects may remain on drug for up to 12 additional cycles  and will have MRI done subsequently at 6 
months intervals.   Subjects in Cohort B who do not have a parti al 
response (>20% reduction in tumor volume) by the end of 12 cycles will 
be taken off study. Unacceptable toxicity  
Unacceptable toxicity 
despite dose  
de-escalation or 
progressive disease Study Entry  
NF Protocol #105   Version 2.1 
05/01/2019 
14 
 1.0  GOALS AND OBJECTIVES  (SCIENTIFIC AIMS)  
 
1.1 Primary Aim:   To estimate the objective response rate (ORR) as defined by 20% volumetric 
MRI response of the target lesion  to cabozantinib at 12 months in children and adults with 
NF1 plexiform neurofibromas by volumetric MRI imaging.   
1.2 Secondary Aim : 
1.2.1 To assess the tolerability and toxicity of cabozantinib in subject s with NF1.  
 
1.3 Exploratory Aims: 
1.3.1 To estimate the objective response rate of up to 2 non- target plexiform 
neurofibromas to cabozantinib by MRI. 
1.3.2 To assess quality of life and pain in subject s with NF1 and plexiform neurofibromas 
on cabozantinib  
1.3.3 To assess the PedsQL NF1 QOL Module, a diseas e specific QOL scale,  and the pain 
scales  for use in this patient population 
1.3.4 To assess activity of cabozantinib on mast cell activity by FACS  
1.3.5 To describe changes by flow cytometry in peripheral blood monocyte counts, 
circulating endoth elial cells, and plas ma angiogenic factors during treatment with 
cabozantinib. (see laboratory correlates section  13.0 C) 
1.3.6 To describe the baseline and change in circulating cytokine factors related to 
proliferating cells (see laboratory correlates section  13.0 C) 
1.3.7 To characterize the pharmacokinetic profile of cabozantinib in this population. 
1.3.8 To determine whether patients who respond (≥20% objective radiographic response of target lesion by 12 cycles ) to cabozantinib will maintain that response for 1 year 
off therapy  
1.3.9 To compare the volumetric assessment of plexiform neurofibroma response to 
therapy performed by two independent analysts using different volumetric analysis 
methods.   
 
2.0 BACKGROUND AND RATIONALE  
Introduction 
Cabozantinib (Exelixis) is a new chemical entity that inhibits multiple RTKs with growth -
promoting and angiogenic properties.  The primary targets of cabozantinib are MET, VEGFR2, 
RET, and c-KIT.  Cabozantinib is an orally bioavailable compound and marked tumor regression was observed in models tested.  In addition, clinical activity with the use of cabozantinib in a variety of tumor settings has been reported.  Receptor tyrosine kinases have been implicated in plexiform neurofibroma formation, particularly in the infl ammatory response of mast cells, which 
appear essential in tumor progression.  Preclinical evaluation of cabozantinib has shown marked tumor regression in several tumor models, including Nf1  animal models of plexiform neurofibroma 
(see below).  In addition, cabozantinib has been tested in several Phase 1 and 2 clinical trials and has been FDA approved for medullary thyroid carcinoma and renal cell carcinoma.  Cabozantinib has been selected for further human clinical testing for NF1 plexiform neurofibromas because of its 
NF Protocol #105   Version 2.1 
05/01/2019 
15 
 activity in in vivo  drug screens, including decrease in tumor size, number and metabolic activity by 
PET imaging.  This study will evaluate cabozantinib in a Phase 2 efficacy trial in children  and 
adults with clinically significant NF1 plexiform neurofibromas.  To maximize safety and 
tolerability, there will intra -patient dose escalation starting at a predicted highly tolerable dose with 
a planned dose escalation  to the target dose.  
 
Rationale for D evelopment  
Neurofibromatosis type 1 (NF1), is a common human genetic disorder that affects approximately 
100,000 people in the United States alone.  Individuals afflicted with NF1 develop a wide range of malignant and non- malignant manifestations. Plexifor m neurofibromas are benign tumors of the 
nerve sheath that occur in approximately 40% of patients with NF1.  They are a significant cause of morbidity in NF1 by causing pain, disfigurement or impairing function.  They are life threatening when they compress vital structures such as the airway or great vessels, or via transformation into malignant peripheral nerve sheath tumors.  Based on a series of novel observations made over the past decade, there is an increasing understanding of the requisite NF1 tumor microenvironment required for plexiform neurofibroma formation.  Nf1  heterozygous mast cell infiltration of pre -
neoplastic peripheral nerves in association with Nf1 -deficient Schwann cells has been shown to be 
critical for tumor development.  Further, on the basis that c -kit receptor activation controls the 
release of mast cells from the bone marrow; mast cells are implicated as active participants in tumor formation. [ 1
]  Based on these data, clinica lly available tyrosine kinase (including c- kit) 
inhibitors were tested in animal models of neurofibromas to evaluate efficacy on tumor as well as mast cell activation.  Of this group of compounds, Cabozantanib has emerged as a drug with significant impact on tumor volume, tumor apoptosis, and mast cell infiltration and as such has 
been selected for further clinical development. 
 C-kit dependent microenvironment in Nf1-dependent tumors  
The notion of targeted therapy against the tyrosine kinase c -KIT for the specific treatment of Nf1-
dependent tumors stems from careful analysis of models which recapitulate both genetic, as well as the tumor microenvironment, in which these tumors develop.[ 1] 
 
a. In a series of experiments, Yang et al. showed that Nf1 loss of heterozygosity in the 
Schwann cell lineage is necessary but not sufficient to induce plexiform 
neurofibromas.[ 1]  In a murine model, animals with germline knockout allele of Nf1  and 
a floxed allele susceptible to recombination in the Schwann cell lineage (approximately 10%) Krox20; Nf1
flox/flox uniformly develop plexiform neurofibromas;  however, animals 
with wild ty pe bone marrow (WT) with Krox20; Nf1flox/flox do not develop 
neurofibromas.  Animals with heterozygous Nf1  +/- bone marrow also do not develop the 
plexiform neurofibroma phenotype; however, animals with the Schwann cell lineage 
(Krox20; Nf1flox/flox) that ar e then subsequently transplanted with the bone marrow of 
animals with Nf1 +/ - bone marrow now develop plexiform neurofibromas.  In a series of 
converse experiments, Yang was able to definitively show that this combination is not just necessary, but is  requ ired to form plexiform neurofibromas in mice.  
 
b. Analyse s of the tumors from this model demonstrate the presence of the classic 
histological features of human plexiform neurofibromas including disruption of normal architecture; wavy Schwann cells and infiltr ating cells with hyperchromatic nuclei, 
NF Protocol #105   Version 2.1 
05/01/2019 
16 
 excess collagen deposition, angiogenesis, classic ultrastructural abnormalities, and 
Schwann cell -specific markers.   
 
c. To further validate the model, mast cells were found to infiltrate the peripheral nerves preceding tumor appearance as evidenced by mast cell specific stains.  A small population of macrophages and rare B lymphocyte and T-lymphocyte populations were also observed.  Mice (Krox20; Nf1
flox/flox) transplanted with wild type bone marrow 
showed no elevated m ast cell infiltration.  
 
d. The c- Kit receptor tyrosine kinase (RTK) controls many aspects of mast cell 
development and function. [ 2]  In addition, c- kit activity governs migration, 
proliferation and survival of Nf1+/- bone marrow- derived mast cells. [3]  Using two 
different strains  of mice with point mutations in the c -kit receptor resulting in a 
reduction in receptor tyrosine kinase activity, the concept of c- kit mediated tumor 
development was tested.  The two strains of c- kit mutated mice deficient in mast cell 
mobilization were intercrossed with Nf1+/- mice.  These mice then served as bone 
marrow donors to the Nf1  LOH Schwann cell lineage mice (Krox20; Nf1flox/flox).  These 
mice had significantly reduced morbidity and mortality due to progression of plexiform neurofibromas compared  to mice that were transplanted without mutations in the c- kit 
receptor that were able to mobilize their mast cells demonstrating the importance of c -
kit signaling in plexiform development.  
 
e. Utilizing a cohort of 8 -9-month-old Krox20; Nf1
flox/- mice with F DG-PET positive 
tumors, imatinib mesylate, a potent inhibitor of c -kit, PDGFR, and c- abl, was 
administered orally at 200 mg/kg/day and compared to placebo control.  Animals treated with imatinib showed striking decrease in FDG -PET acti vity.  Also, histolog ic 
sections of plexiform neurofibromas that develop in the dorsal root ganglia were taken post- mortem showing a clear decrease in dorsal root ganglia plexiform volume in the 
imatinib mesylate treated group as compared to controls.  In the proximal surrounding nerves, mice treated with PBS placebo showed a distinct disruption of the normal nerve architecture and in crease in cellularity compared to imatinib mesylate treated mice.   
 
Together these data makes a strong argument for the further clinical development of 
pharmacologic c- kit targeting for the treatment of Nf1 dependent plexiform neurofibromas. 
 
RTK inhibition of Nf1-dependent tumors by cabozantinib 
 
a. Activity of c abozantinib as inhibitor of multiple receptor tyrosine kinases 
(RTKs).   
Data from pharmacodynamic experiments show that, in vivo , cabozantinib inhibits 
several key RTKs that promote tumor cell proliferation and/or angiogenesis including c- Kit, MET, VEGFR2 , and RET.  There is good correlation between 
increases in plasma drug concentrations and increased inhibition of receptor phosphorylation at the doses tested.  Results from dose- response experiments in 
mice indicated that the ED
50 of targets is  achieved at well- tolerated doses of 
cabozantinib at plasma exposure comparable to exposure observed in clinica l trials.  
Cabozantinib produces prolonged inhibition of receptor phosphorylation; such as 
NF Protocol #105   Version 2.1 
05/01/2019 
17 
 sustained inhibition of MET and VEGFR2 for 10 hours after administration of a 
single dose of cabozantinib.   
 
b. Preclinical drug screen  
Compounds were selected for preclinical in vivo testing that were either undergoing clinical trials and/or commercially available.  All of the selected compounds were tyrosine kinase inhibitors.  These compounds were tested in 12 week in vivo  studies 
in mu rine Nf 1 plexiform neurofibroma models to screen for candidates fo r further 
clinical testing.  The two compounds shown here were cabozantinib (notated 
XL184) and XL647.  Cabozantinib (inhibitor of c-kit, met, RET and VEGFR2), met all established “success” guidelines for moving forward to human trials.  XL647 (inhibits VEGFR2, EGFR, and Her- 2) achieved some but not all success criteria and 
has not been selected to move forward.  i. Criteria for success:  The criteria to move a drug forward included reduction in metabolic activity of a cohort by at least 30 %, reduction of mast cell cellularity 
by at least 50%, and decrease in the absolute number of tumors by 25%  
ii. Drug toxicity:  All compounds selected are currently in clinical trials for other purposes and thus have had extensive preclinical safety and toxicity testing.  None of the drugs tested were found to induce weight loss greater than 15%, nor did any drug cause mortality or other observable morbidity. 
 
c. Evaluation of Histologic criteria 
Figure 1A shows the results for biological effect of compounds on the reduction in 
mast cell cellularity of tumors as compared to tumors from mice that received placebo treatment.  The defined threshold for success is 50% (as noted by the red line).  XL184 (cabozantinib) redu ced mast cell cellularity by greater than 50%.  
  Apoptotic cells in the tumor were evaluated using TUNEL assays (Figure 1B).  Each symbol shown indicates the mean number of apoptotic cells scored from 

NF Protocol #105   Version 2.1 
05/01/2019 
18 
 individual tumors.  XL184 (cabozantinib) treatment induced a consistent 2 -fold 
increase in the apoptotic cells over the vehicle control group.  As a marker of 
proliferation, the tissue sections were stained with Ki-67, a tumor antigen that is found in growing dividing cells but is absent in the resting phase of cell growth.  Both XL184 and XL647 resulted in a reduction in the number of proliferating cells that were scored per high power field (*P<0.01). 
 
 
d. Evaluation of metabolic activity   
 Small animal PET imaging studies was performed and examined changes in FDG 
uptake as a biomarker of response to experimental therapy in Krox20; Nf1flox/- mice.  
Imaging studies were performed prior to initiation of therapy and prior to sacrifice.  All image data sets were transformed to standardized uptake value units (SUVs) and all voxel values above a threshold of SUV=1.0 within a 3-D volume of interest along the spine was integrated to form an FDG biomarker index.  The bar graph in Figure 2 demonstrates the observed results for a representative group of experimental drugs tested.  As expected, the placebo groups had an increase in the FDG uptake over the 12-week period. Consistent with the striking cellular changes observed from histologic specimens, following 12- weeks treatment, mice that 
received XL184 had a significant reduction in SUV uptake. 
 
 
Figure 1 A.  
 Figure 1B  
 
 Figure 1C.  
 
 
 
Figure 1. Histologic analysis. (A) Summary data showing the absolute number in mast cells in tumors of 
mice treated with XL184 and XL647 compared to placebo treated mice.  Red line indicates the designated 
more than 50% decrease in mast cell numbers. *P<0. 01 for vehicle control group and both experimental 
groups. (B) Summary data of TUNEL positive cells  observed in tumors of mice treated with XL184 and 
XL647. *P<0.01 for vehicle control group and XL184 group. (C) Ki67+ cells per high power field. *P<0.01 
compared to vehicle control groups.  

NF Protocol #105   Version 2.1 
05/01/2019 
19 
 Figure 2.  SUV integral.  The SUV integral is a measure  of the elevated retention of FDG in a 3D volume of 
interest around the spinal cord.  The blue bar represents the pretreatment level, the red bar represent the 12 
weeks after the treatment.   
 
e. Tumor number was decreased following long -term treatment with XL 184 
(cabozantinib)  
To evaluate whether the histologic changes and the metabolic reduction in the XL184 
treated mice correlated with the tumor number changes, we measured tumor numbers and tumor size. As shown in Figure 3A, mice treated with XL184 had a 75% reduction in the average number of tumors as compared to that of vehicle controls (* p< 0.01). Of the residual tumors, XL184 treatment reduced the tumor size by greater than 50% compared to control group (*P<0.01) (Figure 3C).  Thus this compound meets both go/no go criteri a 
established previously.  
 
 
f. Summary  
XL184 had a striking reduction in the number of tumors (>70%) and of the few 
residual tumors that were remaining, a 50% reduction in tumor size was observed.  Thus this drug meets both established milestone 2 go/no go criteria and should be considered for a clinical trial. All correlative histologic and imaging data are completely consistent with this striking response.   XL184 has been moved forward and is now in multiple phase 2 clinical trials and also in phase 3 clinical trials.   Figure 3A.  
 Figure 3B.  
 
Figure 3C.  
 Figure 3.  Measurement of the average tumor 
numbers following the long- term treatment with 
Xl184 or XL647.  (A) Mean number of tumors of 
Krox20; Nf1flox/- mice treated with vehicle vs. XL184. 
*p< 0.01 comparing vehicle to XL184. (B) Mean 
number of tumors of Krox20; Nf1flox/- mice treated 
with vehicle vs. XL647. *p< 0.01 comparing vehicle to XL647.  (C) Percent tumor size reduction. Mean percent residual tumo r size as measured in area 
(mm2) is shown. *P<0.01. The red line indicates the 50% threshold of tumor size.  

NF Protocol #105   Version 2.1 
05/01/2019 
20 
  
Imaging and Measurement of Plexiform Neurofibromas 
 
 
 
Tumor response criteria that are used for cancers are based on one -dimensional (1 -D) and 
two-dimensional (2- D) tumor measurements (Estey, Hoth et al. 1986; Therasse, Arbuck et al. 
2000). These methods have limited value in the assessment of treatment outcome for 
plexiform neurofibromas, which are frequently large, have a complex (non- spherical) shape, 
and have a slow, erratic growth pattern. In order to reproducibly quant ify the size of these 
complex lesions and detect small changes in the size over time, we used MR imaging 
characteristics of plexiform neurofibromas to develop an automated method of lesion detection and volume measurement. Short T1- Inversion Recovery (STIR ) MR images, on 
which plexiform neurofibromas are bright lesions compared with normal surrounding tissue, were used to develop a program for automated image analysis within MEDx (v3.41) software (Sensor Systems, Inc. Sterling, VA). Reproducibility and inte r-observer variability of this 
automated method were determined by 2 observers who quantified volumes for plexiform neurofibromas of the orbit (n=2), face/neck (n=3), abdomen (n=1), and pelvis (n=3) on three different days (Solomon, Warren et al. 2004).  F or each MR image (Figure 1A), the tumor is 
roughly outlined manually including a rim of low signal intensity normal tissue (Figure 1B). The program then performs a histogram analysis of signal intensity pixel by pixel and a threshold that distinguishes hig h signal intensity tumor from normal tissue is defined (Figure 
1C). Tumor contours are then determined using a gradient image, connected component analysis and automatic edge following operation (Figure 1D). There is an option for re -
analysis of MR images using an average or selected threshold. Tumor volume is calculated 
by summing the results from all images based on the resulting 2 -D contours and slice 
thickness; and a report is generated.  
 For comparison, the volume of each plexiform neurofibroma was als o determined by each 
observer once by manually tracing the tumor borders on each MR image. The results of the application of the automated method and the correlation with the manual method are shown in the table below.  
Automated Volumetric MRI Analysis  Observer 1  Observer 2  Figure 1: Axial MRI of pelvic plexiform neurofibroma. Steps of 
automated volumetric analysis A-D.  
 
A B
D C
NF Protocol #105   Version 2.1 
05/01/2019 
21 
 Mean tumor volume (ml)  
Median (range)  291 
(80.9 -1581)  290 
(75.7 -1603)  
Median Inter -day CV (%)  
(range)  3.6 
(0.7-6.0) 1.6 
(0.6-5.6) 
Difference in volume between observers (%)  
Median (range)  6.4 (1.4 – 11.9)  6.4 (1.4 – 11.9)  
Correlation automated vs. manual method, R  0.999  0.999  
 
This automated volumetric MRI analysis is applicable to most plexiform neurofibromas, has excellent intra - and inter -observer reproducibility and agrees with volumes determined by 
manual tumor tracing. This method was used in a phase II trial of the farnes yltransferase 
inhibitor tipifarnib, in the phase I and II trials of pirfenidone, in the phase I trial of peg -
interferon alfa -2b, and in the NF Consortium phase 2 trial of Sirolimus  for children with NF1 
and plexiform neurofibromas to assess changes in tumor size. Imaging studies on these multicenter trials are sent to the NCI, POB, where volumetric MRI analysis is performed. Tumor progression on these trials is defined as an increase in plexiform neurofibroma volume by ≥ 20%.   This volume increase correspo nds to much smaller changes in 1- D, or 2- D measurements as 
outlined in the table below: 
 
Response Criteria  RECIST  
Diameter, 
2r WHO  
Product, (2r)2 Current NF1 trials  
Volume, 4/3 Πr3 
Disease progression (Increase)  20 44 73 
 12 25 40 
6 13 20 
 
Shaded areas  show current criteria used to define disease progression by RECIST, WHO, 
and the ongoing NF1 trials listed above.  The use of this method of volumetric MRI analysis of PNs in 49 individuals with NF1 who were followed at the NIH for ≥ 18 months resulted in the following observations: 1) Time to disease progression is a realistic trial endpoint, provided progression is present at trial entry, in that progression can be documented within a clinically meaningful time period. The median time to progression on phase A (50% of individuals receive placebo, 50% receive drug) of the tipifarnib phase II trial is 18 months (range 3 to 36+ months). 2) Plexiform neurofibromas 
appear to grow more rapidly in younger compared to older children (see Figure below), and 3) while the growth rate of PN is variable among patients, the growth rate within patient during the time of observation (median observation period 34 months, range 18- 70 months) 
appeared to be constant (Dombi, Solomon et al. 2007). 4) Given the more rapid growth of PN in younger children, it appears critical that drug development for NF1 PN focuses on young patients.   
NF Protocol #105   Version 2.1 
05/01/2019 
22 
  
Figure 2:  Relationship between the slopes for percent change in plexiform neurofibroma (PN) volume and 
percent change in body weight per year (A). Values above the 45 degree line represent ratios of percent change 
in PN volume to percent change in body wei ght which are greater than 1. Closed symbols represent patients ≤ 
the median age (8.3 years) at study entry, and open symbols patients > 8.3 years.  Percent change in plexiform 
neurofibroma (PN) volume (B) and body weight ( C) per year as a function of patient age at baseline. The shaded 
area indicates the 20% change in PN volume required for documentation of disease progression in ongoing clinical trials. The line in B represents an exponential fit to the data.  
 
 
2.1  Cabozantinib tablets  
 
Exelixis internal number: XL184 
Chemical Name:  Chemical Name: N-{4-[(6,7-dimethoxyquinolin-4- yl)oxy]phenyl} -N’-(4-
fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioate 
 
Cabozantinib tablets are supplied as film coated tablets containing cabozanti nib malate equivalent to 20 mg  
and contain  microcrystalline cellulose, lactose anhydrous, hydoxypropyl cellulose, croscarmellose sodium, 
colloidal silicon dioxide, magnesium stearate and Opadry® yellow. All tablet strengths are prepared from a 
common blend an d are distinguished by shape. The 20 mg tablets are round and the 60 mg tablets are oval . 
 

NF Protocol #105   Version 2.1 
05/01/2019 
23 
  Cabozantinib Tablet Components and Composition  
Ingredient   Function  % w/w  
Cabozantinib malate (25% drug load as cabozantinib)  Active Ingredient  31.7 
Microcrystalline Cellulose (Avicel PH -102) Filler  38.9 
Lactose Anhydrous (60M)  Filler  19.4 
Hydroxypropyl Cellulose (EXF)  Binder  3.0 
Croscarmellose Sodium (Ac -Di-Sol) Disenegrant  6.0 
Colloidal Silicon Dioxide,  Glidant  0.3 
Magnesium Stearate  Lubricant  0.75 
Opadry Yellow Film Coating which includes:  
- HPMC 2910/Hypromellose 6 cp  
- Titanium dioxide  
- Triacetin  
- Iron Oxide Yellow  Film Coating  4.00 
 
 
 
2.2  Cabozantinib Nonclinical Toxicology 
 
Summary of Toxicology  
The nonclinical toxicity of cabozantinib was characterized in single - and repeat -dose toxicology 
studies in rats and dogs (see the current  Investigator Brochure for summary tables); in vitro 
bacterial and mammalian genotoxicity bioassays; an in vivo clastogenic bioassay; reproductive and developmental toxicology studies, and cardiovascular, neurobehavioral, and respiratory safety pharmacolog y studies. The experimental designs, findings, and conclusions from these nonclinical 
toxicity studies are discussed in this section.  
 
Single -Dose Toxicology Studies  
Toxicity associated with single oral doses of cabozantinib was characterized in rats and dogs by dose- dependent changes in clinical signs, by clinical pathology changes reflective of toxicity to 
liver and hematopoietic tissues, and by histopathologic findings in multiple tissues.  The NOAELs for the definitive single oral dose toxicity studies  of cabozantinib in rats and dogs 
were considered to be < 100 mg/kg and 2000 mg/kg, respectively. The Cmax and AUC0-t values in rats dosed at 100 mg/kg are approximately 2-fold and 3-fold higher, respectively, than for dogs dosed at 2000 mg/kg; therefore, the higher systemic exposure to cabozantinib in rats correlates with the greater toxicity observed in this species at lower administered doses.  
 
Repeated -Dose Toxicology Studies  
Repeated oral administration of cabozantinib, for up to 6 months resulted in dose-dependent toxicity in both rats and dogs.   The NOAELs for the subchronic toxicity studies in rats and dogs administered cabozantinib qd for 14 consecutive days were considered to be 1 mg/kg/day and 10 mg/kg/day, respectively.  Findings from chronic toxicity studies in rats and dogs following qd oral dosing of cabozantinib for 180 days (26 weeks) are summarized in the current  Investigator Brochure.  In rats, microscopic 
changes were present only in the kidneys of the 1-mg/kg/day dose group of both sexes, evidenced 
NF Protocol #105   Version 2.1 
05/01/2019 
24 
 by a slight, reversible increase in severity and/or incidence of chronic progressive nephropathy. 
Based on this, the NOAEL following chronic oral administration of cabozantinib for 180 days was considered to be 0.3 mg/kg/day. There was very little evidence of toxicity.   In dogs, the only microscopic findings possibly related to cabozantinib administration (5 mg/kg qd × 180) were present in testes (hypospermatogenesis)  and ovaries (corpora lutea absence). These 
microscopic findings may reflect a lack of sexual maturation in the young adult animals used in this study, rather than a test article -related change. Therefore, the NOAEL for cabozantinib in this 
study was considered to be 5 mg/kg/day.  In a second 6-month toxicity study in dogs a higher cabozantinib dose (30 mg/kg) was tolerated for only 10 days due to body weight decreases of up to 11%. Following an 11-day drug holiday, dosing was reinitiated at a lower dose of  20 mg/kg for 122 and 172 days in males and females, 
respectively (“30/20 mg/kg/day”). The only cabozantinib -related macroscopic finding, which had no microscopic correlate, consisted of mild and/or moderate gray discoloration of the skin or head. Microsc opic changes associated with cabozantinib administration were observed only in 
reproductive tissues ( e.g., moderate to severe bilateral hypospermatogenesis in testes, and lack 
corpora lutea in ovaries), and were correlated with decreased testicular and ovarian weights.  
 
2.3  Clinical Experience 
Clinical Summary  
As of 28 February 2018, 3017 subjects with cancer treated with cabozantinib in Exelisis sponsored 
single -agent studies has been performed. Clinical data are available from 18 studies of cabozantinib 
including four Phase 1 studies, one actively enrolling Phase 1b  study, one Phase 1b/2 study, four 
Phase 2 studies, five  Phase 3 study, one ongoing and enrolling Phase 4 study in MTC, one ongoing 
maintenance “roll-over” study, and one expanded access study . 
 The most frequently observed adverse events (AEs) were diarrhea,  fatigue, decreased appetite, 
nausea, Palmar -Plantar Erythrodysesthesia (PPE) syndrome , weight decreased,  hypertension , 
vomiting,  dysgeusia , and dysphonia.  Some of these events resulted in permanent study drug 
discontinuation, including fatigue, general physical health deterioration, decreased appetite, asthenia, , diarrhea, nausea, and vomiting.  The events to monito r of diarrhea, PPES, and 
hypertension include AEs that were reported in high frequency in previous cabozantinib studies and have been commonly observed with vascular endothelial growth factor – tyrosine kinase inhibitor ( VEGFR -TKIs ).  Less frequent effects  but potentially life -threatening AEs that have been 
reported for subject receiving cabozantinib and other VEGF  pathway inhibitors, are GI perforation , 
fistulas, abscesses , hemorrhage  (grade 3) , arterial thrombotic  events, venous and mixed/unspecified 
thrombotic events, wound complications , osteonecrosis, proteinuria, and reversible posterior 
leukoencephalopathy syndrome (RPLS) which have been observed in clinical studies with cabozantinib.  There have been 44 su bjects in pooled singe- agent studies with  Grade 5 events 
assessed to be related to cabozantinib  (note one subject had two Grade 5 AEs) :  arterial thrombotic 
event ( 3 subject s), fistula ( 5subjects), GI perforation  (5 subject s), Hemorrhage (23 subjects), 
venous and mixed/unspecified thrombotic events (7 subject s), and abscess (1 subject) .   
 
Pediatric Experience  
The Children’s Oncology Group recently completed a Phase 1 trial of Cabozantinib in Children 
and Adolescents with refractory solid tumors. (Chuk et al. ASCO 2014).  In this study, 25 
NF Protocol #105   Version 2.1 
05/01/2019 
25 
 evaluable patients age 4 -18 years  (median 14) were enrolled.  In Part A (dose-finding) of the study 
(18 subjects), there was 1 DLT of grade 3 fatigue and headache at dose level 55 m g/m2/day.  In 
Part B (expansion cohort), there was 1 DLT of Grade 2 oral mucositis and Grade 2 palmar- plantar 
erythrodysesthesia at 40 mg/m2/day, and 2 DLTs of Grade 3 hypertension and proteinuria, and 
hypertension and reversible posterior leukoencephalopa thy  syndrome , respectively,  at 55 
mg/m2/day.  The toxicity profile in this study was concluded to be similar in adults and in children.   
 
 
 
 However, in the steady-state pharmacokinetics analysis, cabozantinib exposure was highly variable and did not appear to be dose proportional.    
 
 
Based on comprehensive analysis of initial DLT data, DLT in later cycles as well as PK dosing , the 
recommend ed phase 2 dose of cabozantinib in children with solid tumors was determined to be 40 
mg/m2/day (equivalent to an adult dose of 72 mg/day).   
 
Adult NF1 Plexiform Neurofibroma Experience (NF105 Cohort A) 
In cohort A of this trial, of 21 subjects evaluable for toxicity, the most common adverse events (any 
grade) on study were gastrointestinal (all 21 subjects), asymptomatic hypothyroidism (n=16), fatigue (n=13), headaches (n=11 ), palmar -plantar erythrodysethesia (PPE, n=10), and leukopenia 
(n=9 ).  Eleven grade 3 adverse events occurred in 8 patients, including PPE (n=4), hypertension 

NF Protocol #105   Version 2.1 
05/01/2019 
26 
 (n=2), anorexia, vomiting, neutropenia, proteinuria, and skin infection. There were no grade 4 or 5 
AEs.  
 
Two patients discontinued cabozantinib due to dose limiting toxicity (DLT) ; both for PPE that did 
not resolve ≤ grade 1 within the protocol- mandated time frame  of 14 days to allow restarting of 
drug. There were a total of 10 dose reductions that occurred in seven subjects while on study for:  
PPE (n=7); skin infection ( n=1); weight loss ( n=2).  
 Of the eight subjects with a partial response, only four reached that response by cycle 8, and the maximal tumor reduction did  not occur until cycle 18 in 4 subjects and cycle 24 in 2 subjects.  
 Because of the overall excellent  safety profile of cabozantinib and the numerous late tumor 
responses, the requirement to stop study treatment in subjects who do not achieve at least a 15% 
reduction in tumor volume by  8 cycles  will be eliminated in the ped iatric cohort (Cohort B).  Of 
note, the initial rationale for this criteria was the hypotheses that the likelihood of achieving a partial response (20% reduction in tumor volume) by 12 months would be minimal if there was not 
a 15% reduction  by 8 cycles.   
 
2.4 Clinical Safety Profile  
 
Adverse Events  
As of 28 February 2018, AE data are available for 3017 subjects who have been dosed with 
cabozantinib.   The most frequent AEs  (≥ 5% incidence) reported at severity of Grade 3 and above include fatigue 
14.3%), hypertension (13.9%), diarrhea (10. 7%), anemia ( 75%),  PPES ( 9.4%), asthenia ( 7.0%), 
pulmonary embolism (5.3%),  and decreased appetite (5.6%). 
 The most frequently (≥ 20% incidence) observed AEs reported as related to cabozantinib, were diarrh ea (5 2.9%), fatigue (5 0.1%), decreased appetite (4 3.0%), nausea (39.9%),  
PPES (3 7.0%), weight decreased (25.3%), vomiting (23.8 %), dysgeusia (2 2.8%), hypertension 
(25.2%), and dysphonia (21.6%). 
 
 
Table 5-2: Summary  of Adverse Events Experienced  by ≥ 10% of Subjects  Treated with  
Single -Agent Cabozantinib,  N = 3017  
 
 
All AEs Related  AEs 
Subjects  
w ith   
Subjects  
with  
 
 
 
MedDRA Preferred  Term  Subjects  
with AE 
n (%) ≥ Grade 3 
AE 
n (%) Subjects  
with AE 
n (%) ≥ Grade 3 
AE 
n (%) 
Number  of subjects  with at least one event  3009  (99.7)  2498  (82.8)  2902  (96.2)  1913  (63.4)  
Diarrhoea  1817  (60.2)  322 (10.7)  1596  (52.9)  293 (9.7)  
Fatigue  1733  (57.4)  432 (14.3)  1513  (50.1)  361 (12.0)  
Decreased  appetite  1573  (52.1)  170 (5.6)  1297  (43.0)  132 (4.4)  
Nausea  1478  (49.0)  132 (4.4)  1204  (39.9)  98 (3.2)  
NF Protocol #105   Version 2. 1 
05/01/2019  
27 
 Palmar -plantar  erythrodysaesthesia  syndrome  1134  (37.6)  284 (9.4)  1117  (37.0)  282 (9.3)  
Vomiting  1015  (33.6)  101 (3.3)  719 (23.8)  64 (2.1)  
Weight  decreased  988 (32.7)  108 (3.6)  764 (25.3)  85 (2.8)  
Constipation  900 (29.8)  34 (1.1)  388 (12.9)  13 (0.4)  
Hypertension  880 (29.2)  418 (13.9)  759 (25.2)  365 (12.1)  
Dysgeusia  723 (24.0)  4 (0.1)  688 (22.8)  4 (0.1)  
Dysphonia  718 (23.8)  9 (0.3)  604 (20.0)  7 (0.2)  
Asthenia  700 (23.2)  210 (7.0)  537 (17.8)  153 (5.1)  
Aspartate  aminotransferase  increased  596 (19.8)  132 (4.4)  483 (16.0)  85 (2.8)  
Dyspnoea  574 (19.0)  95 (3.1)  204 (6.8)  24 (0.8)  
Abdominal  pain 568 (18.8)  110 (3.6)  282 (9.3)  27 (0.9)  
Stomatitis  558 (18.5)  55 (1.8)  526 (17.4)  53 (1.8)  
Mucosal  inflammation  549 (18.2)  56 (1.9)  522 (17.3)  54 (1.8)  
Anaemia  544 (18.0)  227 (7.5)  236 (7.8)  76 (2.5)  
Alanine  aminotransferase  increased  511 (16.9)  102 (3.4)  432 (14.3)  78 (2.6)  
Back  pain 510 (16.9)  97 (3.2)  59 (2.0)  6 (0.2)  
Headache  493 (16.3)  31 (1.0)  183 (6.1)  3 (0.1)  
Pain in extremity  477 (15.8)  56 (1.9)  200 (6.6)  16 (0.5)  
Rash  454 (15.0)  17 (0.6)  371 (12.3)  15 (0.5)  
Cough  443 (14.7)  8 (0.3)  97 (3.2)  1 (< 0.1) 
Oedema  peripheral  416 (13.8)  20 (0.7)  114 (3.8)  4 (0.1)  
Hypothyroidism  413 (13.7)  8 (0.3)  343 (11.4)  4 (0.1)  
Dizziness  368 (12.2)  14 (0.5)  185 (6.1)  3 (0.1)  
Dyspepsia  363 (12.0)  4 (0.1)  264 (8.8)  4 (0.1)  
Hypokalaemia  361 (12.0)  109 (3.6)  161 (5.3)  50 (1.7)  
Arthralgia  345 (11.4)  31 (1.0)  88 (2.9)  4 (0.1)  
Pyrexia  329 (10.9)  15 (0.5)  59 (2.0)  2 (0.1)  
Dry mouth  319 (10.6)  0 261 (8.7)  0 
Hypomagnesaemia  313 (10.4)  37 (1.2)  205 (6.8)  28 (0.9)  
Urinary  tract infection  309 (10.2)  39 (1.3)  31 (1.0)  3 (0.1)  
Insomnia  306 (10.1)  1 (< 0.1) 90 (3.0)  0 
Dry skin 304 (10.1)  0 255 (8.5)  0 
Muscle  spasms  303 (10.0)  2 (0.1)  171 (5.7)  1 (< 0.1) 
AE, adverse event;  MedDRA,  Medical Dictionary for  Regulatory  Activities.  
At each level  of subject  summarization,  a subject  is counted once  if the subject  reported  one or more  events.  Adverse  
events  were coded  based  on MedDRA  version  17.0.  
Note:  This table  summarizes  pooled  data in the clinical  database for  single -agent  cabozantinib  studies  (XL184 -001,  
XL184 -008,  XL184 -201, XL184 -203, XL184 -205, XL184 -301 cabozantinib  arm, XL184 -306 cabozantinib  arm, 
XL184 -307 cabozantinib  arm, XL184 -308 cabozantinib  arm, XL184 -309 cabozantinib  arm, and XL184 -401).  The 
denominator  for percentages  is the number  of treated  subjects.  
 
  
 
 
NF Protocol #105   Version 2. 1 
05/01/2019  
28 
 Events to Monitor  
Adverse events  of interest  have been  identified  as catego ries of AEs that are known class effects  
of VEGF inhibitors, that may im pact the risk/benef it of cabozantinib treatment, and that as a result  
of increased  awaren ess should be diagnosed and appropriately clinically managed.  
 
The AEs of  interest and their observed frequencies  are disc ussed  in this section  and include 
data only from  open- label  studies w ith single-agent  cabozantinib in the c linical database as of 
28 February 2018 (N =  3017).  
 
Events to Monitor (ETMs) in the Pooled Single- Agent Studies  
The defin ition a set of Events to Monitor (ETMs) in order to track events known to be associated 
with TKIs, VEGF pathway inhibition, and other events with potentially serious consequences. 
Each ETM comprises a set of AEs that are related to each other pathophysiologically.  
 The ETMs of diarrhea, PPES, and hypertension include AEs that were reported in high frequency in previous cabozantinib studies and have been commonly observed with VEGFR-TKIs. Less frequent but potentially life-threatening AEs that have been reported for subjects 
receiving cabozantinib and other VEGF pathway inhibitors are represented by the ETMs of GI perforations, fistulas, abscesses–all, intra -abdominal and pelvic abscesses, hemorrhages (≥ Grade 
3), arterial thrombotic events, venous and mixed/unspecified thrombotic events, wound complications, osteonecrosis, proteinuria, and RPLS. In the interest of routine surveillance, QT prolongation is also tracked.  The AEs discussed in this section and summarized in Table 5-4 include data in the clinical database as of the AE cutoff dates for the Safety populations (ie, all subjects who received at least one dose of study treatment) from the pooled single- agent  
cabozantinib (N = 3017).  
   
Table 5-4 Incidence of Events  to Monitor  
 
 
 
 
ETMa Pooled  Single -Agent  Studiesb 
Cabozantinib  (N = 3017)  
All 
n (%) Grade  3-4 
n (%) Grade  5 
n (%) 
Diarrhea 1817  (60.2)  322 (10.7)  0 
PPES 1134  (37.6)  284 (9.4)  0 
Hypertension  911 (30.2)  427 (14.2)  0 
Venous  and mixed/unspecified  thrombotic  events  308 (10.2)  216 (7.2)  7 (0.2)  
Proteinuria  212 (7.0)  37 (1.2)  0 
Hemorrhage (≥ Grade  3) 147 (4.9)c 124 (4.1)  23 (0.8)  
Abscess –all 135 (4.5)  50 (1.7)  1 (< 0.1) 
Intra -abdominal  and pelvic  abscess  44 (1.5)  28 (0.9)  0 
NF Protocol #105   Version 2. 1 
05/01/2019  
29 
 Arterial thrombotic  events  68 (2.3)  42 (1.4)  3 (0.1)  
Wound  complications  60 (2.0)  19 (0.6)  0 
Fistula  48 (1.6)  22 (0.7)  5 (0.2)  
GI perforation  42 (1.4)  37 (1.2)  5 (0.2)  
Osteonecrosisd 39 (1.3)  15 (0.5)  0 
QT prolongatione 31 (1.0)  9 (0.3)  0 
RPLS  1 (< 0.1) 1 (< 0.1) 0 
ETM,  event  to monitor;  GI, gastrointestinal;  PPES, palmar -plantar  erythrodysesthesia syndrome;  RPLS,  reversible 
posterior  leukoencephalopathy  syndrome.  
Note:  A subject  is counted once per  ETM  for the most  severe event if  reporting  one or more event.  
a    The complete lists  of reported  MedDRA  preferred terms  for each ETM  are defined  in Appendix  J. 
b    Subjects included  in the single -agent  pool are those  who received  cabozantinib on XL184 -001, XL184 -008, XL184-
201, XL184 -203,  XL184-205,  XL184 -301, XL184 -307,  XL184- 306, XL184 -308, XL184- 309, and XL184 -401.  
The data cutoff  
dates  for the pooled single -agent  studies are presented in Appendix F. The denominator  for percentages  is the  number  of 
treated  subjects.  
c    By definition,  the ETM  of hemorrhage includes only events  of ≥ Grade 3. The data presented  are for  events  of ≥ Grade 3. 
d    The reported ETMs  for osteonecrosis  comprised  osteonecrosis  of the jaw (1.2%; 28 of 36 subjects  had CRPC  [from  
Studies  XL184- 203, -306, & -307]),  osteonecrosis  (0.1%),  and osteoradionecrosis  (< 0.1%).  
e    The reported  ETMs  of QT prolongation  were electrocardiogram  QT prolonged (1.0%)  and electrocardiogram  QT interval  
abnormal  (< 0.1%).  
 
Discontinu ation  Due to Adverse Events  
As of 28 February 2018, 933 ( 30.9%) subjects in pooled single -agent studies of  cabozantinib 
permanently discontinued cabozantinib  f or the pri mary reason  of AE or SAE. Adverse  event  
data are available for all of these  subjects. The  most frequently reported AEs (≥1%) for subjects  
who discontinued for the  primary reason  of an  AE or SAE were  fatigue  (3.8%), general physical 
health deterioration ( 2.7%), asthenia (1.9 %), decreased appetite (1. 9%), nausea (1.6 %),dia rrhea 
(1.0%), PPES (1.4%), and vomiting (1.0)%  
Deat
hs 
Through 28 February 2018, 275 of 743 subjects who received cabozan tinib in ISTs conducted 
under separate US IND or ex -US equivalents held by the investigators; in these studies, reported 
in 551 SAEs in 310 cases. A  total of 43 SAEs with fatal outcome were reported from ISTs through 
28 February 2018.  Twenty -five subjects died of progression of the underlying malignancy.  Of 
the 17 subjects with fatal SAEs not related to underlying malignancy, 12 died of events that were 
assessed as not related to underlying malignancy, 12 died of events that were assessed as not 
related to study treatment.  These compr ised events of death (2 events), sudden death, sepsis, multi -
organ failure, intracranial tumor hemorrhage, and myelodysplastic syndrome.  One subject each died of fatal SAEs of hemorrhage and hypertensive heart disease that were considered possibly related to study treatment.   
 
Through 28 February 2018, 253 of 912 subjects in NCI-CTEP studies reported 1084 SAEs  in 
456 cases .  A total of 75 subjects experienced SAEs with fatal outcome in NCI -CTEP studies.  
Forty -six subjects died due to progression of the underlying malignancy.  Of the 29 subjects with 
fatal SAEs not related to the underlying malignancy, 17 died of events assessed  as not related to 
NF Protocol #105   Version 2. 1 
05/01/2019  
30 
 study treatment.  Twelve subjects died of a fatal SAE that were considered possibly related to the 
study treatment: sepsis (2 subjects), death, sudden death, intracranial hemorrhage, cardiac arrest, 
acute kidney injury, jejunal perforation, embolism, colon fistula, respi ratory failure , and 
pneumonitis (1 subject each).   
Volumetric Assessment of Plexiform Neurofibroma Size  
PNs are complex -shaped and slow- growing peripheral nerve sheath tumors that are challenging 
to measure by simple linear measurements. Automated volumetric MRI analysis can sensitively 
and reproducibly detect small changes in PN size and it has become the measurement method of choice to determine tumor response and time to disease progression in recent clinical trials.  There are two volume segmentation methods optimized for PN measurement, MEDx developed at the National Cancer Institute (NCI) and 3DQI used by the Tumor Imaging Metrics Core at Massachusetts General Hospital (MGH). The NF Clinical Trials Consortium has utilized MEDx 
in all of its PN trials.  In a small, retrospective study volume measurements and volume changes over time were compared using these two different methods, and found goo d agreement. The 
goal is to prospectively evaluate a larger cohort of clinical trial participants to further define the level of agreement in volume measurements, disease status classifications, and objective response rates between MEDx and 3DQI.  
 Overview  of Proposed Study  
This phase II 
open label study will evaluate children and adults with neurofibromatosis type-1 
(NF1) and plexiform neurofibromas treated with cabozantinib (XL184).  This study will enroll subject s who either meet clinical diagnostic criteria or have an identified pathogenetic NF1 
mutation.  Subjects on study must have clinically significant plexiform neurofibroma defined as potentially life -threatening, impinging on vital structures or significantly impair ing the quality of 
life from pain  or other symptoms.  Patients must not have lesions suspicious for malignant 
tumors such as MPNSTs (malignant peripheral nerve sheath tumors) and suspicious tumors must be proven negative by histopathology prior to enrollment on study.  This study will be open to patients ≥3 years of age that meet eligibility criteria.  There will be two  cohorts:  A. Cohort of 
subjects ≥ 16years of age, B. Subjects ≥3 years to 15 years of age with progressive plexiform 
neurofibroma.    The study will be a Simon two -stage st udy design for cohort  A.  It will be a single -arm open -
label study of cabozantinib and the primary endpoint is the ORR to cabozantinib at 1 year.  In the first stage , 9 evaluable subjects per cohort will be accrued.  If there is at least 1 response, accrual 
will continue to the second stage and an additional 8 evaluable subjects in that cohort will be 
enrolled.  To allow for 25% unevaluable subjects, a maximum of 24 subjects per cohort will be 
enrolled.  Radiographic response will be evaluated as the primary endpoint with 20% volumetric MRI response of the target lesion being the threshold criteria for tumor response.  A t arget lesion 
will be selected at time of enrollment and tumor evaluations will oc cur serially while on study. 
 In Cohort A, a ll subject s will start cabozantinib at 40 mg.  The published MTD for cabozantinib 
is 140 mg and the current recommended dose in Phase 3 clinical trials for subject s with 
medullary thyroid cancer is 100 mg.  Doses of 40 mg and 60 mg continue to show efficacy in on-going phase 2 and phase 3 trials with reduced toxicity (personal communication John Frye, Exelixis).  Subjects who tolerate 40 mg for 2 cycles will escalate to 60 mg.  The rationale for this 
NF Protocol #105   Version 2. 1 
05/01/2019  
31 
 is that the majority of subjects who develop toxicity do so after >2 weeks on drug as 
cabozantinib has a long half- life.  Subjects who experience dose- limiting toxicity  (see Section 
7.0) at 40 mg will dose reduce to 20 mg when their toxicities resolve. Subjects without toxicity at 
40mg will increase to 60mg.  Subjects who experience toxicity at 60 mg will dose reduce to 40 
mg. This dosing schema is designed to maximize safety and tolerability in this new population of 
patients.  
 In Cohort B, we will enroll a minimum of 17 evaluable subjects. To allow for up to 25% 
unevaluable subjects, a maximum of 24 subjects will be enrolled. Based on the preliminary response data (passed the threshold to move to stage 2) and minimal toxicity in Cohort A to date, a 2-stage design is not felt to be necessary for Cohort B. 
 Subjects in Cohort B will start at 30 mg/m
2/day dosing.  Dose will be escalated at cycle 3 if 
tolerated to 40 mg/m2.  Subjects who experience DLT at 40 mg/m2/day will dose reduce to 30 
mg/m2/day.  Subjects who experience DLT at 30 mg/m2/day will dose reduce to 23 mg/m2day.  
Actual dosing will be based on the dosing nomogram in Appendix XI.   Subject s entered on the trial will be carefully monitored for the development of cabozantinib 
associated toxicities, a nd target modifications and interruptions will be performed as outlined in 
this protocol (see section 7.0). 
 In all consenting subject s entered on this trial a complete pharmacokinetic profile of 
cabozantinib after administration will be evaluated.  In addition, cytokine and endothelial progenitor cell biomarkers will be drawn to assess treatment effect and to correlate with response.  In addition, since plexiform neurofibromas may significantly impact the lives of patients with NF1, this study will evaluat e the effects of the disease and treatment with cabozantinib on the 
quality of life (QOL) of these subject s by assessing health related QOL, pain intensity, and pain 
interference.       
3.0 SCREENING AND STUDY ENROLLMENT PROCEDURES  
 
The NF Operations Center should be contacted to ensure availability of a treatment slot and PK 
slot. 
 
3.1 Informed Consent/Assent  
The investigational nature and objectives of the trial, the procedures and treatments involved and their attendant risks and discomforts, and potential alternative therapies will be carefully explained to the patient or the patient’s parent(s) or guardian if the patient is a child .  When 
appropriate, pediatric patients will be included in all discussions. All patients and/or their 
parents or legally authorized representatives must sign a written informed consent.  Assent, 
when appropriate, will be obtained according to institutional guidelines.  
 
NF Protocol #105   Version 2. 1 
05/01/2019  
32 
 • A study participant should sign the institution’s HIPAA Consent. 
• A study participant should sign the instit ution’s Release of Medical Information Waiver.  
 
3.2 Screening  Procedures  
Diagnostic or laboratory studies performed exclusively to determine eligibility for this trial 
must only be done after obtaining written informed consent. Documentation of the informed consent for screening will be maintained in the subjec t’s research char t. Studies or procedures 
that were performed for clinical indications (not exclusively to determine eligibility) may be used for baseline values even if the studies were done before informed consent was obtained.  
 
Before the patient can be enrolled, the responsible institutional investigator must sign and date the completed eligibility checklist. The completed eligibility checklist should be faxed or 
scanned and emailed to the NF Operations Center to confirm eligibility prior to subject  
enrollment.  
 
3.3 Study Enrollment  
Patients may be enrolled on the study once all eligibility requirements for the study have been 
met, and a treatment number for subject has been confirmed by the NF Consortium Operations 
Center. All p atients who give informed consent for the protocol in order to undergo screening 
for eligibility will be registered but are not considered enrolled until the screening is 
completed and they are determined to meet all eligibility criteria. Treatment must start within 14 days of enrollment. Subjec ts must not receive any protocol therapy prior to 
enrollment.  
 
4.0 SUBJECT ELIGIBILITY  
 
All studies to determine eligibility must be performed within 2 weeks prior to enrollment. The 
baseline MRI study documenting disease status is required within 4 weeks prior to study entry. 
All clinical and laboratory data required for determining eligibility of a subjec t enrolled on this 
trial must be available in the subjec t's medical or research record which will serve as the source 
document for verification at the time of audit/monitoring.  
 
4.1 Inclusion Criteria for all subject s: 
 
4.1.1 All subjects must have an identified pathogenetic  constitutional  NF1  mutation  OR the 
clinical diagnosis of NF1 using the NIH Consensus Conference criteria. In addition to a plexiform neurofibroma, one or more of the following diagnostic criteria for NF1 must be present:  
4.1.1.1  Six or more café -au-lait spots (≥0.5 cm in prepubertal subjects or ≥1.5 cm in post pubertal 
subjects)  
4.1.1.2  Freckling in the axilla or groin  
4.1.1.3  Optic glioma  
4.1.1.4  Two or more Lisch nodules  
4.1.1.5  A distinctive bony lesion (dysplasia of the sphenoid bone or dysplasia or thinning of long 
bone cortex)  
NF Protocol #105   Version 2. 1 
05/01/2019  
33 
 4.1.1.6  A first -degree relative with NF1  
 
4.1.2 Subjec ts must have plexiform neurofi broma(s) that are progressive (see section 
4.1.2.1) OR are causing significant morbidity, such as (but not limited to) head and neck 
lesions that are compromising the airway or great vessels, brachial or lumbar plexus lesions 
that are causing nerve compression and loss of function, lesions causing  major deformity 
(e.g., orbital lesions) or are significant ly disfiguring (see section 4.1.2.2), lesions of the 
extremity that cause limb hypertrophy or loss of function, and painful lesions.  Patient s 
with paraspinal plexiform neurofibromas will be eligible for this trial. Histologic 
confirmation of tumor is not necessary in the presence of consistent clinical and radiographic findings, but should be considered if malignant degeneration of a plexiform  
neurofibroma is clinically suspected.   4.1.2.1  For subjects enrolled for tumor progression, progression is defined as:  
• Presence of new plexiform neurofibroma  on MRI or CT (documented by 
comparison with prior MRI or CT), OR 
• A measurable increase in plexiform neurofibroma size (≥ 20% increase in the 
volume, or a ≥ 13% increase in the product of the two longest perpendicular diameters, or a ≥ 6% increase in the longest diameter) documented by comparison of two scans (MRI or CT) in the time period of approximately one year or less prior to evaluation for this study. 
 
4.1.2.2 For subjects enrolled for “ major deformity ” or a “significant ly disfiguring”  tumor, 
eligible tumors will be limited to tumors of the head & neck or those on other areas of the 
body that are unable to be concealed by standard garments.  In order to enroll a plexiform neurofibroma for these indications, the Study Chair or Co- Chair must be contacted to 
review patient eligibility  prior to enrollment. 
 
4.1.3. Disease status:  
Measurable disease:  Subject s must have measurable plexiform neurofibroma(s) 
amenable to volumetric MRI analysis. For the purpose of this study, the target lesion must be seen on at least 3 consecutive MRI slices and the field of view must contain the entire tumor of interest.  Tumors must be at least 3 mL in volume (most PNs 3 cm in 
longest diameter will meet this criteria).  If the tumor is <3 cm in longest diameter, the patient may still be eligible.  Central review of the MRI of the target plexiform is 
required prior to enrollment to ensure that the tumor is measurable and amenable 
to volumetric analysis.  After consenting, please send the images on a CD along with the 
form in Appendix IX to Eva Dombi (see Appendix IX for address).  Central review will take 3 -7 days (please plan accordingly). 
 
4.1.4. Age:   
Subjec ts must be 3 years of age at the time of study entry.   Subjects ≥16 years of age will 
be enro lled in Cohort A.  Subjects 3-15 years of age will be enrolled in Cohort B.   
 
4.1.5. Subjects unable to consent to study:   
Adults (>18 years of age) who are unable to provide informed consent will NOT be 
NF Protocol #105   Version 2. 1 
05/01/2019  
34 
 enrolled on this study.  Written informed consent must be obtained from all patients ( >18 
years of age) or their legal guardians (if the patient is <18 years of age) .  
 
4.1.6. Performance Level :   
Subjects must have Karnofsky  or Lansky  ≥ 50% (Appendix II).  Note: Subjects  who are 
unable to walk because of paralysis, but who are up in a wheelchair, will be considered 
ambulatory for the purpose of assessing the performance score.  
 
4.1.7. Prior Therapy  
Patients who underwent surgery for a progressive plexiform neurofibroma will be eligible to enter the study after the surgery, provided the plexiform neurofibroma was incompletely resected and is measurable.  
 
Patients are only eligible if complete resection of a plexiform neurofibroma with acceptable morbidity is not feasible, or if a  patient with surgical option refuses surgery. 
 Patients may have been previously treated for a plexiform neurofibroma but must have fully recovered from the acute toxic effects of all prior chemotherapy or radiotherapy prior to entering this study. 
 
a. Myelo suppressive chemotherapy :  Must not have received within 4 weeks of entry 
onto this study.  
b. Hematopoietic growth factors: At least 7 days since the completion of therapy with a 
growth factor that supports platelet, red or white cell number or function.   
c. Biologic (anti- neoplastic agent) :  At least 14 days since the completion of therapy 
with a biologic agent.  For agents that have known adverse events occurring beyond 14 days after administration  (or 5 half- lives whichever is longer) , this period must be 
extended beyond the time during which adverse events are known to occur.  These 
patients must be discussed with the Study Chair on a case- by-case basis.  
d. Investigational Drugs:  Subject s must not have received an investigational drug 
within 4 weeks. 
e. Steroids: Patients with endocrine deficiencies are allowed to receive physiologic or 
stress doses of steroids if necessary.   
f. XRT :  ≥ 6 months from involved field radiation to index plexiform neurofibroma(s); 
≥ 6 weeks must have elapsed if patient has received radi ation to areas outside index 
plexiform neurofibroma(s). 
g. Surgery : At least 3 months since undergoing any major surgery.  At least 1 month 
since undergoing any minor surgery.  See section 4.2.1 for more details. 
 
4.1.8. Organ Function Requirements 
 
4.1.8.1.Adequate Bone Marrow Function Defined as: 
- Peripheral absolute neutrophil count (ANC) ≥  1500/ µL 
- Platelet count ≥ 100,000/ µL (transfusion independent) 
- Hemoglobin ≥  10.0 gm/dL (may receive RBC transfusions) 
 
NF Protocol #105   Version 2. 1 
05/01/2019  
35 
 4.1.8.2.Adequate Renal Function Defined as: maximum serum creatinine 1. 5 mg/dL  
 OR a creatinine clearance or radioisotope GFR ≥ 70ml/min/1.73 m2 
 
Serum calcium, magnesium, and phosphorous with institutional normal limits  
(supplementation is permissible)  
 
4.1.8.3.Adequate Liver Function Defined As: 
- Bilirubin (sum of conjugated + unconjugated) ≤  1.5 x upper limit of normal 
(ULN) for age, and  
- SGPT (ALT) ≤ 5 x upper limit of normal (ULN) for age, and 
- Serum albumin ≥  2 g/dL.  
 
4.1.8.4.  Blood pressure within upper limit of normal defined as: 
- A blood pressure (BP)  ≤ 95th percent ile for age, height, and gender and not 
receiving medication for treatment of hypertension.  
4.1.9. Major surgery:  Only patients who are not anticipated to need major surgery within the next 3 months of enrollment are eligible. 
 4.2  Exclusion Crit eria 
 
4.2.1 Exclusion Criteria  
• Evidence of an active optic glioma  or other low -grade glioma , requiring treatment with 
chemotherapy or radiation therapy.  Patients not requiring treatment are eligible for this protocol. 
• Patients with malignant glioma, malignant peripheral nerve sheath tumor, or other malignancy  requiring treatment in the last 12 months. 
• Dental braces or prosthesis that interferes with volumetric analysis of the neurofibroma(s).  
• The subject is unable to swallow tablets  
• Women who are pregnant or breast- feeding.  
• Males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method during the period they are receiving the study drug and for 3 months thereafter. Abstinence is an acceptable method of birth control. Women of childbearing potential will be given a pregnancy test within 7 days  prior to 
administration of cabozantinib and must have a negative urine or serum pregnancy test. 
• The subject has received prior treatment with a small molecule kinase inhibitor or a hormonal therapy (including investigational kinase inhibitors or hormones) within 14 days or 5 half -lives of the compound or active metabolites, whichever is longer, before 
the first dose of study treatmen t -OR- the subject has ever taken cabozantinib.  Note:  
Subjects with prostate cancer currently receiving LHRH or GnRH agonist may be maintained on these agents. 
• The subject has not recovered to baseline or CTCAE ≤ Grade 1 from toxicity due to all prior t herapies except alopecia and other non -clinically significant AEs.  
NF Protocol #105   Version 2. 1 
05/01/2019  
36 
 • The subject requires concomitant treatment, in therapeutic doses, with anticoagulants 
such as warfarin or warfarin -related agents, heparin, thrombin or Factor Xa inhibitors, 
or antiplatelet agents ( e.g., clopidogrel). Low dose aspirin (≤ 81 mg/day), low -dose 
warfarin (≤  1 mg/day), and prophylactic low molecular weight heparin (LMWH) are 
permitted.  
• The subject requires chronic concomitant treatment of strong CYP3A4 inducers (e.g., 
dexamethaso ne, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, 
phenobarbital, and St. John’s Wort).  The subject requires chronic concomitant 
treatment of strong CYP3A4 inhibitors (e.g., indinavir, nelfinavir, ritonavir, clarithromycin, itraconazole, ketoconazole, nefazodone, squinavir, telithromycin, aprepitant, erythromycin, fluconazole, grapefruit juice, verpamil, diltiazem, cimetidine, amiodarone, chloramphenicol, boceprevir, ciprofloxacin, delaviridine, diethyl-dithiocarbamate, fluvoxamine, gestodene, imatinib, mibefradil, mifepristone, 
norfloxacin, norfluoxetine, starfruit, telaprvir, voriconazole).  Because the lists of these agents are constantly changing, it is important to regularly consult a frequently updated list such as http://medicine.iupui.edu/clinpharm/ddis/table.asp x; medical 
reference texts such as the Physicians’ Desk Reference may also provide this information.  As part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new 
medications need to be prescribed or if the patient is considering a new over-the-
counter medicine or herbal product.   
• History of noncompliance to medical regimens  
• Patients unwilling to or unable to comply with the protocol, or who in the opinion of the investigator may not be able to comply with the safety monitoring requirements of the study 
• A known history of HIV seropositivity or known immunodeficiency. HIV testing will not be required as part of this trial, unless HIV is clinically suspected.  
• Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of cabozantinib (e.g. ulcerative disease, uncontrolled 
nausea, vomiting, diarrhea, malabsorption syndrome or small bowel r esection). A 
nasogastric tube (NG tube) is allowed. 
• Patients who have an uncontrolled infection. 
• The subject has experienced any of the following:  
o clinically -significant gastrointestinal bleeding within 6 months before the first 
dose of study treatment 
o hemoptysis of ≥0.5 teaspoon (2.5 mL) of red blood within 3 months before the first dose of study treatment 
o any other signs indicative of pulmonary hemorrhage within 3 months before the first dose of study treatment 
o The subject has radiographic evidence of cavitating pulmonary lesion(s) . Chest 
x-ray will not be required as part of this trial, unless cavitating pulmonary lesion 
is clinically suspected.  
• Other concurrent severe and/or uncontrolled medical disease which could compromise participation in the stud y (e.g. uncontrolled diabetes, uncontrolled hypertension, severe 
NF Protocol #105   Version 2. 1 
05/01/2019  
37 
 infection, severe malnutrition, chronic liver or renal disease, active upper GI tract 
ulceration)  
• Cardiovascular disorders including: 
o Congestive heart failure (CHF): New York Heart Association (NYHA) Class 
III (moderate) or Class IV (severe) at the time of screening  
o Any history of congenital long QT syndrome 
o Baseline QTc interval >470 msec in women and >450 msec in men  
 Concomitant treatment with medications that prolong the QT 
interval and have a known risk of Torsades de Pointes  is not 
contraindicated, but should be avoided if possible and will require more 
frequent EKG monitoring (see Section 6.3) . 
• Any of the following within 6 months before the first  dose of study treatment: 
o unstable angina pectoris 
o clinically -significant cardiac arrhythmias  
o stroke (including TIA, or other ischemic event) 
o myocardial infarction  
o thromboembolic event requiring therapeutic anticoagulation (Note: subjects with a venous filter (e.g. vena cava filter) are not eligible for this study)  
• Any of the fo llowing within 28 days before the first dose of study treatment: 
o intra-abdominal tumor/metastases invading GI mucosa  
o active peptic ulcer disease,  
o inflammatory bowel disease (including ulcerative colitis and Crohn’s disease), diverticulitis, cholecystitis, symptomatic cholangitis or appendicitis  
o malabsorption syndrome 
• Any of the following within 6 months before the first dose of study treatment: 
o abdominal fistula  
o gastrointestinal perforation  
o bowel obstruction or gastric outlet obstruction 
o intra-abdominal abscess. Note: Complete resolution of an intra -abdominal 
abscess must be confirmed prior to initiating treatment with cabozantinib even if the abscess occurred more than 6 months before the first dose of study 
treatment.  
• Other disorders associated with a high risk of fistula formation including PEG tube placement within 3 months before the first dose of study therapy  
• Other clinically significant disorders such as: 
o active infection requiring systemic treatment within 28 da ys before the first 
dose of study treatment 
o serious non- healing wound/ulcer/bone fracture within 28 days before the first 
dose of study treatment 
o history of organ transplant 
o concurrent uncompensated hypothyroidism or thyroid dysfunction within 7 days befor e the first dose of study treatment  
• History of major surgery as follows: 
NF Protocol #105   Version 2. 1 
05/01/2019  
38 
 o Major surgery within 3 months of the first dose of cabozantinib if there were no 
wound healing complications or within 6 months of the first dose of cabozantinib if there were wound c omplications  
o Minor surgery  within 1 months of the first dose of cabozantinib if there were no wound healing complications or within 3 months of the first dose of cabozantinib if there were wound complications 
• In addition,  complete wound healing from prior  surgery must be confirmed at least 28 
days before the first dose of cabozantinib irrespective of the time from surgery 
 
 
5.0 REQUIRED DATA 
 
IRB Approvals  
The PI from each participating institution will provide the NF Consortium Operations Center with a copy of the initial IRB protocol approval and the yearly IRB continuing reviews. The Study Coordinator will submit these to the USAMRMC ORP HRPO. Registration will be halted at a participating institution if a current continuing approval is not on file at the NF Consortium Operations Center.   Each participating institution is required to maintain a current MPA or FWA in order to participate in government -sponsored Group research.  The files will be copied or made available for review 
by authorized persons as required for conduct of this trial.  
Amendments and Consents  
The PI from each participating institution will provide the NF Consortium Operations Center with 
a copy of IRB approval of all amendments to the protocol or consent. The NF Consortium Operations Center will provide these institutional reviews to the USAMRMC ORP HRPO.  As 
this trial receives funding by the US Army, substantive amendments to the research protocol and any amendments that could potentially increase risk to subjects must be submitted to the HRPO for approval prior to implementation and site distribution. The USAMRMC ORP HRPO defines a substantive amendment as a change in Principal Inves tigator, change or addition of an 
institution, elimination or alteration of the consent process, change to the study population that has regulatory implications (e.g. adding children, adding active duty population, etc.), significant change in study design  (i.e. would prompt additional scientific review), or a change that could 
potentially increase risks to subjects.    
  
Data Collection and Toxicity Reporting 
The trial is being conducted by the NF Consortium.  Case report forms developed by the NF 
Consortium Operations Center will be used for submitting clinical data to the Operations Center.  
Data must be submitted to the Operations Center within two weeks of completing each required evaluation while the subject  is on study.  
 The NCI POB will receive MRI s tudies electronically or on CD and completed worksheets  for 
volumetric analysis .  When sending the CD, the site must provide tracking # (FedEx or UPS)  by 
email to Eva Dombi: dombie@mail.nih.gov
. 
 Upon analysis of these studies results will be transmitted to the NF Consortium Operations Center.  
NF Protocol #105   Version 2. 1 
05/01/2019  
39 
  
Biological specimens for banking will be handled and stored in the biorepository located in the Colket Translational Research Building at the Children’s Hospital of Philadelphia (CHOP), Philadelphia, PA.  The specimens will be under the management of the Center for Data Driven Discovery in Biomedicine (D3b) and the Biorepository Core (BioRC), according to their standard operating procedures (SOPs).  Samples will be stored at -80°C.  Biological specimens will be 
coded with a randomly generated study number prior to shipping to the biorepository in order to prevent identification of subjects and protect confidentiality.  The study number will not be derived from or related to information about the subject, and will not contain any elements of PHI.  The specimen number will be entered into the NF Consortium Operations Center eDES, thus providing a link between the specimen and the study data.  Specimens may be shared with outside investigators/laboratories, who may analyze (and store, if applicable) the samples. Shared 
specimens will be labeled only with a study number.  Requests for samples will be reviewed by the NF105 Study Chairs and the NFCTC Biology Committee.  If a subject w ithdraws consent to 
store samples after collection, existing samples in the biorepository will be destroyed; however, any samples already shared to an outside laboratory or other entity will not be destroyed and any data generated already from the samples will not be destroyed. 
 Representatives from the FDA, NF Consortium Quality Assurance Committee,  and the U.S. 
Army Medical Research and Material Command will have access to the data and research records.  
 Alyssa Reddy , MD  will serve as the medical monitor.  She will serve as a patient advocate and is 
independent of the clinical study team.  She will oversee the progress of the protocol, especially 
issues of individual subject/patient management and safety.  The medical  monitor is required to 
review all unanticipated problems involving risks to subjects or others, including all serious and unexpected adverse events associated with the protocol as defined in Section 10.0.  The monitor provides an unbiased written report of the event.   
 
Handling of Research Samples  
This study is conducted at NF Consortium Sites and coordinated by the NF Consortium 
Operations Center.   Sample labeling, collection and initial processing will be conducted as 
outlined in the study Appendix V  and VI . Blood samples obtained for  biomarker analysis will be 
sent to Riley Hospital for Children  (CCRC, Indiana School of Medicine)  for analysis .  Blood 
samples for pharmacokinetic analysis will be sent to Alturas Analytics.  Samples will be stored 
in designated  monitored freezers. The protocol specific subjec t ID number will identify 
samples.   Once analyzed for studies outlined in this protocol any remaining samples will be stored 
by Riley Hospital for Children until the study is complete, and the manuscript describing the study 
has been accepted for publication .  Any use of samples not outlined in this protocol  will require 
prospective IRB review and approval.  The study will remain open and status reported to the IRB 
until all samples have been analyzed, rep orted or destroyed. Unintentional loss or destruction of 
any samples will be reported to the IRB as part of  annual continuing reviews.  MRI studies of PN 
will be obtained as described in Appendix IV  and be sent on CD to the NCI POB. MRI studies 
will be loa ded on one of three Sun Workstations, which are password protected and allow access 
only to Drs Dombi, Widemann, or associate investigators on the trial. CDs will be stored in locked filing cabinets.  
 
Data and Center Audits  
NF Protocol #105   Version 2. 1 
05/01/2019  
40 
 The trial will be audited by the  NF Consortium Operations Center for compliance and safety. 
Independent monitors will visit participating sites and review case report forms and source 
documentation. Missing or spurious information and protocol deviations will be communicated 
in a report to the trial coordinating center .  Protocol deviations, which may result in compromise 
to safely administer study drug, or to determine study endpoints will be included in the annual protocol review to the USAMRMC ORP HRPO.    All unexpected and serious adverse events will be forwarded to the Medical Monitor, the Study PI, the FDA, Exelixis,  and the USAMRMC ORP HRPO by the NF Consortium Operations Center 
as defined in Section 8.0.   Volumetric MRI analysis will be used to determine disease progression, and subjec ts will not be 
removed from study based on 1- D or 2 -D MRI measurements or based on clinical measurement 
of superficial lesions.    
 
5.1 Tests and Observations   
See Section 9 .0 and Appendix I .  Unless otherwise noted, all tests to determine eligibility must be 
completed within 14 days of study entry. 
 
5.2 Records to be kept  
Subjec t Registration and Case Report Forms  
 
Subjec ts will be registered with the NF Consortium Operations Center  via the electronic data entry 
system (eDES) . Electronic and paper Case Report Forms  (CRFs)  will be developed by the 
Consortium Operations Center and PI.  All data must be entered into the eDES.  Sites have the 
option of maintaining  a printed copy of completed forms in the subject ’s study binder  that have 
been initialed and dated by the study team member entering the data into the paper case report form . 
 Subjects must not be identified by name on any study documents that are sent off site to any agency.  The Subject  Identification Number received upon data entry registration and placed on 
all case report forms and regulatory documents will identify subjects. 
 
All data entered on a paper  CRF must be legibly recorded in indelible  ink or typed.  A correction 
should be made by striking through the incorrect entry with a single line and entering the correct information adjacent to it.  The correction must be initialed and dated by the investigator or designated qualified individual.  Any requested information that is not obtained as specified in the 
protocol should have an explanation noted on the CRF as to why the required information was not obtained.  The electronic CRF provides audit trail showing when data is revised. 
 
5.3 Role o f Data Management 
 
5.3.1 Instructions concerning the recording of study data on CRFs will be provided by the NF Operations Center.  
5.3.2 It is the responsibility of the NF Operations Center to assure the quality of data for 
NF Protocol #105   Version 2. 1 
05/01/2019  
41 
 their study.  This role extends from protocol development to generation of the final 
study database.  
 
 
6.0 TREATMENT PROGRAM 
 
6.1 Treatment Overview  
This is a Phase 2, single -arm, open- label study of cabozantinib in subjects with plexiform 
neurofibroma.  The primary endpoint is the ORR to cabozantinib after  12 cycles (~ 12 months). In 
cohort A, subjects who did not achieve at least 15% reduction in index tumor after 8 cycles (~8 
months) were considered treatment failures and taken off study.  For cohort B ( pediatric cohort ), 
because of the overall excellent safety profile of cabozantinib and the numerous late tumor responses in cohort A (adult cohort) (see protocol section 2.3), the requirement to stop study 
treatment in subjects who do not achieve at least a 15% reduction in tumor volume by 8 cycles 
will be eliminated.   Of note , subjects may begin cycle 9 and 13 while central review of tumor 
response is ongoing.  For cohort  A, a Simon 2- stage design will be used.  In the first stage, 9 
evaluable subjects will be accrued.  If there is at least 1 response, accrual will continue to the 
second stage and an additional 8 evaluable  subjects will be enrolled.  In Cohort B, we will enroll 
a minimum of 17 evaluable subjects. To allow for up to 25% unevaluable subjects, a maximum of 24 subjects will be enrolled. Based on the preliminary response data (passed the threshold to move to stage 2) and minimal toxicity in Cohort A to date, a 2- stage design is not felt to be necessary for 
Cohort B.  For each cohort, if there are a total of 3 responses among the total of 17 evaluable  
subjects, cabozantinib will be considered of clinical interest in NF1 plexiform neurofibromas.    
6.2   Rationale for Cabozantinib Dose selection  
 
Cohort A: The dosing for this study was developed based on review of existing efficacy and 
safety data from available cabozantinib therapeutic trials.  A cabozantinib starting dose of 100 
mg qDay has been studied in 171 CRPC (castration- resistant prostate cancer) su bjects enrolled to 
the Phase 2 XL184-203 RDT.  Despite relatively high rates of dose reductions to the next lowest dose of 60 mg qDay within the first 12 weeks of therapy (51%), this starting dose resulted in high rates of pain relief, bone scan improvement, and overall disease control.  In addition, preliminary data from a separate and ongoing dose- ranging study looking at lower 
doses of cabozantinib in CRPC coupled with results from a retrospective review of the Phase 2 
XL184-203 RDT indicate that lower doses below 100 mg qd are likely to retain efficacy while 
improving upon tolerability: 
Preliminary results from an ongoing dose- ranging study : To date, 9 subjects with 
metastatic CRPC enrolled to the first cohort (starting dose of 40  mg qd) are evaluable fo r 
bone scan response. All 9 subjects exhibit evidence of response on bone scan including 
two complete responses. Although most subjects did not have pain at baseline, one 
subject reported pain at baseline, which resolved by Week  6. No dose reductions or 
interruptions have been reported to date, although one subject discontinued study 
treatment for fatigue that was present at baseline and another subject discontinued because of a pathologic fracture. This provides preliminary evidence that lower doses are pharmacologically active in a patient population with advanced CRPC.  
 
NF Protocol #105   Version 2. 1 
05/01/2019  
42 
 Retrospective review of Phase 2 XL184-203 RDT : While the overall rate of dose 
reduction from 100 mg to 60 mg was 51%, only 14% required an additional reduction in 
dose from 60 mg to the next lowest dose of 40 mg, which is consistent with an overall improvement in tolerability profile at the 60 -mg dose level. The majority (69%) of 
subjects with pain at baseline who experienced early dose reduction (before Week 6) to 60 mg went on to report pain improvement at Week  6. Moreover, 80% of these subjects 
remained progression-free and continued to report pain relief at the Week 12 time point. 
Thus the dose of 60 mg qd appears to offer improved tolerability while maintaining 
efficacy in a patient po pulation with advanced CRPC and cancer- related pain at baseline.  
 
Further analysis of the timing of AEs that led to dose reductions or interruptions was 
conducted. The median time to first AE triggering a dose reduction or interruption at 100 mg qd was 29 days, with very few subjects experiencing significant toxicity in the first 2 weeks of study treatment.  
 
As such, for Cohort A, this study will take a conservative approach to maximize safety and 
tolerability in our subjec t population.  This study will adopt a starting cabozantinib dose of 40 
mg qDay.  Subjects wi ll dose escalate after 2 cycles to 60 mg based on dose tolerability.  
Subjects who do not tolerate 40 mg will dose reduce to 20 mg (see section 7.0).  Doses will be capped at 60 mg.  The goal of t his regimen is to improve the overall tolerability of cabozantinib 
while maintaining efficacy in this subject  population.  The rationale for delaying dose escalation 
until cycle 3 is based on previous experience of AE with cabozantinib.  Because of the long half-life of cabozantinib, the median AE on previous trials was 29 days further justifying a later dose escalation schema.  
Rationale for Dose selection for Cohort B: 
The recommended Phase 2 dose in pediatric solid tumors was established by the recently completed COG Phase 1 trial to be 40 mg/m
2/day (see Section 2.3 ).  Based on this experience, 
this study will take a conser vative approach to maximize safety and tolerability in our subjec t 
population.  This study will adopt a starting cabozantinib dose of 30 mg/m2/day.  Subjects wi ll 
dose escalate after 2 cycles to 40 mg/m2/day based on dose tolerability.  Subjects who do not 
tolerate 30 mg /m2/day will dose reduce to 23 mg/m2/day (see section 7.0) .  Doses will be capped 
at 60 mg/day max daily dose .  The goal of this regimen is to improve the overall tolerability of 
cabozantinib while maintaining efficacy in this subject  population.  The rationale for delaying 
dose escalation until cycle 3 is based on previous experience of AE with cabozantinib.  Because of the long half-life of cabozantinib, the median AE on previous trials was 29 days further justifying a later dose escalation  schema.  
 Cabozantinib pharmacokinetics will be collected at steady state to compare drug kinetics and metabolism in this subject population compared to existing data from non- NF oncology subject s. 
(See Appendix I, VI)  
 
6.3 Administration, Dose, Schedule  and Route  
Treatment Program:   Subjects will receive cabozantinib orally once daily in continuous 
administration.  Cycles will be designated to last 28 days.  There will be no planned dose 
NF Protocol #105   Version 2. 1 
05/01/2019  
43 
 interruptions except holds for toxicity.  The starting dose will be cabozantinib free base 40 mg 
daily with dose escalation after 2 cycles to 60 mg free base if no dose- limiting  toxicity  (see 
section 7.0) experienced in the previous cycle.  Cabozantinib will be held for subjects who experience dose- limiting toxicity  until the toxicity grade has decreased to grade 1.  Cabozantinib 
will then be reduced by one dose level and not re-escalated in subsequent cycles.  Subjects who 
experience dose- limiting toxicit y at the 20 mg dose level will be off study.  If 2 or more subjects 
experience dose- limiting toxicity  at a particular dose level, study enrollment with be held while 
the DSMB reviews the toxicities.  Subjects already at that dose level who do not experience dose- limiting toxicity  may continue.   
 A cycle of therapy is considered to be 28 days, with the reporting period for each cycle being day 1 to day 28.  In the absence of progressive disease or dose limiting toxicity (DLT), subjects  may 
continue on therapy for a total of 12 total cycles .  Subjects  who have a radiographic response 
(20% or greater reduction in tumor volume) on therapy at  the end of 12 cycles  can continue on 
therapy for up to an additional year.  The maximum duration for treatment under this study design is 24 cycles .  In cohort A, subjects who did not achieve at least 15% reduction in index 
tumor volume after 8 cycles (~8 months) were considered treatment failures and taken off study.  For cohort B ( pediatric cohort ), because of the overall excellent safety profile of cabozantinib 
and the numerous late tumor responses in cohort A (adult cohort) (see protocol section 2.3), the requirement to stop study treatment in subjects who do not achieve at least a 15% reduction in tumor volume by 8 cycles will be eliminated .  Of note, subjects may begin cycle 9 and 13 while 
central review of tumor response is ongoing.  
Cabozantinib must be taken on an empty stomach.  Subjects must be instructed not to eat 
for at least 2 hours before and at least 1 hour after taking cabozantinib.  Subjects should be 
instructed to take their cabozantinib dose at approximately the same time  every day.  If a subject 
misses a dose, the dose may be taken later only if it is within 12 hours of when the missed dose should have been taken.  The missed dose should not be made up if it is within 12 hours of the 
next scheduled dose.   
 Cabozantinib tablets should be swallowed whole with at least 8 ounces of water.  The tablets should not be crushed. Grapefruit, grapefruit juice, Seville oranges and their products should be avoided by subjects taking cabozantinib.  
Cabozantinib should NOT be re- taken i f vomiting occurs after taking a scheduled dose.  
Dosing may continue the next day as scheduled.  
 
Medications that prolong the QT interval and have a known risk of Torsades de Pointes should 
be avoided if possible, but are not explicitly excluded.  Such medications include: amiodarone, 
arsenic trioxide, astemizole, azithromycin, bepridil, chloroquine, chlorpromazine, cisapride, citalopram, clarithromycin, disopyramide, dofetilide, domperidone, droperidol, erythromycin, escitalopram, flecainide, halofantrine, haloperidol, ibutilide, levomethadyl, mesoridazine, methadone, moxifloxacin, pentamidine, pimozide, probucol, procainamide, quinidine, sevoflurane, sotalol, sparfloxacin, terfenadine, thioridazine, vandetanib.  Because the lists of these agents are const antly changing, it is important to regularly consult a frequently updated list 
NF Protocol #105   Version 2. 1 
05/01/2019  
44 
 such as  www.azcert.org/medical -pros/drug- lists/list- 01.cfm?sort=Generic_name .  If the subject 
starts  such a medication, then EKG monitoring must be end of each cycle  while on the 
medication . 
 
Medications that may prolong the QT interval and have a possible risk of Torsades de Pointes 
(see http://www.azcert.org/medical-pros/drug- lists/list-02.cfm?sort=Generic_name ) should be 
avoided if possible, but are not explicitly excluded.  If the subject starts  a medication with 
substantial evidence that the drug prolongs the QT interval, then EKG monitoring must be end of 
each cycle  while on the medication . 
 Subjects or their parents/guardians will keep a diary to document the intake of each dose of cabozantinib and potential side effects.  Subjects  should be instructed to use the diary to record 
the date and time of each dose as well as observed side effects and supportive treatments used while on study. The subject may use the diary in Appendix III or a suitable alternative devel oped 
by the local institution .  The subject diary should be reviewed by the treating physician with the 
subject or subject’s family at each required clinical study evaluation.  In addition, leftover study medication should be collected at each on study evaluation, and drug should be accounted for at 
this time.   
 
All subjects will receive MRI measurements after 4, 8 , and  12 cycles .  Subjects who continue on 
drug beyond 12 cycle s will undergo imaging after 18 and 24 cycles. 
  
6.4  Criteria for starting subsequent cycles  
A cycle may be repeated every 28 days if the subject  does not have evidence of progressive 
disease and has again met laboratory parameters as defined in the eligibility criteria , with the 
exception of ANC , which must be >1000 to start each cycle. 
 
 
6.5  Dose escalation Schema  
 
Cohort A:  The starting dose will be 40 mg with dose escalation after cycle 2 if no DLT (as 
defined in section 7.2) is experienced in the first 2  cycle s.  Cabozantinib will be held for subjects 
who experience DLT  until the toxicity grade has decreased to grade 1.  Cabozantinib will then be 
reduced by one dose level and not re- escalated in subsequent cycles.  Subjects who experience 
toxicity at dose level -1 will be off study. 
 
 Dose Level   Dose (mg/dose) 
            -1                                    20 mg 
 1                             40 mg   2    60 mg  
Cohort B :  The starting dose will be 30 mg /m
2 with dose escalation after cycle 2 if no DLT (as 
defined in section 7.2) is experienced in the first 2  cycle s.  Cabozantinib will be held for subjects 
who experience DLT  until the toxicity grade has decreased to grade 1.  Cabozantinib will then be 
reduced by one dose level and not re- escalated in  subsequent cycles.  Subjects who experience 
toxicity at dose level -1 will be off study. 
NF Protocol #105   Version 2. 1 
05/01/2019  
45 
  
 Dose Level   Dose (mg/ m2/dose with max dose 60 mg/day) 
            -1                                    23 mg/m2 
 1                             30 mg /m2  
 2    40 mg/m2 
 Actual dosing will be based on the dosing nomogram in Appendix XI.  
6.6  Agent Information 
Composition, Formulation, and Storage 
At study sites, all study medication will be stored as described in the pharmacy manual and 
inventoried in accordance with applicable state and federal regulations.  
Investigational Treatment  
Chemical Name:  Chemical Name: N-{4-[(6,7 -dimethoxyquinolin -4-yl)oxy]phenyl} -N’-
(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-
hydroxybutanedioate 
Cabozantinib Tablets and Storage 
Exelixis internal number: XL184  
Cabozantinib tablets are supplied as film coated tablets containing cabozantinib malate 
equivalent to 20 mg and 60 mg of cabozantinib and contain microcrystalline cellulose, lactose anhydrous, hydoxypropyl cellulose, croscarmellose sodium, colloidal silicon dioxide, magnesium stearate and Opadry® yellow. All tablet strengths are prepared from a common blend and are distinguished by shape. The 20 mg tablets are round and the 60 mg tablets are oval.  The components of t he tablets are listed in the table below.  
 
Table  Cabozantinib Tablet Components and Composition  
Ingredient   Function  % w/w  
Cabozantinib malate (25% drug load as cabozantinib)  Active Ingredient  31.7 
Microcrystalline Cellulose (Avicel PH -102) Filler  38.9 
Lactose Anhydrous (60M)  Filler  19.4 
Hydroxypropyl Cellulose (EXF)  Binder  3.0 
Croscarmellose Sodium (Ac -Di-Sol) Disenegrant  6.0 
Colloidal Silicon Dioxide,  Glidant  0.3 
Magnesium Stearate  Lubricant  0.75 
Opadry Yellow Film Coating which includes:  
- HPMC 2910 / Hypromellose 6 cp  
- Titanium dioxide  
- Triacetin  
- Iron Oxide Yellow  Film Coating  4.00 
Cabozantinib should be stored at controlled room temperature (20◦C to 25◦C, 68◦F to 77◦F) 
NF Protocol #105   Version 2. 1 
05/01/2019  
46 
 7.0  MODIFICATIONS FOR ADVERSE EVENTS  
 
7.1 General Guidelines for Treatment Delay, Dose Reduction, or Study Drug 
Discontinuation for Toxicity 
Subjects will be monitored continuously for AEs throughout the study and for 30 days after the last dose of study treatment, and for any serious adverse event (SAE) assessed as related to study treatment or study procedures, even if the SAE occurs more than 30 days after the last dose of study treatment.  
 Subjects will be instructed to notify their physician immediately of any and all AEs.
 Subjects 
experiencing one or more AEs due to the study treatment may require a dosing delay or reduction(s) 
in their dose in order to continue with study treatment.   
7.2   Definition of Dose -Limiting Toxicity (DLT) 
Dose Limiting Toxicity Criteria  
 
Adverse events will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) (v4.0). Dose -limiting toxicity is defined as any of the 
following adverse events occurring during the DLT evaluation period that  are at least possibly 
related to cabozantinib.  DLT evaluation period is cycles 1 and 2 on initial dose, and cycles 3 and 4 for subject s who 
increase dose.  
 
For adverse events meeting the DLT definition at any time, dose limiting hematological and non-
hematological toxicities  are handled differently. For hematologic toxicities , there must be recovery 
to meet eligibility or baseline parameters within 14 days of drug discontinuation. For general non -
hematologic toxicities , there must be recovery  of the dose- limiting toxicity  to (less than or equal) 
≤ Grade 1  or to meet eligibility or baseline parameters within 14 days of drug discontinuation .  
Dose modification parameters for specific non -hematologic toxicities  including proteinuria, 
hypertension, deep vein thrombosis, liver toxicity, pancreatic toxicity  and diarrhea are addressed 
in section 7.3.  If the required recovery for either hematol ogic or non- hematologic toxicity occurs 
within 14 days, then the subject may re -start Cabozantinib, but the dose will be reduced to the 
previous dose level.  If the subject is at 20 mg dose and does not meet the parameters for recovery 
by 14 days, then the subject will be off study. 
 
Dose limiting hematological and non-hematological toxicities are def ined differently.  
Non-Hematological Dose  Limiting Toxicity  
 Any Grade 3 or Grade 4 non- hematological toxicity attributable to the 
investigational drug with the specific exclusion of: 
- Grade 3 nausea and vomiting of < 3 days duration 
- Grade 3 diarrhea ≤ 3 days duration - Grade 3 liver enzyme elevation, including ALT/AST/GGT/bilirubin, that return to levels that meet initial eligibility criteria or baseline within 7 days of study drug interruption and that does not recur upon re -challenge 
with  Cabozantinib. Note: For the purposes of this study the ULN for 
ALT is defined as 45 U/L.  
NF Protocol #105   Version 2. 1 
05/01/2019  
47 
 - Grade 3 fever < 5 days duration. 
- Grade 3 electrolyte abnormalities  responsive to supplementation within 
one week.  
- Grade 3 asymptomatic amylase or lipase elevati on that resolves to ≤ 
Grade 1 within 7 days of study drug interruption and that does not recur upon re- challenge with cabozantinib.   
- Grade 3 proteinuria, if confirmed by repeat P/C ratio obtained within 72 
hours of first measurement. 
 
• Dose -limiting hyp ertension  
a. Any Grade 4 hypertension  
b. A blood pressure >25 mmHg above the 95th percentile for age, height, and 
gender confirmed by repeated measurement is dose limiting.  
c. In subject s who begin antihypertensive therapy a blood pressure > 10 mmHg but 
≤ 25 mmHg above the 95th percentile for age, height, and gender  for > 14 days 
is dose limiting.  
 
• Any Grade 2 non -hematological toxicity that persists for ≥ 7 days and 
is considered sufficiently medically significant or sufficiently intolerable by subject s that it requires treatment interruption.  
 
• Any toxicity requiring interruption of study drug for ≥ 7 days or which recurs upon drug challenge.  
 
• Note: Allergic reactions that necessitate discontinuation of study drug will not be considered a dose- limiting toxicity.  
 
Hematological dose limiting toxicity  
Hematological dose limiting toxicity is defined as:  
 
• Grade 3 febrile neutropenia of > 5 days duration  
• Grade 4  neutropenia 
• Grade 3 thrombocytopenia (platelets < 50,000) 
• Grade 3 anemia (Hb < 8 ) 
 
 
 
7.3   D ose Modifications For Adverse events  
 
The Study Chair must be notified of any dosage modification or use of myeloid 
growth factor.  Dose Modifications for Hematological Toxicity 
If a subject  experiences dose- limiting Grade 4  neutropenia or grade 3 
thrombocytopenia, the treatment will be withheld. Counts should be checked every 3 - 4 days for thrombocytopenia and every other day for 
NF Protocol #105   Version 2. 1 
05/01/2019  
48 
 neutropenia during this time. If the toxicity resolves to meet eligibility 
parameters within 14  days of drug discontinuation, the subject  may resume 
treatment at the next lower dose level. Doses reduced for toxicity will not be re -escalated, even if there is minimal or no toxicity with the reduced 
dose.  
 
If dose- limiting toxicity does not resolve to meet eligibility or baseline parameters 
within 14 days of drug discontinuation, the subject  must be removed from 
protocol therapy. 
 If dose- limiting toxicity recurs in a subject who has resumed treatment at the 
reduced dose, the subject  must be removed from protocol therapy. 
 
Dose Modifications for Non-Hematological Toxicity 
If a subject experiences non -hematological dose -limiting toxicity, the treatment 
will be withheld. If the toxicity resolves to (less than or equal  to) ≤ grade 1 
or to meet eligibility or baseline parameters within 14 days of drug 
discontinuation, the subject  may resume treatment at the next lower dose 
level. Doses reduced for toxicity will not be re -escalated, even if there is 
minimal or no toxicity with the reduced dose. 
 
If dose- limiting toxicity does not resolve to (less than or equal to ) ≤ grade 1 or to 
meet eligibility or baseline parameters within 14 days of drug 
discontinuation, the subject  must be removed from protocol therapy. 
 
If the same dose- limiting toxicity recurs in a subject who has resumed treatment 
at the reduced dose level, the subject  must be removed from protocol 
therapy.  
 
Dose Modifications for Proteinuria  
• If urinalysis shows ≥ trace protein then obtain urine protein/creatinine 
(P/C) ratio .   
• If the urine P/C ratio is >1, consider confirming with a 24 hour protein assessment within 7 days.  
• If the urine P/C ratio ≤ 1.9 continue cabozantinib. If subject  has Grade 
3 proteinuria (urine P/C ratio >1.9), a second measurement should be obtained within 72 hours. A second confirmation of Grade 3 proteinuria will be considered a DLT.  
• If the second measurement confirms Grade 3 proteinuria (urine P/C ratio >1.9), then interrupt cabozantinib treatment and re- assess weekly.   
• If cabozantinib is held for ≥ 14 days then remove from protocol therapy.  
If the urine P/C ratio decreases to ≤ 1.9 in < 14 days then resume cabozantinib at a lower dose.  
• Monitor the urine P/C ratio weekly for 2 consecutive weeks once 
protocol therapy resumes and obtain a 24- hour collec tion if ≥ 1 as above. 
• Cabozantinib should be discontinued in subjects who develop nephrotic 
NF Protocol #105   Version 2. 1 
05/01/2019  
49 
 syndrome (proteinuria > 3.5 grams per day in combination with low 
blood protein levels, high cholesterol levels, high triglyceride levels, and edema).  
 
 
Dose Modifi cations for Hypertension  
• Baseline blood pressure (BP) is defined as the blood pressure obtained 
at the examination used for study enrollment. This baseline BP should be obtained as follows: 1) Obtain 3 serial blood pressures from the same extremity with th e subject  in the same position at rest with an 
appropriately sized cuff that are separated by at least 5 minutes. Avoid using the lower extremity if possible. 2) Average the systolic blood pressure from the 2
nd and 3rd measurements. 3) Average the diastoli c 
blood pressure from the 2nd and 3rd measurements. 4) The baseline BP is 
the average of the systolic over the average of the diastolic measurements.  
• Elevation  in either the systolic or diastolic blood pressure should be 
considered when following the algorithm below. 
• The upper limit of normal (ULN)  is defined as a BP equal to the 95th 
percentile for age, height, and gender. . 
• The NCI CTCAE will be utilized to determine the grade of hyper tension 
for reporting purposes. 
• Elevated BP measurements should be repeated on the same day to 
confirm the elevation. If confirmed, subject s with elevated BP should 
have BP measurements performed at least twice weekly until BP is ≤ 
ULN.  
• The algorithm below will be used to manage cabozantinib - related 
hypertension. 
• Hypertension should be managed with appropriate anti -hypertensive 
agent(s) as clinically indicated. It is strongly recommended that nephrology or cardiology be consulted in the  evaluation and management 
of hypertension.  
NF Protocol #105   Version 2. 1 
05/01/2019  
50 
  
 
 
 Arm 1 of algorithm:  
• If blood pressure (BP) ≤ 95% for age, height, and gender, continue cabozantinib  at the 
same dose.  
 
 
Arm 2 of algorithm:  
• If BP ≤ 10 mm Hg above the ULN for age, height, and gender, continue  cabozantinib  
at the same dose and recheck the BP within 72 hours.  
o If the BP is ≤ ULN on recheck, continue cabozantinib  at the same dose.  
o If the BP remains above the ULN on recheck, then start antihypertensive therapy 
(Section 8) and follow Arm 3 of the algorithm from the point that anti -hypertensive 
therapy is started.  
 
 
Arm 3 of algorithm:  
• If BP is 11 to 25 mm Hg above the 95% for age, height, and gender on ≥ 2 of 3 measurements or > 35 mmHg above baseline on ≥ 2 of 3 measurements, start anti-
hypertensive therapy (see Section 8), continue 
cabozantinib  at the same dose, and 
monitor BP at least twice weekly.  

NF Protocol #105   Version 2. 1 
05/01/2019  
51 
 o If the BP returns to ≤ ULN within 14 days, continue cabozantinib  at the same 
dose and continue anti -hypertensive therapy.  
o If the BP rem ains elevated ≤ 25 mm Hg above the 95% or > 35 mm Hg above 
baseline for more than 14 days after the institution of anti -hypertensive therapy, 
hold cabozantinib , monitor BP at least every 3 days, and follow Arm 4 of the 
algorithm from the point that cabozan tinib  is held. The antihypertensive therapy 
should be continued until the BP is less than the ULN.  
 If the BP returns to ≤ ULN within 14 days, restart cabozantinib  at a reduced 
dose (Section 6. 5). 
 If the BP remains > ULN for more than 14 days, subject  is Off Protocol 
Therapy. 
o  If the BP increases to > 25 mm Hg above the ULN despite anti -hypertensive 
therapy, hold cabozantinib , but continue the anti -hypertensive agent(s). Monitor 
the BP as clinically indicated and follow Arm 4 of the algorithm from the point 
that cabozantinib  is held.  
 If the BP is ≤ ULN within 14 days, cabozantinib  may be restarted at a reduced 
dose (Section 6. 5). 
 If the BP is > ULN for > 14 days, the subject  is Off Protocol Therapy ( Section 
11.1).  
 
Arm 4 of algorithm:  
• If BP is > 25 mm Hg above the 95% for age, height, and gender hold cabozantinib , 
monitor BP and administer anti -hypertensive therapy as clinically  indicated.  
o If the BP returns to ≤ ULN within 14 days, cabozantinib  may be restarted at a  
reduced dose ( Sectio n 6.5). 
o If the BP is > ULN for >14 days, the subject  is Off Protocol  Therapy . 
 
 
Arm 5 of algorithm:  
• If the participant develops Grade 4 hypertension, discontinue  cabozantinib , monitor 
BP and administer anti -hypertensive therapy as clinically  indicated. The  subject  is Off 
Protocol Therapy . 
 
 
 
Deep Venous Thrombosis  
If a subject  develops a DVT while on cabozantinib, they will be taken Off Protocol 
Therapy . 
 
Dose Modifications for Liver Toxicity 
Cabozantinib should be held for grade 3 elevation of ALT, AST or bilirubin. Note: 
For the purposes of this trial the ULN for ALT is defined as 45 U/L. Cabozantinib 
may be re -administered at the same dose if levels of ALT, AST and bilirubin meet 
eligibility criteria or baseline within 7 days of drug discontinuation. Elevated laboratory parameters should be checked at least twice weekly until eligibility criteria are met.  
 If lab values do not resolve to initial eligibility criteria or baseline within 7 days of interruption or if toxicity recurs with re -challenge, then this will be considered 
dose- limiting.  Cabozantinib will then be dose -reduced when eligibility criteria are  
NF Protocol #105   Version 2. 1 
05/01/2019  
52 
 met. 
 
Dose Modifications for Pancreatic Toxicity 
Cabozantinib should be held if subject experiences Grade 3 asymptomatic amylase 
or lipase elevation. Elevated laboratory parameters should be checked at least twice 
weekly until ≤ Grade 1.  If lab v alues do not resolve to ≤ 1 Grade within 7 days of interruption or if toxicity 
recurs with re -challenge, then this will be considered dose -limiting.  Cabozantinib 
will then be dose-reduced when eligibility criteria are  met.  
 
Dose Modifications for Diarrhea  
• If dose -limiting Grade 3 (> 3 days) or Grade 4 therapy -associated diarrhea 
is experienced by a subject  despite maximal use of anti- diarrheal 
medications, the dose of Cabozantinib should be  held and reduced to the 
next lower dose level  once the diarrhea has resolved . Doses reduced for 
toxicity will not be re -escalated, even if there is minimal or no toxicity with 
the reduced dose.  
• If dose -limiting Grade 3 (> 3 days) or Grade 4 diarrhea recurs despite 
maximal use of anti- diarrheals and dose reduction, the subject  should come 
off protocol therapy. 
• Treatment of Diarrhea:  Each subject will be instructed to have Loperamide 
available and begin treatment at the first episode of poorly formed or loose stools or at the earliest onset of bowel movements more frequent than normally expected for the subject .  Subject s will also be instructed to contact 
their physician if any diarrhea occurs.  Take 4 mg (4 teaspoonfuls of the 1 mg/5mL solution or 2 capsules/tablets) after the first loose bowel movement, followed by 2 mg  (2 teaspoonfuls of the 1 mg/5mL oral solution 
or 1 capsule/tablet) every 2 hours.  During the night, the subject  may take 4 
mg (4 teaspoonfuls of the 1 mg/5 mL oral solution or 2 capsules or tablets) every 4 hours.  Do not exceed 16 mg per day. 
 8.0   SUPPORTIVE CARE AND OTHER CONCOMITANT THERAPY  
 
Concurrent Anticancer Therapy  
Concurrent cancer therapy, including chemotherapy, radiation therapy, immunotherapy, or biologic therapy may NOT be administered to subject s 
receiving study drug. If these treatments are administered the subject  will be 
removed from protocol therapy.  
Investigational Agents 
No other investigational agents may be given while the subject  is on study. 
 
Supportive Care  
Appropriate antibiotics, blood products, anti -emetics, fluids, electrolytes and general 
supportive care are to be used as necessary. See Section 4.1 for drugs that should not 
NF Protocol #105   Version 2. 1 
05/01/2019  
53 
 be used concomitantly due to potential interactions with cabozantinib. 
 
Diarrhea is a common side effect of cabozantinib. Loperamide should be used at the first sign of significant diarrhea.  
 Palmar -plantar erythrodysesthesia syndrome (PPE; also known as hand- foot 
syndrome) is a common side effect of cabozantinib. Careful att ention should be paid 
to skin exams and supportive care instituted early if any swelling or erythematous skin changes or symptoms of pain or burning/tingling are noted. Subject s should be 
instructed to apply moisturizing creams, avoid any trauma, harsh che micals and limit 
hot water exposure. Topical steroid creams may be used and consider early dermatology referral  (please see APPENDIX X for suggested prophylaxis and 
treatment for PPE) .   
 
Growth Factors  
Growth factors that support platelet or white cell nu mber or function can only be 
administered for culture proven bacteremia or invasive fungal infection. The Study Chair should be notified before growth factors are initiated. 
 
Concomitant Medications  
Medications that are strong inhibitors or inducers of CYP3A4 should be avoided   The use of enzyme inducing anticonvulsants is not permitted.   Medications that prolong the QT interval and have a known or possible risk of Torsades de Pointes should be avoided if possible, but are not explicitly excluded (see section 6/3)  
Surgery  
Subject s should not have elective surgical procedures while on therapy. For 
subject s who require emergent or urgent procedures  (including dental surgery or 
invasive dental procedures ), cabozantinib should be stopped at least 28 days prior 
to procedure, if feasible .  Therapy may not be restarted until adequate wound 
healing (at least 2 weeks  after major procedures , 7 days after minor procedures such 
as port-a- catheters, and  3 days for external lines [e.g. Hickman or Broviac]. 
 
Concurrent Anti -Hypertensive Therapy  
The algorithm above will be used to grade and manage cabozantinib related hypertension. Should initiation of anti -hypertensive therapy be required, single 
agent therapy (commonly including the calcium channel blockers amlodipine or nifedipine, which are permissible without discussion with the study chair) should be started and the blood pressure should be monitored at least twice weekly until BP is within the 95
th percentile for age, height, and gender. 
 
Management of Hypothyroidism 
NF Protocol #105   Version 2. 1 
05/01/2019  
54 
 Subjects with Grade 2 hypothyroidism adequately managed with thyroid hormone 
replacement may continue on protocol therapy. Subjects with Grade 3 or greater hypothyr oidism will be considered to have had a dose -limiting toxicity. These 
subjects should be managed according to guidelines for non- hematologic toxicity 
and should also be evaluated by an endocrinologist for further management. Subjects who enter the study on  thyroid replacement should have their medication 
adjusted to maintain TSH in the normal range.   
 9.0 EVALUATIONS/MATERIAL
 AND  DATA  TO BE ACCESSIONED  
 Pre and on study evaluations are described in Appendix I. 
 
9.1 Required Clinical, Laboratory and Disease Evaluation 
All entry/eligibility studies must be performed within 2 weeks prior to enrollment into the trial.  
The baseline MRI study documenting disease status is required within 4 weeks prior to study entry.  
Entry/eligibility studies (laboratory and MR I) may be counted as the baseline (pre- study) studies, 
as long as there has been no concerning change in clinical status prior to starting study drug (which must start within 14 days of enrollment).  
 
9.2 History and physical examination and vital signs 
Physical examination will be performed prior to entry, at Day 15 +3 days, at the end of cycle  1 +1 
week, at cycle  2 Day 15 +1 week, at the end of cycle  2 +1 week, at cycle  3 Day 15 +1 week, at the 
end of cycle  3 +1 week, after cycle s 4-12 +2weeks , and after cycles  14, 16, 18, 20, 22, 24 +2weeks .  
In addition, at the end of treatment +2 weeks if this is not encompassed in the times above. The 
exam must comprise a total body examination (general appearance, skin, neck, including thyroid, eyes, ears, nose, throat, lungs, heart, abdomen, back, lymph nodes, extremities and basic nervous system). Significant findings made after the start of study drug which meet the definition of an Adverse Event must be recorded.  
Vital sign assessment consists of height (first vis it in Cohort A, and every visit in Cohort B), pulse, 
blood pressure, respiration rate, oxygen saturation by pulse oximeter , temperature and weight. 
Blood pressure, pulse and respiration rate should be measured on subject s after at least 3 minutes 
in the si tting position.  
  
9.3 Phone Call
 
Subjects will be called to assess drug compliance and toxicity at the end of cycles 13, 15, 17, 19, 
21, 23 + 2weeks . 
 
9.4 Laboratory Testing 
CBC with differential and platelets, comprehensive metabolic panel with Ca, Mg, Phos, lipase, 
and amylase must be performed  within two weeks prior to entry on trial, at Day 15 +3 days, at the 
end of cycle  1 +1 week, at cycle  2 Day 15 +1 week, at the end of cycle  2 +1 week, at cycle  3 Day 
15 +1 week, at the end of cycle  3 +1 week, and after cycle s 4-24 +2weeks.  In addition, at the end 
of treatment +2 weeks if this is not encompassed in the times above.   
 
NF Protocol #105   Version 2. 1 
05/01/2019  
55 
 PT, PTT, INR must be performed  within two weeks prior to entry on trial, at the end of cycle s 1-
3 +1 week, and after cycle s 4-24 +2weeks.  In addition, at the end of treatment + 2 weeks if this is 
not encompassed in the times above. 
 
Urinalysis must be performed  within two weeks prior to entry on trial, at the end of cycle s 1-3 + 1 
week, and after cycle s 4-24 + 2weeks.   In addition, at the end of treatment +2 weeks if this is not 
encompassed in the times above. 
 
Urine protein:creatinine ratio must be performed within two weeks prior to ent ry on trial, at the 
end of cycle s 1-3 + 1 week, and after cycle s 4-24 + 2weeks.   In addition, at the end of treatment +2 
weeks if this is not encompassed in the times above. 
 
Thyroid stimulating hormone must be performed  within two weeks prior to entry on tr ial, at the 
end of cycle  1 +1 week, at the end of cycle  3 +1 week, after cycle s 6, 9, 12, 16, 20, 24 +2 weeks.  
In addition, at the end of treatment +2 weeks if this is not encompassed in the times above. 
 
Urine or serum pregnancy test tests will be given to all females of childbearing age within 7 days 
prior to starting treatment medication.  In addition, tests will be administered at the end of cycle s 
2 +1 week, and after cycle s 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 + 2weeks.   In addition, at the end 
of treatment +2 weeks if this is not encompassed in the times above. 
 
9.5 EKG  
12-lead EKG should be performed within two weeks prior to entry on trial, at the end of cycle  1 
+1 week, after cycle  2 +1 week, and after cycle s 4, 6, 9, 12, 16, 20, 24  +2weeks.   In addition, at 
the end of treatment +2 weeks if this is not encompassed in the times above. 
 9.6 MRI for volumetric analysis of plexiform neurofibroma 
 
Evaluate the plexiform neurofibromas(s) by MRI withi n 4 weeks prior to cycle  1 and after cycle s 
4 +2 weeks, 8 +2 weeks, 12 +2 weeks, 18 +2 weeks, and 24  +2 weeks while on study and at end 
of study +2 weeks.   To evaluate the durability of response, s ubjects who responded while on 
treatment, will be recommended but not required to have a follow- up MRI scan at approximately 
4 months and 12 months following completion of therapy.  If a subject starts another tumor -
directed therapy during the one year follow- up time , then they are off-study (and no further MRIs 
requested).  See Appendix IV for imaging protocol. 
 9.7 Quality of Life and Pain Evaluations (Required)  
This study will evaluate quality of life, pain intensity, and pain interference in patients during 
treatment with cabozantinib. The Pediatric Quality of Life Inventory (PedsQL) NF1 Module 
(Adult and Teen self- report forms) will be used to assess disease -specific QOL  in subjects 16 
years and older (see table below) .  The Pediatric Quality of Life Inventory (PedsQL) Generic 
Core Scales will be used to assess general health related QOL  in children 3-15.     
 
Pain intensity in both cohorts will be assessed by self -report with the Numeric Rating Scale -11 
(NRS -11) and pain interference will be measured by the Brief Pain Inventory (BPI) Interference 
Scale in subjects > 16 and the Pain Interference Index in subject s 5-15 years .  The following 
NF Protocol #105   Version 2. 1 
05/01/2019  
56 
 table summarizes the quality of life and pain questionnaires to be completed by age of the 
subjects.     Quality of Life and Pain Questionnaires to be Completed by Age of Subject at Study Entry  
Subjects >16 years  
 
Questionnaire  Age of Subject  (years) 
at Study Entry  
 16-20* 21+*  
Disease Specific QOL  
Subject : PedsQL NF1 Module -Teen  
      or     Peds QL NF1 Module -
Adult   
X  
X 
Pain  
 Age of Subject  (years)  
 16+**  
Subject : NRS -11 Pain Intensity  X 
    and    BPI -Pain Interference  X 
 
 Background Information Forms to be Completed by the Subject
 
 
 
 
 
*If subject s are 21 years old at study entry, they should be administered the Adult PedsQL NF1 Module. If subject s 
are 16 to 20 years old at study entry, they should be administered the Teen PedsQL NF1 Module.  However, if 
subject s turn 21 years old during the study,  they should continue to be administered the Teen version of this scale 
that they started at study entry.  
**All subject s should complete the same self -report pain intensity and pain interference measures and background 
form.  
Patient  Questionnaire  Age of Patient (years)  
 3 - 7 8 - 15 
Pain Intensity    
Patient self-report:  Numeric Rating Scale -11  √ 
Pain Interference    
Patient self-report:  Pain Interference Index   √ 
Global Impression of Change    
Patient self-report:  Global Impression of Change 
Scale  √ 
(follow -up evaluations only)  
General QOL    
Patient self-report:  PedsQL Acute form   
 √ 
8 - 12 
(Child)  √ 
13 - 18 
(Teen)  Questionnaire  Age of Subject  (years)  
 16+**  
Background Information  
All subject s 
QOL Background Form  X 
NF Protocol #105   Version 2. 1 
05/01/2019  
57 
  
Subjects 3 – 15 years  
 
 
Paren t Questionnaires  Age of Patient (years)  
 3 - 7 8 - 15 
Background Information    
Parent report:  Pediatric Background Form  √ √ 
Pain Interference    
Parent proxy report : Pain Interference Index   √ 
(5 - 7) √ 
Global Impression of Change     
Parent  report :  Global Impression of Change Scale   √ 
(5 - 7; follow -
ups evals only)  √ 
(follow -up evaluations only)  
General QOL    
Parent proxy report:  PedsQL Acute form  √ 
2 - 4 
(Toddler) √ 
5 - 7  
(Young Child)  √ 
8 - 12 
(Child)  √ 
13 - 18 
(Teen)  
 
 
Clinician Questionnaire  Age of Patient (years)  
 3 - 7 8 - 15 
Global Impression of Change    
Clinician  observer report : Global Impression of 
Change Scale  √ 
(follow -up evaluations only)  √ 
(follow -up evaluations only)  
√ Administer items with a check mark under the correct age range of the patient  
  
To allow for more meaningful analysis of the QOL data, the subject  (for those > 16 years) and the 
parent/primary caregiver (for pediatric subjects 3 – 15 years ) also will complete a background 
information form at study entry and each QOL assessment.  This form will collect general information such as their level of education, work /school status, psychiatric diagnoses, and pain 
medications, as well as the visibilit y of NF1 tumors and severity of NF1 symptoms. 
 
These forms should be completed pre- treatment, after cycle  4 +2 weeks, 8 +2 weeks, 12 +2 
weeks, 18 + 2 weeks, and 24 +2 weeks.  In addition, at the end of treatment +2 weeks if this is not 
encompassed in the times above.  When administering these forms, review the instructions with the subjects and check to make sure they answered all the items.  If subject s have difficulty 
reading, it is permissible to read the items to them, but the subject s should answer the items 
themselves.  Completed forms should be sent (fax or mail copies) to the NF Consortium 
Operations Center within 2 weeks of completion.  For any questions regarding the QOL/pain assessment please contact: Pam  Wolters at 
woltersp@mail.nih.gov .  See Appendix VII  for a 
description of the QOL and pain measures and forms. 
NF Protocol #105   Version 2. 1 
05/01/2019  
58 
  
The QOL documents will be reviewed centrally by Dr. Pam Wolters.  If any responses are noted that suggest serious emotional distress, the PI at the subject’s site will be notified.  The site PI will be responsible for acknowledging to Dr. Wolters receipt of these concerns and for initiating appropriate action as deemed clinically necessary.  
 
9.8 Biomarker studies  
1.  Plasma biomarker (cytokine) assays will be performed using multiplex simultaneous 
quantification of thirty soluble cytokines and growth factors including: VEGF, TGF-β, PDGF-AB/BB, MCP -1, MIP1α, MIP1β, TNFα, GM- CSF, EGF, IL -13, IL -1rα, IL -10, IL -4, IL6, FGF -2, 
and RANTES. The multiplex assay will be performed according to the manufacturer’s protocol (Millipore Milliplex, Billerica, MA) and analyzed on a Luminex 200 cytometer with StarStation software (Luminex Corp, Austin, TX). Plasma samples for each subject  and each treatment time 
point will be stored at -80C and thawed once for simultaneous assay.  Samples will be collected 
within two weeks prior to cycle 1, at Day 15 +3 days, at the end of cycles 2 +1 week , and at the 
end of cycles 4 +1 week . 
 Rationale:  It has been well recognized  that cytokines mediate and regulate immunity and  
inflammation, which are an important component of the biological milieu associated with cancer progression.  Cytokines have been used as biomarkers in research for prognosis and have been associated with sy mptoms and adverse outcomes in multiple conditions, including cancer.  We 
have previously shown that multiple cytokines/growth factors are altered in subject s with 
plexiform neurofibromas as well as in tumor murine model of NF1.  Our unpublished data suggest that the cytokine levels are associated with tumor progression and responsiveness to Gleevec therapy.  The examination of cytokine patterns has been limited by traditional laboratory methods.  Multiplex now permits the characterization of a broader arra y of cytokines in a single 
specimen.  Because cytokines operate in integrated networks, a more complete understanding will be gained as multiple cytokines can be examined for patterns of response that may be associated with response to the treatment and th e prognosis of NF1. 
 Please see Appendix V for details regarding obtaining sample and shipment.  
2.  Polychromatic Flow Cytometry (PFC)  & Identification of Circulating Progenitor Cells 
(CPCs ):  PFC for the identification of CPCs will be performed at three time points.  Whole blood 
will be drawn in EDTA tubes and sent for processing to the Indiana University Simon Cancer Center’s Angiogenesis, Endothelial and Pro- Angiogenic Cell Core (AEPCC) Fa cility, which is 
directed by Dr . Karen Pollok.  Using the PFC protocol developed by Dr. Case (Estes et al., 
Current Protocols in Cytometry), the phenotypic detection and enumeration of CPCs will be performed, and the ratio of pro- angiogenic (i.e.  CD133+) vs. non- angiogenic CPCs will be 
calculated on all samples.  Data obtained will then be correlated with tumor response.   Samples 
will be collected within two weeks prior to cycle 1, at Day 15 +3 days, at the end of cycles 2 +1 
week , and at the end of cycles 4 +1 week  and sent immediately to the AEPCC Facility . 
 
9.9 Biological Specimens for banking (Appendix XV) 
Blood Samples  will be drawn at baseline (pre- treatment), after course 4 (+2 weeks), after course 
12 (+2 weeks), and at the end of treatment (+2 weeks) if this is not encompassed in the times 
NF Protocol #105   Version 2. 1 
05/01/2019  
59 
 above.   In addition, blood samples should be drawn around the time of tumor biopsy if tumor 
tissue is being submitted.  
 The following will be collected at each time point: 
• Streck tube (for plasma):  ~ 2 mL.  
• EDTA tube (for DNA):  ~ 5 mL.   
• PAXGene tube (for RNA) ~ 2.5 mL. 
 Tubes should be inverted at least 10 times after being drawn.  The samples will only be obtained if the total blood volume does not exceed 5 mL/kg.  If not enough blood can be drawn for all tubes, the priority order for obtaining the specimens is:   1) Streck tube, 2) EDTA tube, 3) PAXGene tube.  Label the spe cimens with the specimen labels provided with the specimen kit.  
 Blood specimens must be shipped (unprocessed) same day at ambient temperature to the biorepository by overnight delivery using shipping container provided by the biorepository (see Appendix XV ). 
 Tumor Tissue  (optional) will be collected from subjects undergoing a clinically indicated 
procedure and who consent: 
• Fresh frozen tissue:  1- 2 pea sized aliquots (~ 0.3 cm3, equivalent to 0.8 cm in diameter) 
of excess (left over) tumor tissue.  Place each aliquot in a separate cryovial and label the specimen with subject’s study number. Snap freeze the aliquots in liquid nitrogen (preferred) or dry ice and then store in a freezer at -80°C or below until they can be sent to 
the biorepository. 
• 1 H&E stai ned slide cut from each submitted piece to confirm tumor is present.  
• If fresh frozen tissue is unavailable, please submit processed DNA (at least 3 micrograms) and RNA (at least 400 nanograms with optimal RIN > 7) if available.  
 Fresh frozen tissue or DNA/RNA must be shipped on dry ice via overnight delivery using shipping materials provided by the biorepository (see Appendix XV). H&E slide should be shipped at ambient temperature.  
  
10.0 ADVERSE REPORTING  REQUIREMENTS  
 
10.1 Definitions  
 
• Adverse Events : An adverse event is any new, undesirable medical occurrence or change 
(worsening) of an existing condition in a subject that occurs during treatment, whether or not 
considered to be product related. Therefore, adverse events are treatment emergent signs or 
symptoms. Elective hospitalizations for pretreatment conditions (e.g., elective cosmetic procedures) are not adverse events. Non -clinically significant abnormal laboratory values 
should not be reported as adverse events; however, any clinical consequences of the 
NF Protocol #105   Version 2. 1 
05/01/2019  
60 
 abnormality should be reported as adverse events.  All adverse events must be noted on the 
case report forms and submitted to the operations center within 2 weeks of completion of every treatment cycle . 
 
For all adverse events, the investigator must pursue and obtain information adequate both to determine the outcome of the adverse event and to assess whether it meets the criteria for classification as a serious adverse event requiring immediate notification (within 24 hours) to the site PI and clinical coordinator, as well as the NF Operations Center.  Follow -up of the 
adverse event, even after the date of therapy discontinuation, is required if the adverse event or its sequelae persist. Follow -up is required until the event or its sequelae resol ve or stabilize 
at a level acceptable to the investigator and sponsor.  
 
• Serious Adverse Events : A serious adverse event is defined by regulatory agencies as one that 
suggests a significant hazard or side effect, regardless of the investigator’s or sponsor’s opinion 
on the relationship to investigational product. 
 
This includes, but may not be limited to, any event that (at any dose): 
is FATAL  
is LIFE THREATENING (places the subject at immediate risk of death);  
requires HOSPITALIZATION or prolongation of exi sting hospitalization;  
is a persistent or significant DISABILITY/INCAPACITY; or  
is a CONGENITAL ANOMALY/BIRTH DEFECT  
 Important medical events that may not be immediately life threatening or result in death or 
hospitalization, but may jeopardize the subject or require intervention to prevent one of the 
outcomes listed above, or result in urgent investigation, may be considered serious. Examples include allergic bronchospasm, convulsions, and blood dyscrasias.  
 
10.2 Grading of Adverse Events using Common Terminology Criteria (CTCAE)  
 
Adverse events (toxicities) will be graded according to the National Cancer Institute  CTCAE 
version 4.0 for reporting of adverse events.  A copy of the current version of the CTCAE version 4.0 can be downloaded from the CTEP home page: http://ctep.cancer.gov/reporting/ctc.html 
 
  
10.3 Attribution: Definitions of relationship to study medication are as follows: 
 
• UNRELATED : bears no relation to timing of medication, similar to symptoms or signs expected 
in the disease process, does not recur on rechallenge.  
• UNLIKELY : does not have temporal relationship to intervention, could readily have been 
produced by the subject’s clinical state, environmental, or other interventions, does not reappear or worsen with reintroduction of intervention
. 
• POSSIBLY : bears relation to timing of medication, similar to symptoms or signs expected in the 
NF Protocol #105   Version 2. 1 
05/01/2019  
61 
 disease process, does not recur on rechallenge.  
• PROBABLY : bears clear relation to timing of medication, distinct from symptoms or signs 
expected in the disease process, does not recur on rechallenge.  
• DEFINITELY : bears clear relation to timing of medication, distinct from symptoms or signs 
expected in the disease process, occurs on rechallenge.  
 
The expected adverse events related to administration of cabozantinib are listed in S ection 7.3.  
All other adverse events not attributed to cabozantinib will be considered unexpected. Adverse 
events attributable to cabozantinib will be reported if the adverse events are at an intensity that 
is more severe than previously documented or considered significant by the investigator. 
 
 
10.4 Reporting Procedures for All Adverse Events  
 
All observed or volunteered adverse events, regardless of suspected causal relationship to study drug, will 
be recorded as Adverse Events in the case report forms and submitted to the Operations Center within 2 weeks of completion of each treatment cycle . Events involving adverse drug reactions, illnesses with 
onset during the study, or exacerbation of pre -existing illnesses should be recorded. Objective test 
findings (e.g. abnormal laboratory test results) should also be recorded.  
 
It will be left to the investigator’s clinical judgment whether or not an adverse event is of sufficient 
severity to require that the subject should be removed from treatment. A subject may also 
voluntarily withdraw from treatment due to what he or she perceives as an intolerabl e adverse 
event. If either of these occurs, the subject will be given appropriate care under medical supervision until symptoms cease or until the condition becomes stable. 
 
The severity of toxicities will be graded in accordance with the Common Terminolog y Criteria for 
Adverse Event (CTCAE) version 4.0 ( http://ctep.cancer.gov/reporting/ctc.html 
). 
 
The relationship of adverse events to the study medications will be assessed by means of the question: “Is 
there a reasonable possibility that the event may have been caused by the study medication?” Please answer 
Yes or No.  
 
 
10.5 Expedited Reporting Gui delines  
 
The following adverse events require expedited reporting:  
• All adverse events that are both serious and unexpected 
• Adverse events that might influence the benefit -risk assessment of administration of 
cabozantinib as outlined in the protocol 
• All gr ade 5 adverse events  
• Any adverse event that might require a target reduction  
• A serious adverse event that occurs within 30 days of the last dose of the investigational agent  
• Pregnancy  
NF Protocol #105   Version 2. 1 
05/01/2019  
62 
 If a subject or a subject’s partner becomes pregnant while receiving investigational 
therapy or within 30 days after the last dose of study drug, a report should be 
completed and expeditiously submitted as an SAE. Follow -up to obtain the outcome 
of the pregnancy should also occur. Abortion, whether accidental, therapeutic, or 
spontaneous, should always be classified as serious, and expeditiously reported as an SAE. Similarly, any congenital anomaly/birth defect in a child born to a female subject exposed to the cabozantinib should be reported as an SAE. 
• Expedited AE reporting timelines defined:  
“24 hours; 3 business days” – The investigator must initially report the AE within 24 hours 
(or immediately if the event is fatal or life -threatening) of learning of the event to the Study 
Chair ( fisherm@email.chop.edu ) and NF Operations Center followed by a complete written 
report within 3 business days of the initial 24 -hour report. 
 
Adverse events requiring expedited reporting will be reported and documented on Form FDA 3500A MedWatch Form http://www.fda.gov/medwatch/getforms.htm)  and forwarded to: 
 
NF Consortium Operations Center 
Clinical Nurse  Manager :  Lynn Merritt, RN                                   205-934-5376 
Program Director:  Karen Cole – Plourde, BS                               205-934-5140 
Research Compliance Manager:  Juliette Southworth, BS             205-975-4075 
Direct Email:  nfcop@uab.edu   
 
 
The clinical research manager  from the NF Consortium Operations Center will forward all 
related adverse events that are both serious and  unexpected to the FDA on Form FDA 3500A 
MedWatch Form  http://www.fda.gov/medwatch/getforms.htm  to: 
  
MedWatch  
Fax: 1 -800- FDA -0178 
 
The final MedWatch Form or CIOMS- 1 form must be submitted by the study site to Exelixis 
within one to two business days of submission to the FDA or applicable regulatory agency 
(including confirmation of date that the report was submitted) to allow Exelixis time to cross -
report to Exelixis’ IND. E- mail: drugsafety@exelixis.com  ; Fax 650-837-7392. 
 
10.6 Reporting of Protocol Violations/Deviations and Unanticipated Problems 
 
Site reporting to NF Operations Center 
Sites will report unanticipated problems  and/or protocol deviations  that impact subject safety or 
the scientific integrity of the study to the Operations Center promptly  to nfcop@uab.edu.  Other  
protocol violations and deviations should be reported to the NF Operations Center annually.   
 
NF Operations Center reporting requirements 
The Operations Center will report unanticipated problems that impact subject safety or the scientific integrity  of the study to the USAMRMC ORP HRPO promptly.  Unanticipated problems 
NF Protocol #105   Version 2. 1 
05/01/2019  
63 
 will also be reported to the protocol team, Medical Monitor, and DSMB. 
 All unanticipated problems involving risk to subjects or others must be promptly reported by the NF Operations Center via phone (301-619- 2165), email (
usarmy.detrick.medcom -
usamrmc.other.hrpo@mail.mil ), or facsimile (301 -619- 7803) to the HRPO.  A complete written 
report will follow the initial notification.  In addition to the methods above, the complete report 
can be sent to the US Army Medical Research and Materiel Command, ATTN: MCMR -RP, 810 
Schreider Street, Fort Detrick, Maryland 21702-5000.   
 Suspensions, clinical holds (voluntary or involuntary), or terminations of this research by the IRB, the institution, the Sponsor, or regulatory agencies will be promptly reported to the USAMRMC ORP HRPO.  
 Other protocol violations and deviations  that do not impact subject safety or affect scientific 
integrity of the study  will be provided annually to the Sponsor. 
 
 
 
 
11.0 CRITERIA FOR REMOVAL FROM PROTOCOL THERAPY AND OFF STUDY 
CRITERIA  
 
11.1 Criteria for Removal from Protocol Therapy  
a.   Progr essive disease  
b.  < 15% reduction in index tumor volume after 8 cycles . (Of note, subjects may begin cycle 9 while 
central review of tumor response is ongoing) (Cohort A only)  
c.   < 20% reduction in index tumor volume after 12 cycles . (Of note, subjects may begin cycle 13 
while central review of tumor response is ongoing)   
d.  Completion of cycle 24 
e.  Cabozantinib- related toxicity  requiring removal (see Section 7) 
f.  Refusal of further protocol therapy by subject /parent/guardian  
g.  Other cancer develops 
h.  Non- compliance that in the opinion of the investigator does not allow for on- going participation.  
i.  Physician determines it is not in the subject ’s best interest.  
j.  Participant is prescribed a non-allowed concomitant medicine during study. k. Subject  must have surgery on a target PN. 
l.  Subject becomes pregnant 
• If a subject becomes pregnant while receiving investigational therapy or within 30 days after the last dose of study drug, the subject should be followed until  the outcome of the 
pregnancy. 
 
Subject s who are off protocol therapy are to be followed until they meet the criteria for OFF Study 
(see below) . 
 
11.2  Off Study Criteria  
For subjects who did not have a response (<20% shrinkage of target tumor) or have tumor 
progression (≥ 20%) at any time:  
NF Protocol #105   Version 2. 1 
05/01/2019  
64 
 a) Thirty days after the last dose of cabozantinib (but note that subjects with ongoing toxicity 
should be followed until the toxicity resolves or 30 days, whichever is longer) 
 
For subjects who had a response ( ≥20% target tumor shrinkage by 12 cycles) and never experience 
tumor progression: b) Completion of their one year follow -up MRI scan 
 For all subjects (supercedes “a” or “b”):  
c)  Death  
d)  Lost to follow-up e)  Withdrawal of consent for any further data submission. f)  Initiation of  subsequent other medical treatment directed towards the plexiform neurofibroma 
g)  Initiation of medical treatment (e.g. chemotherapy, biologic therapy, radiation therapy) 
directed towards other NF1-related tumor, such as an optic pathway glioma.  
h) Outcome of Pregnancy (for subjects who become pregnant while receiving investigational 
therapy or within 30 days after the last dose of study drug). 
 
 
12.0 STATISTICAL AND ETHICAL CONSIDERATIONS   
 
12.1 Subject Accrual  
Subjects of both genders, from all racial and ethnic groups are eligible for this trial if they meet 
the criteria outlined in Section 4.0. To date, there is no information that suggests differences in 
drug metabolism or disease response among racial or eth nic groups or between the genders, 
indicating that results of the trial will be applicable to all groups. Most plexiform neurofibroma 
grow out of proportion to somatic growth for a period of time during childhood, but may reach a 
plateau by the end of pube rty.  Efforts will be made to extend the accrual to a representative 
population, but in a phase II study with limited accrual, a balance must be struck between patient safety considerations and limitations on the number of individuals exposed to potentially toxic or ineffective treatments on the one hand, and the need to explore gender, racial, and ethnic aspects of clinical research on the other. If differences in outcome that correlate to gender, age, racial, or ethnic identity are noted, accrual may be expanded or additional studies may be performed to investigate those differences more fully.  
 
 
12.2 Statistics and Feasibility  
 
Sample Size  
Cohort A :  Minimum: 9 evaluable subjects   Maximum: 19 evaluable subjects Target: 17 evaluable 
subjects. To allow for 25% unevaluable subjects, a maximum of up to 24 subjects will be enrolled. 
We anticipate enrollment to be completed in 24 months with primary outcome measure defined in 30 months.  
 The sample size for this trial is based on three primary factors:  safety b ased on risk versus benefit; 
efficacy of 25% response rate and power of 80% to achieve feasibility if this rate were true.   In 
order to balance these factors, we propose a two stage Simon Optimal Design (ref Controlled Clinical Trials 10:1 -10 1989)  for co hort A.  Two stage designs are designed to provide an overall 
NF Protocol #105   Version 2. 1 
05/01/2019  
65 
 Type I error that is based on the probability of stopping at the end of Stage 1 plus the conditional 
probability of rejecting the drug given one passed Stage 1 to get to Stage 2.  Thus, the over all Type 
I error was set at 5% and power at 80%.   We assume a null hypothesis success rate of 5% versus a treatment with a 25% response rate.   
 Stage 1  for cohort A  will consist of 9 subjects to provide evidence of effectiveness and safety.   If 
at least  1 of the 9 subjects achieves a radiographic response ( ≥20% reduction in tumor volume) the 
study will be allowed to recruit the total sample size of 17 evaluable subjects.  The Stage I 
boundary is the same 0 of 9.  The second stage of the design requires only 3 or more of the 17 subjects to have a positive response. If the null hypothesis is true, there is a 63% chance of terminating after Stage 1.  If the probability of success is actually 0.25, there is a 92% chance that 1 or more subjects will exhibit a 20% reduction in tumor volume at Stage 1.  Thus, it is expected 
that the trial will continue with continuous recruitment if the 25% success rate is correct.   
 For safety reasons, in cohort A, subjects who did not achieve at least a 15% reduction in tumor 
volume were not be continued beyond 8 cycles, as the likelihood of achieving a response (20% 
reduction in tumor volume) by 12 months is minimal. These subjects will be discontinued from 
the trial and counted in an "Intent to Treat" analysis as evaluable and as failures.  If there are no 
subjects with a response (20% or more reduction in tumor volume) by the end of 8 cycles, but one or more with a 15% or more tumor volume reduction, recruitment will be suspended until the decision on futility (0 of 9 with at least 20% or more reduction in tumor volume after 12 cycles) or successful continuation can be definitively recommended.   That is, if there are a number of 
subjects with 15% up to but not achieving a 20%  reduction in tumor volume, the study will follow 
those subject s up to their post cycle 12 visit to determine if the recruitment can be restarted.  If 
none of these 9 achieves a 20% tumor volume reduction by 1 year, the study will be terminated.  Cohort B:  Enroll up to 24 evaluable subjects. Target: minimum of 17 evaluable subjects. To allow for up to 25% unevaluable subjects, a maximum of 24 subjects will be enrolled. We anticipate enrollment to be completed within 12 months with the primary outcome measure defined in 24 months.  The sample size for this trial is based on the safety and feasibility data needed:  thus, safety based on risk versus benefit.  For feasibility, we expect at least efficacy of a 25% response rate.   We are only interested if cabozantinib is positive and thus, assume a 1 sided test using a Type I error of 5%.  We assume a null hypothesis success rate of 5% versus a treatment with a 25% response rate.  If all 20 patients are evaluable there is 80% power to detect differences between 25% and 5% with 
80% power.   The power in this strata is 64% when the minimal sample size is realized.  Based on the preliminary response data (passed the threshold to move to stage 2) and minimal toxicity in Cohort A to date, a 2- stage design is not felt to be necessary for Cohort B. 
 For cohort B (pediatric cohort ), because of the overall excellent safety profile of cabozantinib and 
the numerous late tumor responses  in cohort A (adult cohort) (see protocol section 2.3), the 
requirement to stop study treatment in subjects who do not achieve at least a 15% reduction in tumor volume by 8 cycles will be eliminated .   
  
NF Protocol #105   Version 2. 1 
05/01/2019  
66 
 12.3 Statistical Analysis Plan  
The basic statistical analysis plan for this proof of concept study will describe the subject  
population by baseline characteristics:  clinical, PK/PD, Quality of Life and pain scores at 
baseline.  Following complete accrual, study logistics will be summar ized as per a Consort 
Diagram with reasons for withdrawal or unable to complete the study tabulated for each cohort separately .  Appropriate data analysis sets will be defined. The full- analysis set will include data 
from all subjects who receive ≥ 1 dose of therapy on this study; a safety analysis set will 
comprise data from subjects in the full- analysis set with any treatment doses. Other data sets 
(responding, evaluable, and pharmacodynamic/pharmacokinetic data sets) will be defined and will include data from subjects who have the necessary baseline and on- study measurements to 
provide interpretable results for specific parameters of interest.  
 Descriptive summaries will be prepared to show sample size, mean, standard deviation, 95% confidence intervals (CIs) on the mean, median, minimum, and maximum for continuous variables and counts, percentages, and 95% CIs on the percentage for categorical variables. This will be done for each cohort separately.   For endpoints relating to tumor control, subject  well -
being, and biomarkers, analyses will be done based on the full-analysis, responding, evaluable, or pharmacodynamic data sets, as appropriate. Time- to-event analyses will be performed with 
reference to the date of first treatment on this study.  Analy ses will focus on evaluation of 
outcomes within each treatment arm and will be largely descriptive in nature as per the sample size justification section  within cohort.  Changes in tumor volumes, etc. will be summarized by 
medians, ranges, and the corresponding 95% CI.  Continuous and categorical variables will also be summarized as appropriate.   
 If both cohorts achieve the maximum number of participants, a pooled, but stratified analysis will be conducted to assess the estimates of success.  Relationship of outcomes will be compared between cohort A and cohort B using stratified regression analyses and/or Cochran- mantel -
Haenszel tests.  
 Based on the safety analysis set, information regarding study treatment administration, drug dosing and cycle  compliance, safety variables, will be described and summarized. Using data 
from the pharmacokinetic analysis set plasma concentrations will also be described and summarized.  Peak, Trough, Area under the curve and mean serum levels will be compared to tumor responsi veness.  Safety will be assessed via tabulations of AEs and SAEs as well as Diary 
recordings following treatment dose/cycle  of therapy.  
 All analyses for outcome results will be based on evaluable subjects, as defined in section 12.4.  At the end of the tr ial, we will report poor performance if the treatment is rejected at Stage 1, not 
meeting the criteria of at least 1 success in 9 cases.  If there is no success at Stage II, we will report a failure to reject the null hypothesis using the conditional proba bility of the added 
subjects. If the null hypothesis is rejected, the probability of the estimated success rate will be reported and 95% confidence intervals as well as the distribution of changes in tumor size.  
An early stopping rule will be invoked for both cohorts to potentially prevent accrual of  subjects 
onto the study in the event that cabozantinib is associated with a higher than acceptable rate 
NF Protocol #105   Version 2. 1 
05/01/2019  
67 
 of dose- limiting  toxicity (DLT)  requiring removal from study (set at 10% or higher) during the 
first 2 cycles. Toxicity will be continuously monitored.  As per the 2nd table below, if at any time 
>2 of the first 10 subjects or 4 or more of the first 15 total subjects are removed for DLT, then 
accrual will be stopped until the DSMB reviews safety and efficacy  data for the study and 
recommends termination or despite the DLT (because of the benefit:risk assessment or other reasoning) recommends reopening recruitment.  Boundaries for DSMB for consideration of terminating each cohort (both cohort A and B) would be the same.  
 Table 1:  Stopping Boundaries requiring DSMB to consider terminating trial  
Number of subjects Trial will be stopped if the number of subject s with severe 
toxicity is greater than or equal to the number below 
10 3   
(equivalent to a p- value of  0.07 that the rate of severe 
toxicity is 10% or less)  
15 4 
(equivalent to a p-value of 0.055 that the rate of severe 
toxicity is 10% or less)  
  Using these rules and the binomial distribution, the chance of putting the trial on hold and potentially stopping early within the first 10 subject s: 
True probability of toxicity Chance of stopping early 
.10 7% 
.20 32% 
.25 47% 
.30 62% 
.35 74% 
.40 83% 
  
For the comparison of volumetric measures, 60 consecutive patients enrolled on 
Neurofibromatosis Clinical Trials Consortium PN studies will be included (including NF108). Two groups of independent volume measurements (NCI- MEDx and MGH -3DQI) will be 
NF Protocol #105   Version 2. 1 
05/01/2019  
68 
 performed of the target lesions on up to 5 MRIs per subject (pre-study, baseline, pre-cycle 5, pre-
cycle 9, pre- cycle 13). Interval change will be calculated to classify disease status as follows: 
progressive disease (PD) if volume increase is > 20%, partial response (PR) if volume decrease 
is > 20%, and stable disease (SD) if change is < 20% between time points.  Of note, the results of 
the MEDx analysis at the NCI will be utilized in analyzing and making decisions on the clinical 
trial, as has been done on all previous Neurofibromatosis Clinical Trials Consortium PN trials.  
The results of the 3DQI analysis of each scan performed at the MGH will not be released to sites or the study team while the study is ongoing.  Wilcoxon signed rank test will be used to statistically compare the numerical difference between PN volumes at each time-point, and the numerical difference between the percent changes in PN volumes over time. The Jonckheere-Terpstra trend test will be used to establish the degree of significance of the association in disease status classifications. After establishing the overall degree of agreement, the McNemar test for paired categorical data (for two categories) or an exact marginal homogeneity test (for 3 ordered categories) will b e used to demonstrate the degree of balance in the discordant results. 
For the fraction of concordant disease status classifications and the overall response rate 95% confidence intervals will be calculated.  
 12.4 Definitions of Evaluable 
 
12.4.1  Evaluable for Toxicity - 
Subjects who receive at least 1 dose of the study drug  and are removed from treatment for 
toxicity are evaluable.  Any subject who completed one full cycle  of therapy is evaluable 
for toxicity.  
 
12.4.2 Evaluable f or Response – Subjects who have completed at least two cycles of 
therapy and have had their first follow-up MRI evaluation. Subjects who did not respond and are later found to have a target tumor other than a plexiform neurofibroma (e.g. malignant peripheral nerve sheat h tumor) are not evaluable for response.  
 
 
13.0 RESPONSE CRITERIA  
 
Tumor Assessment  
Tumor response should be assessed by MRI at study entry and at after 4, 8, and 12 cycles.  Subjects with at least a 20% reduction in tumor volume  may continue on study and will be 
assessed by MRI after 18 and 24 cycles . Subjects with PD should have their treatment 
discontinued, and they should enter the post-treatment phase of the study. The same method for tumor assessment should be employed at ev ery assessment.  
 
A.  Tumor Response Criteria for Plexiform Neurofibromas:   Tumor response is primary 
study variable and is the primary aim of this trial.  Tumor response will be evaluated by volumetric MRI STIR imaging.  Subjects who complete at least 2 cycl es of therapy  will 
be evaluable for disease response.  Serial measurements of lesions are to be done with MRI.  The same method of assessment is to be used to characterize each identified and reported lesion at baseline and during follow-up.   
NF Protocol #105   Version 2. 1 
05/01/2019  
69 
  
B. Methodology to Determine Tumor Measurement :   
 
Volumetric MRI Method:  
Tumor response criteria that are used for cancers are based on one-dimensional (1- D) and two -
dimensional (2-D) tumor measurements. These methods have limited value in the assessment of 
treatment ou tcome for plexiform neurofibromas, which are frequently large, have a complex 
(non-spherical) shape, and have a slow growth pattern.   In order to reproducibly quantify the size of these complex lesions and detect small changes in the size over time, we us ed MR imaging characteristics of plexiform neurofibromas to develop 
an automated method of lesion detection and volume measurement. Axial and coronal short T1-inversion recovery (STIR) MR images are obtained to encompass the entire PN using a slice thickne ss of 5 -10 mm with no skips between slices. PN volume is determined using a method 
developed on the MEDx software platform. This method is based on 1) contrast, defined by intensity in the tumor (high signal intensity) compared with the surrounding tissue (low signal intensity), 2) intensity gradient, defining the outside border (margin) of the lesion, and 3) size of the lesion. PN are substantial in size, and small isolated areas of high signal intensity can be ignored, because their contribution to the PN volume is insignificant. The steps of volumetric analysis are outlined in Figure 9.  
Figure 9:  Steps of automated volumetric MRI analysis of plexiform neurofibromas (PN): A)  
Original axial short T1 inversion recovery MRI of a neck PN. The PN appears bright vs. normal 
surrounding tissue. During the analysis a region of interest including the tumor and some low signal intensity surrounding tissue is manually outlined on each MRI slice. B) The program 
derives a histogram of pixel signal intensity and identifi es a threshold that separates PN from 
surrounding tissue and C) The program  automatically defines the tumor contour. 
 
This automated method is sensitive (detects volume changes as small as 10%) and reproducible (coefficient of variation 0.6-5.6%), and yields similar results to manual tumor tracings 
(R=0.999).  This automated volumetric MRI analysis is applicable to most plexiform neurofibromas, and wa s 
used in a phase II trial of the farnesyltransferase inhibitor tipifarnib, in the phase I and II trials  of 
pirfenidone, in the phase I trial of peg- interferon alfa -2b, and in the NF Consortium phase 2 trial 
of Sirolimus  for children with NF1 and plexiform neurofibromas to assess changes in tumor size. 
Imaging studies on these multicenter trials are sent to the NCI, POB, where volumetric MRI 
analysis is performed. Tumor progression on these trials is defined as an increase in plexiform neurofibroma volume by ≥ 20%. This volume increase corresponds too much smaller changes in 1-D, or 2- D measurements as outlin ed in the Table below:  

NF Protocol #105   Version 2. 1 
05/01/2019  
70 
  
Table 4 -2: 
Equivalent percent change in diameter (RECIST), product of perpendicular diameters (WHO), 
and volume for spherical lesions (e.g., increasing the diameter of a sphere by 6% results in a 20% increase in the volume). Bold typeface highlight the definition of progression according to the standard RECIST and WHO criteria, and the definition for progression by volumetric measurements used on several currently ongoing clinical trials for NF1 -related plexiform 
neurofibromas.   
 
Percent Change in Tumor Size  
RECIST  
Diameter (1D)  WHO  
Product (2D) Ongoing NF1 Studies  
Volume (3D) 
6% 13% 20%  
12% 25%  40% 
20%  44% 73% 
 
C.  Overall Response Assessment :   
Response Criteria for target lesions:  For the purposes of this study, only the primary or 
target lesion will be assessed for response.  Subjects will have volumetri c MRI of target 
lesion done at 4 months, 8 months, and 12 months.  Subjects who show objective response at 12 months can continue at the discretion of the investigator for up to 24 total cycles.  For cohort A, subjects who did not show at least a 15% 
reduction in index tumor 
volume at 8 months we re consider ed treatment failure s and taken off study.  For cohort B 
(pediatric cohort), because of the overall excellent safety profile of cabozantinib and the 
numerous late tumor responses in cohort A (adult cohort) (see protocol section 2.3), the requirement to stop study treatment in subjects who do not achieve at least a 15% reduction in tumor volume by 8 cycles will be eliminated.  
 If subject has lesions outside of target lesion, up to two non- target lesions may be 
selected and imaged at the same recommended intervals and submitted for analysis.    
 
Partial Response (PR):  ≥20% decrease in the volume of target lesion taki ng as reference 
the initial baseline measurements.  
 
Stable Disease (SD):   Neither sufficient decrease in the volume of target lesion  to qualify 
for PR (taking as reference the initial baseline measurements), nor sufficient increase in target lesion  to qual ify for PD, (taking as reference the smallest disease measurement 
since the treatment started).  
 
Progressive Disease (PD):  20% or more increase in the volume of ANY target or non-
target lesion, taking as reference the smallest product observed since the st art of 
treatment.  
  
NF Protocol #105   Version 2. 1 
05/01/2019  
71 
 Correlative Response Variables  
1.  Serum bioactivity and cytokine measurements:   
We have reported that mast cells, a cellular component in neurofibromas, play important role in the 
pathogenesis of neurofibromas and other  skin malignancies in both human and murine systems 
(Coussens,1999; Galli SJ,1993; Hirota, 1993; Ryan, 1994; Galli,1993; Kerdel, 1987). Mast cells produce 
and release multiple mediators into the tumor microenvironment. These factors include histamine, 
serotonin,  proteoglycans, and leukotrienes subsequent to activation of the c -kit receptor ( Galli, 1993; Serve, 
1995).  Furthermore, mast cells release multiple growth factors such as vascular endothelial growth factor 
(VEGF) ( Boesiger, 1998), an angiogenic factor, c hemotactic factor for Schwann cells ( Sondell, 1999), 
PDGF -B which promotes fibroblast proliferation and collagen synthesis.  We have shown that kit -ligand is 
a key growth factor that is pivotal in all aspects of cellular functions of mast cells, such as pr oliferation, de 
novo synthesis of cytokines, degranulation, and migration to emerging tumors (Yang, 2003). Most 
importantly, targeting ckit pathway significantly reduced tumor size in a murine model of NF1 and a single 
case of NF1 patient with a plexiform neurofibroma. In the present study, we propose to evaluate cytokine 
levels in serum of NF1 subject s. The cytokine panel includes ~30 cytokines/chemokines/growth 
factors that have been reported altered in neurofibromas and other cancer types by us and other s. 
Plasma biomarker assays will be performed using multiplex simultaneous quantification of about 
thirty soluble cytokines and growth factors including: VEGF, TGF -β, PDGF -AB/BB, MCP -1, 
MIP1α, MIP1β, TNFα, GM- CSF, EGF, IL -13, IL -1rα, IL -10, IL -4, IL6, FGF -2, and RANTES. 
The multiplex assay will be performed according to the manufacturer ’s protocol (Millipore 
Milliplex, Billerica, MA) and analyzed on a Luminex 200 cytometer with StarStation software 
(Luminex Corp, Austin, TX). Plasma samples of each subject  at each  treatment time point will be 
stored at -80C and thawed once for simultaneous assay. 
 
 
 
2.  Polychromatic Flow Cytometry & Identification of Circulating Progenitor Cells  
 
Endothelial progenitor cells (EPCs) and circulating progenitor cells (CPCs) ar e bone 
marrow -derived cells (BMDCs), which serve as important biomarkers of disease and for 
measuring the impact of anti- angiogenic treatments of cancer.  Using conventional flow 
cytometry, Duda et al., recently standardized a method for enumerating specif ic EPC 
populations in blood that serve as biomarkers for vascular disease risk and response to anti -
angiogenic therapies in human cancers [15]. Flow cytometry is a rapidly 
developing/expanding field, and recent improvements in technologies and various flow cytometry strategies have now been employed to measure circulating EPC and CPC concentrations in human peripheral blood. Utilizing a novel polychromatic flow cytometry (PFC) strategy to further characterize and purify CPCs, our group has shown that CPCs are phenotypically and functionally distinct from that of the well -studied EPCs [16].  This PFC 
technique is highly reproducible, allowing for use in longitudinal studies and eliminates any ambiguous data interpretation.  In addition, the PFC protocol is cost and time effective, and can be completed in 2- 2.5 hours utilizing existing comm ercially available technology.  
 
NF Protocol #105   Version 2. 1 
05/01/2019  
72 
 In fact, subtle differences in phenotype separating the CPC population into pro- angiogenic 
and non- angiogenic populations turn out to be quite important, and is primarily based on 
the expression of the cell surface marker, C D133.  By identifying the CD133+ sub-
population of the CPCs, which represent pro- angiogenic CPCs, the ratio of pro- CPCs 
versus non- CPCs are quite different in various disease states  (Estes et al., Cytometry A, 
77A(9):115- 121, 2011).  In normal patients, the ratio is 1.2- 2.  Cancer patients have a ratio 
>2.5, which has been shown to decrease to within the normal range following treatment 
with the anti- angiogenic compound Sutent.  Furthermore, in patients with peripheral artery 
disease (PAD), the ratio is <1  (Estes et al., Cytometry A, 77A(9):115- 121, 2011).  
Therefore, the ratio of pro -CPCs vs. non- CPCs may be utilized as a reliable marker for 
certain diseases, disease status and to monitor response to therapy/treatment.     
 
 
 
 
For example, 
treatment of metastatic breast 
cancer patients with Sunitinib resulted in 
decreased 
numbers of pro-angiogenic CPCs 
as compared to untreated patients.  Interestingly, when the treatment regime was coupled with Taxol, an increase in the non- angiogenic CPC fraction was obse rved. Therefore, it is 
extremely important to perform optimal PFC acquisition and analysis of these 2 phenotypically and functionally distinct cell sub- populations in order to obtain 
reproducible, reliable and accurate results.  
 
 
  
  
Untreated  
 Sunitinib  
 Taxol  

NF Protocol #105   Version 2. 1 
05/01/2019  
73 
 Furthermore, in a recent study by 
Pradhan et al., looking at CPCs in pediatric patients with various solid tumors as compared to age matched healthy controls, it was demonstrated that patients with cancer had a higher ratio of pro -
CPCs versus non- CPCs. The  median 
ratio of the pro- CPCs versus non-
CPCs was 2.12 (0.34- 5.95) at 
baseline for the patients, while the healthy controls had a median ration of 1.23 (0.24- 1.54). Following 
treatment, the median ratio for the 
patients dropped to 1.59 (0.21- 8.75) (Pradhan et al., Cytometry Part B: Clinical Cytometry, 
80B(5):335- 338, 2011). This was the first time that the two subsets had been reported in 
any human malignancy.  
 Additionally, injection of the purified pro-angiogenic CPC fraction was shown to enhance tumor growth in a murine xenograft model.  In summary, NOD/SCID mice harboring pre -
established melanoma xenografts (~100mm
3) were intravenously injected with purified 
human pro- CPCs, phosphate buffered saline (PBS), non- CPCs (Figure 4, Expt I) or CD34+ 
cells (Figu re 4, Expt II).  Intravenous injection of pro- CPCs in mice harboring melanoma 
xenografts resulted in a statistically significant increase in tumor growth overtime when compared to controls (i.e. PBS, CD34
+ cells or non- CPCs) (Figure 4). In addition, at the  
completion of the study, excised tumors were weighed to further document changes in tumor growth. Tumors from mice injected with the pro -CPCs were significantly larger than 
tumors from the mice that received vehicle control (PBS) or CD34
+ cells (Figure 5)  (Estes 
et al., Cytometry A, 77A(9):115- 121, 2011). Histological analysis of tumors for the 
presence of human CPCs is in progress. In all future experiments, we will use CD34+ cells 
as the negative control population. While we realize that pro- CPCs are cer tainly present in 
the CD34+ cell population, our data suggest that the level of the pro- CPCs is not high 
enough in the bulk CD34+ population to promote tumor progression unless the pro- CPCs 
are first purified from the CD34+ population. 
 This evidence is compelling, and supports the role of pro- angiogenic CPCs in tumor 
progression, as well as the potential utility of the CPC ratio as a powerful biomarker in various disease states, including cancer.  We will examine the role of CPCs as a biomarker in NF1 ple xiform subjects treated with cabozantinib. 
  Figure 5.Comparison ofTu m o r Weights .Atthe end ofthe
study, the mice were euthanized and the tumors from each
cohort of mice were harvested and weighed .Tumor weights
are from Expt II.*p< 0.001, CPCs vsCD34orPBS control .N=4
mice/cohort .00.20.40.60.811.2
CPC CD34 PBSweight (g)*
NF Protocol #105   Version 2. 1 
05/01/2019  
74 
  
PFC and CPCs :  PFC for the identification of CPCs will be performed at four time points  
as per protocol.  Whole blood will be drawn in EDTA tubes and sent immediately  for 
processing to the Indiana University Angio BioCore, which is  directed by Dr. Karen 
Pollok.   As samples are received, using the PFC protocol developed by Dr. Jamie Case 
(Estes et al., Current Protocols in Cytometry, 52(9):9.33.1-9.33.11, 2010) , the phenotypic 
detection and enumeration of CPCs will be performed, and the ratio of pro- angiogenic (i.e. 
CD133+) vs. non- angiogenic CPCs will be calculated on all samples.  Data obtained will 
then be correlated with tumor response. 
 
3.  Pharmacokinetics  
Plasma samples will be collected for the purpose of determining XL184 concentrations 
for pharmacokinetic analysis of XL184 and/or metabolite concentrations.  
For Cohort A: Blood samples will be obtained at the following time points: Cycle 1 Day 
1 (pre, 4 hours after the first dose), Cycle 1 Day 15 (pre, and 4 hours after dose), Cycle 1 Day 28 (pre and 4 hours after dose) for subjects remaining on study, and if possible any time a subject experiences a DLT.   
 
For Cohort B: Blood samples will be obtained at the following time points: Cy cle 1 Day 
1 (pre first dose), Cycle 2 Day 1 (pre-dose), Cycle 3 Day 1 (pre-dose) and Cycle 4 day 1 (pre-dose) 
 Blood samples (3 ml) will be collected in 3 -mL K
2-EDTA Vacutainer tubes (lavender 
top) tubes for pharmacokinetic evaluation. Record the exact tim e that the sample is drawn 
along with the exact time that the drug is administered.  
 Tubes should be chilled on wet ice or in a refrigerator prior to collection. Immediately after blood collection, blood tubes should be inverted several times and then kept on wet 024681012
9 13 16 20 27 31fold increase
Days post -injectionCPC
CD34
PBSExpt II: -
0.5x105CPCs/mouse
051015202530
3 7 10 17 22 27fold increase
Days post -injectionCPC
nonCPC
PBSExpt I: -
1x105CPCs/mouse
****
*
*
*
Figure 4.Intravenous Injection ofCPCs Results in Significant Increases inMelanoma Xenograft Growth .NOD/SCID mice
bearing human melanoma xenografts were intravenously injected with CPCs, control cells (Expt I=nonCPCs ;Expt II=CD34+
cells) orPBS.Tumor growth was monitored over time bycaliper measurement . *p<0.001, CPCs vs.control cells orPBS.N=3-
4mice/cohort .
NF Protocol #105   Version 2. 1 
05/01/2019  
75 
 ice until centrifuged. Within 30 minutes of blood collection, samples should be separated 
by centrifugation for 10 minutes (1000 - 1200 g) at approximately 4°C. The resultant plasma should be withdrawn in approximately equal volumes into two (2) appropriately 
labeled polypropylene tubes for PK assay and stored (within 1 hour of the blood sampling 
time) at -70°C or lower until shipment. The analyst should attempt to transfer the 
maximum amount of plasma without disturbing the barrier between the red blood cells (bottom layer) and the plasma (top layer). One tube is the primary sample; the other tube 
is the back -up sample. Samples should be shipped to the following address: 
Alturas Analytics, Inc.  
Attn: Jennifer Zimmer, PhD  
Senior Scientist Executive Laboratory Manager 
1324 Alturas Dr. 
Moscow, ID 83843 Phone: (208) 883-3400 Fax: (208) 882-9246 
Email: jzimmer@alturasanalytics.com
 
Refer to Appendix VI for additional sample processing and shipping instructions. 
PK data will be analyzed and summarized by Exelixis Inc.  
  
NF Protocol #105   Version 2. 1 
05/01/2019  
76 
 14.0 HUMAN SUBJECTS PR OTECTION & DATA SAFETY MONITORING PLAN  
 
Rationale for Subject Selection  
Neurofibromatosis type 1 is a genetic disorder and the incidence of the disease in the 
various racial and ethnic groups may vary. This may impact on our ability to recruit sufficient numbers of patients within each group to this trial.  Subject accrual in regards to gender, and racial and ethnic groups is described in Section 4.0.  None of these groups are excluded from participation in the trial.  Females who are pregnant or breast feeding will not be eligible for entry onto the trial because of the potent ial risks that cabozantinib could 
pose to the fetus or newborn.  This trial is designed to determine the activity of cabozantinib 
in adolescents and adults with NF1 and inoperable PN.  Individuals will be enrolled only 
at sites that participate in the NF  consortium. Subjects may also be referred from outside 
centers but treatment will be directed at an NF consortium site.  
  Evaluation of benefits and risks/discomforts  
The potential benefit from participation in this trial is the stabilization or reductio n in the 
size of the PN, relief of symptoms caused by the PN, and prolongation of life. The primary risk to the subjects from participation in this trial is due to cabozantinib toxicities  (Section 
7.3), which have been reversible when they occur.  Subject s enrolled on this trial will be 
carefully monitored for the development of toxicities, and guidelines for target modifications, discontinuation of drug, and a toxicity stopping rule are in place. Blood samples will be obtained on this trial for pharmacokinetic, pharmacodynamic, and pharmacogenetic studies; these are mandatory .  Samples will be identified by a code 
number that can be traced to the subject  only by contacting the trial coordinating center.  
However, as the blood samples are linked to the subject’s name, a small risk persists that 
unauthorized persons could gain access to information. Some testing may eventually reveal information that could result in discrimination with health or life insurance or employment.  We believe that these risks are m inimal since it is already known that subject s enrolled on 
the study have neurofibromatosis. All research results will be kept confidential.  Results 
from the pharmacodynamic and pharmacogenetic studies will be considered preliminary and will require further analysis for verification. Therefore, results will not be communicated with the research subjects. Subject s also have the right to withdraw the 
blood specimens obtained for research purposes at any time.  
 
Risks to subjects from banking biological specimens include the risks of the blood draws for research purposes. Tumor specimens will be taken only from leftover specimens that were obtained for clinical purposes. The amount of blood to be obtained is minimal (approximately 10 ml) and no more than 5 mL/k g will be taken from any subject in a single 
day.  Risks associated with blood draw are pain, bleeding or bruising at the spot where the needle is inserted, and rarely fainting or infection. Every attempt to draw the research blood samples in conjunction with other clinical blood draws will be made so that the risk of infection is not increased. Blood draws will be performed by trained personnel who are experienced in working with children and familiar with the challenges of drawing blood from this population.  The risk of biological specimen banking is minimized by coding the specimens prior to shipping to the biorepository in order to prevent identification of subjects and protect confidentiality.  In addition, the study subject ID number linked to the specimen will be maintained separately at the NF Consortium Operations Center at UAB.   
NF Protocol #105   Version 2. 1 
05/01/2019  
77 
 Depending on the age of the subject  MRI studies may require sedation or anesthesia, which 
is associated with additional risks. Separate informed consent will be obtained f rom 
research subjects for sedation  or anesthesia for MRI scans.  
 
Risk/benefit analysis  
The primary objective of this phase II trial is to define the objective response rate of PN 
treated with cabozantinib, and thus subject s entered on the trial will be treated with 
therapeutic intent and response to the therapy will be closely monitored. Therefore, this protocol involves greater than minimal risk, but presents the potential for direct benefit to individual subjects. The pot ential benefit of this treatment with cabozantinib is that it may 
stop or slow down the growth of PN, or shrink PN. In addition cabozantinib may lessen the 
symptoms, such as pain, that are caused by the tumor. The MRI data in this study will be analyzed by a special approach called “volumetric MRI,” in addition to being read in a 
standard manner by a radiologist. The volumetric MRI approach will provide more precise measurement of the size of PN, and therefore will give more complete and objective informa tion on which to base any possible future treatment decisions.  Volumetric MRI is 
currently not available on a routine clinical basis.  
 Consent and assent process and documentation  
The investigational nature and objectives of this trial, the procedures and treatments 
involved and their attendant risks and discomforts and benefits, and potential alternative therapies will be carefully explained to the patient and the patient’s parents or guardian if 
he/she is a child, and a signed informed consent document will be obtained. Consent will be obtained by the site PI or an associate investigator on the trial according to state and institutional guidelines.  When appropriate, pediatric patients will be included in all 
discussions and assent documented.  All patien ts and/or their parents or legally authorized 
representatives must sign a written informed consent.  Assent, when appropriate, will be obtained according to institutional guidelines. This is a multi- institutional trial, and the NF Operations Center will re quire evidence of 
local IRB approval and of USAMRMC ORP HRPO approval of the protocol prior to allowing for accrual of subject s at that institution. This trial will be conducted in 
compliance with the protocol, Good Clinical Practice (GCP) and the applicable regulatory requirements.  
 
Medical Monitor and Data Safety Monitoring Plan 
The trial PI and clinical coordinator will review the study progress regularly. Subject s 
entered on the trial and adverse events will be reviewed to ensure that the study is 
implemented as outlined in the protocol. Monthly reports will be generated by the NF Consortium to assess completeness of data. There will be monthly phone conferences between the NF Consortium and the Principal Investigator to address QA issues.  A Data Safet y Monitoring Board has been established for the purpose of ensuring data compliance 
and regular monitoring of this trial.  
 Alyssa Reddy, MD  will be  the med ical monitor for this study. She is a qualified physician 
and is not associated with this particular protocol.  She will work closely with the Principal 
Investigator to monitor the participants’ treatment while on this study.  
NF Protocol #105   Version 2. 1 
05/01/2019  
78 
  
For research determined to be greater than minimal risk, DODI  3216.02 requires that the IRB 
approve, by name, an independent /medical monitor  with expertise consonant with the 
nature of risk(s) identified within the research protocol .  The IRB must approve a written 
summary of the monitors’ duties, authorities, and responsibilities.  
  
The medical monitor ’s duties should be based on specific risks or concerns about the research. The 
medical monitor  may perform oversight functions and report their observations and findings to the 
IRB or a designated official.   The medical monitor  may be identified from within or outside the 
PI’s institution.  
  Medical monitor  functions may include: 
• observing recruitment and enrollment procedures and the consent process for individuals, groups or units,  
• overseeing study interventions and interactions,  
• reviewing monitoring plans and UPIRTSO reports;  
• overseeing data matching, data collection, and analysis  
  There may be more than one medical monitor  (e.g., if different skills or experiences are necessary). 
The monitor may be an ombudsman or a member of the data safety monitoring board. At a minimum, the medical monitor : 
• may discuss the research protocol with the investigators, interview human subjects, and consult with others outside of the study about the research;  
• shall have authority to stop a research protocol in progress, remove individual human subjects from a research protocol, and take whatever steps are necessary to protect the safety and well-being of human subjects until the IRB can assess the monitor’s report; 
• shall have the responsibility to promptly report their observations and findings to the IRB or other designated official and the HRPO.  
 In addition, on this study, t he medical monitor is specifically required to review all unanticipated 
problems involving risk to subjects or others, serious adverse events and all subject deaths associated with the protocol and provide an unbiased written report of the event.  At a minimum, the medical monitor should comment on the outcomes of the event or problem, and in the case of a serious adverse event or death, comment on the relationship to participation in the study.  The medical monitor should also indicate whether he/she concurs with the details of the report provided by the study investigator.    
15.0 PUBLICATION OF DATA AND PROTECTION OF TRADE SECRETS  
The Principal Investigator (Protocol Chair) holds the primary responsibility for 
publication of the study results; provided that the PI will provide any such publication to Exelixis, Inc. for review at least sixty (60) days prior to submission and also comply with any provisions regarding publication as are agreed to between the Neurofibromatosis 
Clinical Trials Consortium and Exelixis, Inc. in the Clinical Trial Agreement related to 
this study. The results will be made public within 24  months of the end of data collection. 
However, if a report is planned to be published in a peer-reviewed journal, then that initial release may be an abstract that meets the requirements of the International 
NF Protocol #105   Version 2. 1 
05/01/2019  
79 
 Committee of Medical Journal Editors. In any event, a full report of the outcomes should 
be made public no later than three (3) years after the end of data collection. Authorship for abstracts and manuscripts resulting from this study will be determined accordin g to 
guidelines established by the International Committee of Medical Journal Editors. 
 
16.0 REFERENCES  
 
1. Yang, F.C., et al., Nf1-dependent tumors require a microenvironment containing Nf1+/ -- and c -
kit-dependent bone marrow. Cell, 2008. 135(3): p. 437-48. 
2. Galli, S.J., M. Tsai, and B.K. Wershil, The c -kit receptor, stem cell factor, and mast cells. What 
each is teaching us about the others.  Am J Pathol, 1993. 142(4): p. 965-74. 
3. Ingram, D.A., et al., Genetic and biochemical evidence that haploinsufficiency of the Nf1 tumor 
suppressor gene modulates melanocyte and mast cell fates in vivo.  J Exp Med, 2000. 191(1): p. 
181-8. 
4. Kumar, R., et al., Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors.  
Br J Cancer , 2009. 101 (10): p. 1717-23. 
5. Abrams, T.J., et al., SU11248 inhibits KIT and platelet -derived growth factor receptor beta in 
preclinical models of human small cell lung cancer. Mol Cancer Ther, 2003. 2(5): p. 471-8. 
6. Yang, F.C., et al., Nf1-dependent t umors require a microenvironment containing Nf1+/ -- and c -
kit-dependent bone marrow. Cell, 2008. 135(3): p. 437-48. 
7. Staser, K., F.C. Yang, and D.W. Clapp, Mast cells and the neurofibroma microenvironment. Blood, 
2010. 116 (2): p. 157-64. 
8. Kurzrock, R., et al., Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in 
Patients With Medullary Thyroid Cancer. J Clin Oncol, 2011. 
 
 
 
  
NF Protocol #105   Version 2. 1 
05/01/2019  
80 
 APPENDIX I:  SCHEDULE OF EVALUATIONS  
STUDIES TO BE OBTAINED  Pre-
Study1 Cycle  1 Cycle  2, 3 Cycle  4-12  
Cycle  13-24 Completion 
of Rx  
History  X End Day 15, End  
(each cycle ) End 
(each cycle ) Post cycle  14, 16, 
18, 20, 22, 24  X 
Physical exam with vital signs 
and pulse ox  X Day 15, 
End Day 15, End  
(each cycle ) End 
(each cycle ) Post cycle  14, 16, 
18, 20, 22, 24  X 
Height, weight, BSA2 X End Day 15, End  
(each cycle ) End 
(each cycle ) Post cycle  14, 16, 
18, 20, 22, 24  X 
Blood pressure  X Day 15, 
End Day 15, End  
(each cycle ) End 
(each cycle ) Post cycle  14, 16, 
18, 20, 22, 24  X 
Performance Status  X End Day 15, End  
(each cycle ) End 
(each cycle ) Post cycle  14, 16, 
18, 20, 22, 24  X 
Subject Diary  X End End 
(each cycle ) End 
(each cycle ) Post cycle  14, 16, 
18, 20, 22, 24  X 
Phone Call (to assess drug 
compliance and toxicity)      Post cycle  13, 15, 
17, 19, 21, 23   
CBC, differential, platelets  X Day 15, 
End Day 15, End End 
(each cycle ) End 
(each cycle ) X 
CMP3 with Ca, Mg, Phos, lipase, 
amylase  X Day 15, 
End Day 15, End End 
(each cycle ) End 
(each cycle ) X 
PT, PTT, INR  X End End 
(each cycle ) End 
(each cycle ) End 
(each cycle ) X 
Urinalysis  X End End 
(each cycle ) End 
(each cycle ) End 
(each cycle ) X 
Urine protein/creatinine  X End End 
(each cycle ) End 
(each cycle ) End 
(each cycle ) X 
Pregnancy test4 X5  End cycle  2  Post cycle  4, 6, 
8, 10, 12  Post cycle  14, 16, 
18, 20, 22, 24  X 
Thyroid stimulating hormone  X End End cycle  3 Post cycle  6, 9, 
12 Post cycle 16, 20, 24  X 
12- lead EKG6 X End End cycle  2 Post cycle  4, 6, 
9, 12  Post cycle  16, 20, 24  X 
MRI of target tumor  X   Post cycle  4, 8, 
12 Post cycle  18, 24  X7 
QOL   X   Post cycle  4, 8, 
12 Post cycle  18, 24  X 
Plexiform Neurofibroma 
Symptom Checklist  X   Post cycle  4, 8, 
12 Post cycle  18, 24  X 
Plexiform Neurofibroma 
Location & Associated 
Morbidities Form  X      
Plexiform Neurofibroma 
Clinician Morbidity Checklist  X   Post cycle  4, 8, 
12 Post cycle 18, 24  X 
Peripheral blood for cytokine 
assays  X Day 15  End cycle  2 Post cycle 4   
CPC biological markers – flow X Day 15  End cycle  2 Post cycle  4   
Pharmacokinetics8 X Cohort 
A:Day 
15, End  
Cohort 
B: Day 1, 
Day 28  Cohort B: 
Cycle 3 Day 
1 Cohort B: Cycle 
4 Day 1   
 
Blood and Tissue collection9 X   Post c ycle 4, 12  X 
NF Protocol #105   Version 2. 1 
05/01/2019  
81 
 1. All studies to determine eligibility must be performed within 2 weeks prior to enrollment unless otherwise 
indicated (See section 9.0 ).  Consent must be obtained prior to enrollment but does not expire at 2 weeks.  
2. Height only required at baseline  in Cohort A.  Obtain at each study visit for Cohort B.  
3. CMP should include: sodium, potassium, chloride, bicarbonate, blood ur ea nitrogen, creatinine, glucose, albumin, 
total protein, SGOT (AST), SGPT (ALT), total bilirubin, alkaline phosphatase  
4. For females of childbearing age  
5. Within 7 days prior to starting treatment  
6. If the subject starts a medication with substantial e vidence that the drug prolongs the QT interval, then EKG 
monitoring must be end of each cycle  while on the medication (see section 6.3)  
7. For subjects with tumor response, MRI is recommended at 4 months and 12 months off therapy (except if they start othe r tumor -directed therapy).  
8. PK  for cohort A will be done Day 1, 15, 28: predose and 4 hours postdose.  PK for Cohort B will be done  Cycle 1 
Day 1, Cycle 2 day 1,  Cycle 3 day 1  and Cycle 4 Day 1  
9. Blood samples should be drawn at the indicated time points as well as around the time of tumor biopsy if tumor 
tissue is being submitted (if the patient undergoes a clinically indicated tissue collection procedure). The following will be collected at each time point: Streck tube (for plasma):  ~ 2 mL; EDTA tube (for DNA):  ~ 5 mL; PAXGene 
tube (for RNA) ~ 2.5 mL.
 
NF Protocol #105   Version 2. 1 
05/01/2019  
82 
 APPENDIX II: PERFORMANCE STATUS SCALES/SCORES  
 
 
PERFORMANCE STATUS CRITERIA  
Karnofsky and Lansky performance scores are intended to be multiples of 10  
Karnofsky Lansky 
Score  Description  Score  Description  
100 Normal, no complaints, no evidence 
of disease  100 Fully active, normal. 
90 Able to carry on normal activity, 
minor signs or symptoms of disease. 90 Minor restrictions in physically strenuous 
activity.  
80 Normal activity with effort; some  
signs or symptoms of disease. 80 Active, but tires more quickly 
70 Cares for self, unable to carry on 
normal activity or do active work. 70 Both greater restriction of and less time 
spent in play activity.  
60 Required occasional assistance, but is 
able to care for most of his/her needs. 60 Up and around, but minimal active play; 
keeps busy with quieter activities.  
50 Requires considerable assistance and 
frequent medical care.  50 Gets dressed, but lies around much of the 
day; no active play, able to participate in 
all quiet play and activities.  
40 Disabled, requires special care and 
assistance.  40 Mostly in bed; participates in quiet 
activities.  
30 Severely disabled, hospitalization 
indicated.  Death not imminent.  30 In bed; needs assistance even fo r quiet 
play.  
20 Very sick, hospitalization indicated.  
Death not imminent.  20 Often sleeping; play entirely limited to 
very passive activities.  
10 Moribund, fatal processes progressing 
rapidly. 10 No play; does not get out of bed. 
  
NF Protocol #105   Version 2. 1 
05/01/2019  
83 
  
APPENDIX III: PARTICIPANT DOSE DIARY 
Reviewed by trea ting phy sicia n:    Date:         /         /                   
Paren t/Participant Sign ature:   Date:         /         /                   
† Rate  nausea mild if you are able to  eat and drink a reasona ble amo unt, moder ate if you c an eat and drink but the amount is substantially decreased, or  severe if  you are unable to eat and drink. Note:  Cabozantinib should 
be taken daily at same time if possible.  Cabozantinib should be taken on an empty stomach (fasting is required 2 hours before and 1 hour after each cabozantinib dose).  Do NOT re- take if vomiting occurs after taking a 
scheduled dose.  
  
PID 1: ______   PID 2:  _______  
Cycle Number:  
Cycle Start Date:   
 Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 
Dose Tak en 
place X in  box  1 = Taken  
 2 = Missed   1 = Taken  
 2 = Missed   1 = Taken  
 2 = Missed    1 = Taken  
 2 = Missed  
  1 = Taken  
 2 = Missed  
  1 = Taken  
 2 = Missed  
  1 = Taken  
 2 = Missed  
 Dose  
(taken once  per da y)  
          mg  
          mg  
          mg  
          mg  
          mg  
          mg  
          mg 
Date Dose Taken   
 
  /   /  ______   
 
   /   /  ______   
 
   /   /  ______   
 
   /   /  _______   
 
   /   / ________   
 
   /   / ________   
 
        /   /  ______  
 
Time Do se Tak en  
  :   AM 
PM   
  :   AM 
PM   
  :   AM 
PM 
  
  :   AM 
PM   
  :   AM 
PM   
  :   AM 
PM   
  :   AM 
PM  
SIDE EF FECTS 
Nausea  † 
see sc ale below and 
place X in  box  0 = None  
 1 = Mild  
 2 = Moderate  
 3 = Severe  
  0 = None  
 1 = Mild  
 2 = Moderate  
 3 = Severe  
  0 = None  
 1 = Mild  
 2 = Moderate  
 3 = Severe  
  0 = None  
 1 = Mild  
 2 = Moderate  
 3 = Severe  
  0 = None  
 1 = Mild  
 2 = Moderate  
 3 = Severe  
  0 = None  
 1 = Mild  
 2 = Moderate  
 3 = Severe  
  0 = None  
 1 = Mild  
 2 = Moderate 
 3 = Severe  
 Vomiting  
# of times  in 24 hr        
Diarrh ea 
# of times  in 24 hr        
Rash 
Specify Location           
Other: write in                       
OTHER MEDICATIONS  
 Medication  Name  Dose Frequen cy Start  Date  Stop Date  Reason for  Use of Medic ation 
      /   /       /   /     
    
  /   /     
  /   /     
      /   /       /   /     
NF Protocol #105   Version 2.1 
05/01/2019  
84 
 APPENDIX IV:  PROTOCOL FOR REQUIRED PRE -STUDY AND ON-STUDY 
MRI STUDIES  
Prior to starting treatment on this study a target plexiform neurofibroma must be identified.  
In addition, up to two non-target plexiform neurofibromas may be identified as well.  
The goal will be to use 3- D MRI only to follow the target and non- target  plexiform 
neurofibroma(s) (a maximum of three lesions), which will be defined as index lesion(s).  
Pre-study imaging evaluation: 
1. Identify and select the index plexiform neurofibroma(s) (a maximum of three lesions) 
for 3 -D MRI evaluation based on prior imaging studies. Should there be more than 3 
progressing plexiform neurofibromas; the three most clinically relevant plexiform 
neurof ibromas should be followed by 3 -D MRI analysis.  
2. Perform 3 -D MRI sequences on the selected index lesions as outlined in the MRI 
acquisition protocols below.  
 
On study imaging evaluation: 
 
Unless clinically indicated otherwise obtain MRI of the index lesion s only as outlined in 
the MRI acquisition protocol below at baseline and then after cycle  4, 8, 12, 1 8, 24 and end 
of study. 
 
MRI protocols:  
 
Images intended for volumetric analysis need to be performed without gaps between slices. 
Every attempt should be made to image the entire PN. The target tumor should be positioned close to the center of the imaging field and the outer edge of the tumor should be within the field of view. Peripheral nerve sheath tumors can be well visualized without the use of contras t agents on short TI inversion recovery (STIR) sequences because they 
have high signal intensity relative to normal tissues. The imaging protocol in the table below should be used for the imaging of the target and non target PN.   If necessary, participating institutions may modify the MRI sequences to optimize differentiation of tumor and surrounding tissue.  Modifications should be noted, such that the same imaging protocol, and, if possible, the same MRI scanner, can be used for all 
subsequent MRI studies.  All MRI studies requested per protocol will be submitted to the NCI POB within 1 week of acquisition for volume analysis.         
NF Protocol #105   Version 2.1 
05/01/2019  
85 
  
  
Volumetric sequence for PN**  
Axial STIR  Recommended  
Range  Head -Neck or 
Small## Trunk -
Extremity PN  Large## Trunk -
Extremity PN  
Echo Train Length 5 - 15 7 15 
TR 3000 - 6000 6000 4000 
TE 30 - 50 34 30 
TI 150-180 150 150 
Slice Thickness  3 - 10 mm 3 mm 10 mm 
Skip 0 0 0 
Matrix  256x256 -  
512x512  256x256 320 x256 - 
512x512  
FOV  18 - 50 cm 22 cm 45 cm 
Phase FOV  0.8 0.8 0.8 
NEX  2 - 4 3 2 
Frequency Direction  A→P A→P A→P 
**Spinal/paraspinal PN should be imaged with the appropriate protocol based on tumor size. 
Tumors that include the neck and trunk, for which the majority of the tumor is in the trunk, should 
be imaged with the Large Trunk- Extremity PN protocol.  
##Tumors < 5 cm in longest diameter would be considered small.  Tumors > 10 cm longest diameter would be considered large.  Tumors bet ween 5 -10 cm in longest diameter should be imaged with 
the appropriate protocol based on best FOV coverage.   
Please contact Dr. Dombi if there are questions regarding the appropriate coverage or imaging 
protocol. 
NF Protocol #105   Version 2.1 
05/01/2019  
86 
 Data Analysis:  
• All MRI data will be analyzed at the Pediatric Oncology Branch of the NCI.  The MRI 
data from each scan will be processed to assess the volume of the index plexiform neurofibroma(s). The tumor will be traced on subsequent contiguous MR slices, the numbers summed and then multiplied by the slice thickness to obtain a numerical volume measurement.  The tumor will be identified by high signal on the STIR images not corresponding to known normal anatomic structures and corresponding with the cycle  of known nerves. Each subject ’s volumetric measurement obtained from the 
initial MRI will serve as the baseline against which to assess incremental changes in volume that occur during the subsequent intervals.  Volumetric measurements and 1-D, and 2- D data analysis will be done by 3 physicians  trained in 1- D, 2-D, and 3- D 
MRI data analysis at the Pediatric Oncology Branch, NCI at an Image Review Workstation using MEDx software (Sensor Systems Inc.). Volumetric measurements will be used to determine disease progression as outlined in Section 13.0. Drs. Dombi 
and Widemann will inform Participating Investigators, the Principal Investigator, and the NF Consortium Operations Center about the results of the MRI study by written report.  
 
Image and Data Acquisition: 
• In order to perform quantitative analysis the Pediatric Oncology Branch must receive 
the imaging data from the investigator sites. All MRI studies requested per protocol 
will be submitted to the NCI POB within 1 week of acquisition for volume analysis. The Pediatric Oncology Branch will check all materials received for completeness and will notify the site if data, images, or information are missing or incomplete.   Dr. Dombi 
will confirm for each patient in screening that the MRI imaging is adequate and that the target PN is measurable and  amenable to volumetric MRI analysis.    
• Address for shipment of imaging studies: Eva Dombi, MD NCI, POB  
10 Center Drive, Building 10, room 1-5750 Bethesda, MD 20892-1101 Phone : 301-451-7023 
E-mail: dombie@mail.nih.gov   
NF Protocol #105   Version 2.1 
05/01/2019  
87 
 APPENDIX V:  BIOMARKER STUDIES  
 
Biomarker Submission 
A.  Cytokines 
Peripheral blood (6mL) will be collected via venous puncture into an 8 mL EDTA purple top tube (or divide between two 6 mL EDTA tubes).  Spin at 2200 rpm 
(1200-1300g) for 15 minutes (break and acceleration ‘on’) at 4°C.  Collect plasma 
and distribute/aliquot 1-1.5 mL into each 2mL cryovial (1-5 cyrovials). Fix a printed label on each tube with: site, patient ID number, sample time point, date, a 
# and amount/vial. Store samples  at -80⁰C until being shipped as a batch on dry 
ice.     
Ship by FedEx Monday to Thursday on dry ice to: 
CCRC, Indiana University School of Medicine  
705 Riley Hospital Dr. 
RI 2641 
Indianapolis, IN 46202 Attn: Khadijeh (Sholeh) Bijangi -Vishehsaraei, MS, PhD  
 
B. Endothelial Progenitor Cell (Contacts: Emily Sims, ecwillar@iu.edu  and Matt 
Repass, mjrepass@iu.edu ) 
Once a subject has been identified and a baseline visit has been scheduled email:  
nfstudy@iu.edu  to have CPT and balance CPT  tubes sent to your site.  CPT tubes 
have a 6 month shelf life.  Store CPT tubes in an upright position out of direct 
sunlight and heat.  
 
16 mL of peripheral blood (PB) will be collected via venous puncture into three 
6mL EDTA purple top tube.  For local processing, the PB sample will then be brought to the Angio BioCore at Indiana University  with processing beginning 
within one hour of collection.  
 For off- site samples, 16 mL of PB will first be collected via venous puncture into three 
6mL EDTA purple top tubes.  The PB will then be transferred into two  8mL CPT tubes, 
gently invert eight times to mix blood with anticoagulant. The sample must be processed within 2 hours  of blood collection . C entrifuge for 30 minutes at 1500-1800g at room 
temperature.  The centrifugation wi ll separate the mononuclear cell (MNC) fraction and 
the plasma above the ficoll plug with the red blood cells passing through and going beneath the plug. Following centrifugation, the plasma/MNCs will then be poured into two clean/new 6mL EDTA tube s and shipped overnight (at room temperature)  to the 
Angio BioCore .  The MNCs are stable for 24 hours post collection after centrifugation 
and, therefore, must be shipped same day. All tubes should be labeled with site, patient ID number, sample time p oint, and date. 
 Please only ship samples by Federal Express priority overnight Monday through 
Thursday .  Please inform the Angio BioCore of your incoming shipment 
NF Protocol #105   Version 2.1 
05/01/2019  
88 
 (ecwillar@iupui.edu, mjrepass@iupui.edu ). 
 
Ship by FedEx to: 
Emily Sims & Matt Repass  
 Angio BioCore Lab  
980 West Walnut Street, R3 Room C343 Indianapolis, IN, 46202 317-278-7232 
  
NF Protocol #105   Version 2.1 
05/01/2019  
89 
 APPENDIX VI:  PHARMACOKINETIC STUDIES  
Pharmacokinetic  Worksheet  
 
Subject Consortium ID number: _____________ 
BSA (m2):  Cabozantinib (mg)   mg given :   
 
Cohort A (≥16 years of age) 
Each study site will need: 
1.  Centrifuge with horizontal rotor capable of producing 1200 x g ( set to 4oC). 
2.  Non -defrosting freezer ( -70°C or below) 
 
Once sites have approval for enrollment and have possible candidate(s) , contact  Linh 
Nguyen , linguyen@exelixis.com  & Clinical_Supplies@exelixis.com  to request PK 
laboratory kits.  Request should include completed PK request form. Provide correct contact person and shipping address for shipments and allow 5 days for shipment.  Clinical sites will receive a Pharmacokinetic (PK) kit for each subject from Exelixis.  Since PK kits are subject specific, do not interchange materials between the kits.  Each kit contains several extra tubes and labels in addition to those required for the scheduled collections.  
 For Cohort A t here will be a total of 6 samples drawn.   Blood samples (3mL will be drawn 
for pharmacokinetic profile during cabozantinib (XL184) therapy at the following 
timepoints:  
• Cycle 1, Day 1 (C1D1):  Pre-cabozantinib dose (collected within 15 minutes prior to cabozantinib dosing) and 4 hours post cabozantinib dose 
• Cycle 1, Day 15 (C1D15): Pre-cabozantinib dose (collected within 15 minutes prior to cabozantinib dosing), and 4 hours post cabozantinib dose  
• Cycle 1, Day 28 (C1D28): Pre-cabozantinib dose (collected within 15 minutes prior to cabozantinib dosing), and 4 hours post cabozantinib dose  
  
Procedure for Cohort A:    
Samples will be drawn as 3 mL whole blood into K2EDTA (lavender top) tubes  
1. Prior to obtaining blood from subj ects at each timepoint, gather the following 
supplies together from the Study XL184- IST-014 PK Kit and your site supplies:   
• Obtain three barcoded plasma labels for PK sample. Confirm that the sample 
type, the date and collection time pre-printed on each label correspond with the sample type, date and time you will be collecting  
• One 3 mL K2 -EDTA Vacutainer tube for each PK sample timepoint 
• Two Polypropylene tubes for PK plasma aliquot   
• Transfer pipettes  
• Dry ice (if –20 or -70°C freezer is not available)  
2. Write the subject number, and site number (as applicable) in the spaces provided on the label.  Record the last four digits from the barcode on the label onto the subject’s 
NF Protocol #105   Version 2.1 
05/01/2019  
90 
 chart and PK shipping logs in the comment column. See Figure below for an example of 
the barcoded labels  
3. Apply the barcoded labels to each of the three tubes for PK samples (1 for whole 
blood and 2 for plasma aliquots). 
4. Secure each label with a strip of transparent cellophane tape.  
 
(Note: it is important that the following steps are completed in sequence immediately 
within 30 minutes after collection of blood samples, unless otherwise noted):  
5. Collect 3  mL of blood into a pre- labeled K2 -EDTA Vacutainer tube (the tube with 
the Lavender Top)  
6. Record the exact time (24 -hour clock) that each sample was collected (be sure to use 
the same clock for recording both sampling and dosing times). 
7. Invert the collection tube gently at least 5  times. (If separation of the plasma fraction 
cannot be immediately performed at this time, store the samples on ice, or refrigerate 
the sample, and re-mix the samples by gentle inversion prior to proceeding to step 8). 
8. Separate the plasma fraction by centrifugation (1000 -1200 ×  g for 10  minutes) using 
standard laboratory methods, materials, and equipment. A refrigerated centrifuge is preferred, and if available, should be set to 4ºC. 
9. Aliquot the plasma (equal volume) into each of two pre- labeled 5 -mL polypropylene 
tubes (primary and backup aliquots), being careful not to transfer blood cells.  
10. Verify that each tube is tightly capped.  
11. Store the plasma aliquots immediately in a non -defrosting freezer at -70°C ( -20°C 
freezer can be used if -70°C freezer is not available). Samples must be stored on dry 
ice if a freezer is not immediately available.  
12. For each subject, plasma samples should be shipped on dry ice to Alturas. 
 
  
NF Protocol #105   Version 2.1 
05/01/2019  
91 
 Figure: Example of the barcoded label for Plasma PK Samples  
 
 
  
lllllllllllllllllllllllllllllllllll  
  
  
  
Subject #:  _______  
  
  
 
  
Coll Date: Y  
  
Coll Time: Z  
  
Site #: _________  
  
Matrix: Plasma  
  
Subject No.  
 
Site No  
Record on CRF and PK 
Shipping Log 
Handwrite the following onto the label: 
  41092000XXXX  
   41092000XXXX  
NF Protocol #105   Version 2.1 
05/01/2019  
92 
 Cohort B (3-15 years of age)  
Sites will use their own supplies to collect PK samples and apply a pre -printed label. The 
following supplies will be needed per timepoints: 
1. Vacutainer Lavender Top Plastic, K2 EDTA, 3 mL tube 
2. Transfer tube cryovial, 1.5 mL 
3. Transfer pipettes  
4. Labels  
5. Dry ice  
6. Centrifuge with horizontal rotor capable of producing 1200 x g ( set to 4oC). 
7.  Non -defrosting freezer ( -70°C or below) 
 
For Cohort B there will be a total of 4 samples drawn.  Blood samples (3ml will be drawn for pharmacokinetic profile during cabozantinib (XL184) therapy at the following 
timepoints:  
• Cycle 1, Day 1 (C1D1): Pre -cabozantinib dose (collected within15 minutes prior to 
cabozantinib dosing)  
• Cycle 2, Day 1 (C2D1) ±2 days: Pre -cabozantinib dose (collected within 15 minutes 
prior to Cabozantinib dosing),  
• Cycle 3 Day 1  (C3D1) ±2 days: Pre -cabozantinib dose (collected within15 minutes 
prior to cabozantinib dosing) 
• Cycle 4 Day 1 (C4D1) ±2 days: Pre -cabozantinib dose (collected within15 minutes 
prior to cabozantinib dosing)  
Procedure for Cohort B:    
Samples will be drawn as 3 mL whole blood into K2EDTA (lavender top) tubes 
 
1. Prior to obtaining blood from subjects at each timepoint, gather the following supplies:   
• One 3 mL K2 -EDTA Vacutainer tube for each PK sample timepoint 
• Transfer tube cryovial, 1.5 mL  
• Transfer pi pettes 
• Labels  
• Dry ice (if –20 or -70
°C freezer is not available)  
2. Write the subject number, site number (as applicable) and Visit (C1D1, C2D1, C3D1 
or C4D1) on the label s. 
3. Apply the labels to each of the three tubes for PK samples (1 for whole blood and 2 for plasma aliquots). 
4. Secure each label with a strip of transparent cellophane tape.  
 
(Note: it is important that the following steps are completed in sequence immediately 
within 30 minutes after collection of blood samples, unless otherwise noted): 
 
5. Colle ct 3 mL of blood into a pre -labeled K2 -EDTA Vacutainer tube (the tube with the 
Lavender Top)  
6. Record the exact time (24 -hour clock) that each sample was collected (be sure to u se 
the same clock for recording both sampling and dosing times). 
7. Invert the coll ection tube gently at least 5  times. (If separation of the plasma fraction 
NF Protocol #105   Version 2.1 
05/01/2019  
93 
 cannot be immediately performed at this time, store the samples on ice, or refrigerate 
the sample, and re-mix the samples by gentle inversion prior to proceeding to step 8). 
8. Separat e the plasma fraction by centrifugation (1000-1200 × g for 10  minutes) using 
standard laboratory methods, materials, and equipment. A refrigerated centrifuge is preferred, and if available, should be set to 4ºC. 
9. Aliquot the plasma (equal volume) into each of two pre -labeled 5 -mL cryovial  tubes 
(primary and backup aliquots), being careful not to transfer blood cells.  
10. Verify that each tube is tightly capped.  
11. Store the plasma aliquots immediately in a non -defrosting freezer at -70°C ( -20°C 
freezer can be used  if -70°C freezer is not available). Samples must be stored on dry 
ice if a freezer is not immediately available.  
12. For each subject, plasma samples should be shipped on dry ice to Alturas. 
 Packaging Instructions:  
1. The first aliquot of PK samples should be shipped to Alturas Inc. after each subject completed the C1D28 (for Cohort A) and C4D1 (for Cohort B).  
2. The second aliquot of PK samples should be maintained at the sites as backup samples and be shipped along with the next available shipment.  
3. Please pack all the samples for each subject in each sealable bag  
4. Prior to shipment, verify that each tube is tightly sealed. 
5. Place the tubes into a sealable plastic bag (one subject per bag) surrounded by absorbent material.  
6. Complete the PK s ample Shipping Log ( noted below) based on the information on 
the site form recorded by the site staff. For each subject, place a copy of the shipping log into its own plastic bag, seal, and then add it to the bag containing that patient’s samples. Retain a  copy of each shipping log for your records. Seal 
the bag. 
7. Place the plastic bags into a suitable Styrofoam shipping container (e.g.,  ThermoSafe) and fill with enough dry ice for 2 days in transit 
(e.g.,  14 pounds). 
8. Write the FedEx tracking number on each shipping log sheet and fax the log sheet to the attention of Dr. Zimmer at Alturas at (208) 882-9246. 
9. Complete the Federal Express air bill and place it on the outside of the shipping container.  
 
After each shipment, please notify Linh Nguyen, PhD ( linguyen@exelixis.com) , Jennifer 
Zimmer, PhD  (jzimmer@alturasanalytics.com ) at Alturas Ajalytics,  and the NF 
Consortium Operations Center  representative, Lynn  Merritt, RN (nfcop@uab.edu). 
 Shipping Instructions:   Samples will be shipped on dry ice Monday thru Thursday by 
Federal Express.  
 
Ship samples to:  
Alturas Analytics, Inc.  
Attn: Jennifer Zimmer, PhD 
Executive Laboratory Manager  
NF Protocol #105   Version 2.1 
05/01/2019  
94 
 1324 Alturas Dr. 
Moscow, ID 83843 Phone: (208) 883-3400 Fax: (208) 882-9246 Email: jzimmer@alturasanalytics.com
 
  ** NOTE:  Samples should be stored in -70°C freezer until the C1D28 (for Cohort A) and C4D1 (for Cohort B),and shipped as a batch per subject.  
  
NF Protocol #105   Version 2.1 
05/01/2019  
95 
 Cohort A: Protocol XL184- IST-014 PK Plasma Samples Shipping Log Relative to 
Dosing Time 
Site Number:  Site Name:  
Subject ID:   
Comments  : 
(Please note any 
discrepancies)  
 
Visit  PK Sample Shipped  
Not 
Done  Date 
Collected                      
(dd mmm 
yyyy)  Time  
(24-h 
clock)  Nominal 
Time 
Relative to 
Dosing Hour  Plasma Sample  
Prima
ry Back
up 
 
Cycle 1, Day 
1 (C1D1)  0 (pre -dose)         _____:__
___  
4 hours post -
dose        _____:__
___  
Cycle 1, Day 
15 
(C1D15)  0 (pre -dose)         _____:__
___  
4 hours post -
dose        _____:__
___  
Cycle 1, Day 
28 
(C1D28)  0 (pre -dose)  
 
4 hours post -
dose  
  
 
  
  
 
  
 
 
 
  _____:__
___ 
 
_____:__
___  
 
  Shipping Prepared by: ______________________ Date S hipped: __________________ 
  Courier Used: ____________________________ Track ing No. __________________ 
 Fax to the attention of Dr. Jennifer Zimmer at Alturas at Fax: (208) 882-9246.     
N F  Pr ot oc ol # 1 0 5   V ersi o n 2. 1 
0 5 / 0 1 / 2 0 1 9   
9 6 
 C o h ort B: Pr ot o c ol X L 1 8 4- I S T - 0 1 4 P K Pl as m a S a m ples S hi p pi n g L o g Rel ati ve t o 
D osi n g Ti me 
 
Site N u m ber:  Site N a me:  
S u bject I D :   
C o m me nts  : 
( Pl e ase n ote 
a n y 
discre p a ncies)  
 
Visit  P K S a m ple S hi p pe d  
N ot 
D o ne  D ate 
C ollecte d                      
( d d m m m 
y y y y) Ti me  
( 2 4 -h 
cl oc k)  N o mi n al 
Ti me 
Rel ati ve t o 
D osi n g 
H o ur  Pl as m a S a m ple  
Pri m a 
r y  B ac k u 
p 
 
C ycle 1, Da y 1 
( C 1 D 1)  0 ( pre -d os e)      _ _ _ _ _: 
_ _ _ _ _   
C ycle 2, Da y 1 
( C 2D 1)  0 ( pre -d os e)      _ _ _ _ _: 
_ _ _ _ _   
C ycle 3, Da y 1  
( C 3D 1)  0 ( pre -d os e)      _ _ _ _ _: 
_ _ _ _ _   
C ycle 4, Da y 1  
( C 4D 1)  0 ( pre -d os e)      _ _ _ _ _: 
_ _ _ _ _   
 
 
 
S hi p pi n g Pre par e d b y: _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ Date S hi p pe d: _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ 
 
 
 
C o urier Use d: _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ Trac k i n g N o. _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ 
 
F a x t o t he att e nti o n of Dr. Je n nif er Zi m mer at Alt ur as at F a x: ( 2 0 8) 8 8 2- 9 2 4 6.  
 
NF Protocol #105   Version 2.1 
05/01/2019  
97 
 APPENDIX VII:  CONSORTIUM QOL AND PAIN MEASURES  
 
Below is a description of the QOL and pain measures to be administered in this protocol organized by the domain that the questionnaire assesses.    
SUBJECTS > 16 YEARS:  
 
NF1 Disease Specific QOL Measure  
The Adult PedsQL™ NF1 Module  is a 74 -item a self -report instrument to assesses NF1 
disease-specific quality of life (QOL) in adults, ages 21 years and older. It is comprised of 
16 scales: 1) Physical functioning (8 items), 2) Emotional functioning (5 items), 3) Social functioning (3 items), 4) Cognitive functioning (5 items), 5) Communication (3 items), 6) 
Worry (7 items), 7) Perceived physical appearance (3 items), 8) Pain and Hurt (3 items), 9) Paresthesias (2 items), 10) Skin irritation (5 items), 11) Sensation (4 items), 12) Movem ent and Balance (4 items), 13) Fatigue (3 items), 14) Daily activities (12 items), 
15) Treatment anxiety (4 items) and 16) Sexual functioning (3 items) (Nutakki et al., submitted; N. Swigonski, personal communication, September 26, 2012).   
 
The Teen PedsQ L™ NF1 Module  is a 75 -item self -report for adolescents and young adults, 
ages 14 to 20 years of age, which includes 16 scales: 1) Physical functioning (8 items), 2) Emotional functioning (5 items), 3) Social functioning (3 items), 4) Cognitive functioning (7 items), 5) Communication (3 items), 6) Worry (6 items), 7) Perceived physical appearance (3 items), 8) Pain & Hurt (3 items), 9) Paresthesias (2 items), 10) Skin irritation (5 items), 11) Sensation (4 items), 12) Movement & Balance (4 items), 13) Fatigue (3 items), 14) Daily activities (12 items), 15) Treatment anxiety (4 items) and 16) School Activities (3 items).  
 The PedsQL™ NF1 Module format, instructions, and Likert response scale are similar to the PedsQL™ 4.0 Generic Core Scales and other PedsQL™ Disease -Specific Modules. 
The instructions ask how much of a problem each item has been during the past one month.  A 5-point response scale is used for all items in the three versions of the instrument (0= 
never a problem, 1= almost never a problem, 2= sometimes a problem, 3= often a problem, 4= almost always a problem). Items are reverse scored and linearly transformed to a scale of 0-100 similar to PedsQL™
 4.0 Generic Core Scales (0= 100, 1= 75, 2= 50, 3=25, 4=0).  
Higher scores indicate better HRQOL and  fewer symptoms or problems.  The total scale 
score is computed as the sum of all items on the PedsQL™ NF1 Module divided by the number of items answered (this accounts for missing data).  Subscale scores are computed as the sum of the items divided by the  number of items that were answered in that scale.  If 
more than 50% of the items in the scale are missing, the scale score is not computed.  Feasibility, measured by the percentage of missing responses, was 4.8 % for all scales on the adult version of the  PedsQL™ NF1 Module.  Internal consistency reliability for the 
Total Scale score (alpha =0.97) and Scale reliabilities ranging from 0.72 to 0.96 were acceptable for group comparisons. The PedsQL™ NF1 module distinguished between NF1 adults with excellent to very good, good, and fair to poor health status.  Thus, preliminary data demonstrates the initial feasibility, reliability and validity of the PedsQL™ NF1 
NF Protocol #105   Version 2.1 
05/01/2019  
98 
 module in adult subject s (Nutakki et al., personal communication).  The preliminary data 
in a small sample of adolescents also looks promising with good feasibility (percentage of 
missing responses was 8.9%) and a total scale reliability of 0.96 (N. Swigonski, personal communication, October 10, 2012).   
 
Pain Measures  
 
1. Pain Intensity 
The Numerical Rating Scale- 11 (NRS -11) is a self -report segmented 11 -point numeric 
scale that assesses pain intensity22.  It consists of a horizontal line with 0 representing “no 
pain” at the right end of the line and 10 representing “worst pain you can imagine” at the 
left end.  Subject s are asked to circle the one number from 0 to 10 that best describes their 
“most important tumor pain”  and 2) their “overall tumor pain”  at its worst during the past 
week.  It takes less than 1 minute to complete.  The NRS -11 is r ecommended as a core 
outcome measure of pain intensity for clinical trials21.   
 
2. Pain Interference  
The Brief Pain Inventory (BPI) —Pain Interference Scale is a 7 -item self -report 
questionnaire that measures the extent to which pain interferes with daily functioning20.  
Subject s are asked to indicate how much pain interfered with various activities (general 
activity, mood, walking, normal work, relations with other people, sleep, and enjoyment of life) in the past week, with scores ranging from 0 (does not interfere) to 10 (completely interferes).  A total score is obtained by taking the mean of the scores for all 7 items; thus, the total pain interference score can range from 0 to 7. This scale takes less than 2 minutes to complete.  These items are recommended to assess pain interference in clinical trials
21.  
 
Background Information 
To allow for more meaningful analysis of the QOL data, the participant (for subject s > 16 
years) will complete a background information form at study entry and each subsequent 
QOL evaluation.  This form will collect general information such as the subject ’s level of 
education, work status, psychiatric diagnoses, and pain medications, as well as the perceived visibility of NF1 tumors and severity of NF1 symptoms.   
 
Administration Guidelines  
These QOL and pain measures should be completed pre -treatment, afte r cycle  4 +2 weeks, 
8 +2 weeks, 12 +2 weeks, 18 +2 weeks, and 24 +2 weeks.  When administering these forms, 
review the instructions with the subject s and check to make sure they answered all the 
items.  If subject s have difficulty reading, it is permissible to read the items to them, but 
the subject s should answer the items themselves.  Completed forms should be sent (fax or 
mail copies) to the NF Consortium Operations Center within 2 weeks of completion.  For 
any questions regarding the QOL/pain assessment please contact: Pam Wolters at 
woltersp@mail.nih.gov . 
 
If subject s are 21 years old at st udy entry, they should be administered the Adult PedsQL 
NF1 Module.  If subject s are 16 to 20 years old at study entry, they should be administered 
the Teen PedsQL NF1 Module. However, if subject s turn 21 years old during the study, 
NF Protocol #105   Version 2.1 
05/01/2019  
99 
 they should continue to be administered the Teen version of this scale that they started at 
study entry.  
All subject s should complete the same self -report pain intensity and pain interference 
measures and background form.  
 Please see section 9 for a table listing the self -repor t QOL and pain measures to be 
completed by the subject . 
 
 
  
NF Protocol #105   Version 2.1 
05/01/2019  
100 
 NF1 QOL BACKGROUND INFORMATION SHEET  
 
 
 
   

NF Protocol #105   Version 2.1 
05/01/2019  
101 
 PAIN QUESTIONNAIRE  
 
 
 
NF Protocol #105   Version 2.1 
05/01/2019  
102 
QOL INSTRUMENT (TEEN REPORT) : 16 to 20 years old  
  
QOL INSTRUMENT (TEEN REPORT)  
For teens and young adults (16 to 20 years old) with NF-1 
 
 
 
                                                    DIRECTIONS  
Teens with neurofibromas sometimes have special problems. Please tell us how much of a problem each 
one has been for you during the past ONE month by choosing the appropriate options : 
 
0 if it is never  a problem              
1 if it is almost never  a problem  
2 if it is sometimes a problem 
3 if it is often  a problem  
4 if it is almost always  a problem  
  
There are no right or wrong answers. 
If you do not understand a question, take your best guess. 
Thank you for your help! 
                                                                                                                                                    
                                                                                                                                                    
  
NF Protocol #105   Version 2.1 
05/01/2019  
103 
QOL INSTRUMENT (TEEN REPORT) : 16 to 20 years old  
 Participant’s Study ID:     Course Number:    
Protocol:      Visit Date:     
 
 
Please select which of the following describes you the best:  
o I am a teen or young adult  (14 to 20 years old) with Neurofibromatosis Type 1 (NF-1) 
o Other, please specify _______________________________  
 How old are you? (in years)  ________________ 
 Do you have plexiform neurofibromas?  
o Yes  
o No 
o Don’t know 
If yes, on a scale of 0 to 10 (where 0 is plexiform neurofibromas have no impact to 10 where plexiform neurofibromas have a huge impact), please rate the impact of your plexiform neurofibromas on your day -to-day life. ___________ 
 
In general, how would you rate your health? 
o Excellent  
o Very Good 
o Good 
o Fair 
o Poor 
  
How many times did you visit the doctor for your NF-1 in the past ONE year?  ____________ 
On average, how many different medications do you take for your NF-1 in a day? _________  
   
 
 
 
  
NF Protocol #105   Version 2.1 
05/01/2019  
104 
QOL INSTRUMENT (TEEN REPORT) : 16 to 20 years old  
 Participant’s Study ID:     Course Number:    
Protocol:      Visit Date:     
 
 
In the past ONE month , how much of a problem  has this been for you...  
PHYSICAL FUNCTIONING  (problems with...)  Never  Almost  
Never  Some - 
times  Often  Almost  
Always  
1.  Having headaches  0 1 2 3 4 
2.  Feeling physically weak  0 1 2 3 4 
3.  Walking more than one block  0 1 2 3 4 
4.  Climbing stairs  0 1 2 3 4 
5.  Running  0 1 2 3 4 
6.  Doing a sports activity or exercise  0 1 2 3 4 
7.  Lifting something heavy  0 1 2 3 4 
8.  Doing chores around the house  0 1 2 3 4 
 
EMOTIONAL FUNCTIONING  (problems with...)  Never  Almost  
Never  Some - 
times  Often  Almost  
Always  
1.  Feeling anxious  0 1 2 3 4 
2.  Feeling sad  0 1 2 3 4 
3.  Feeling angry  0 1 2 3 4 
4.  Feeling frustrated  0 1 2 3 4 
5.  Feeling helpless or hopeless  0 1 2 3 4 
 
SOCIAL FUNCTIONING  (problems with...)  Never  Almost  
Never  Some - 
times  Often  Almost  
Always  
1.  Feeling isolated from others       0       1      2     3      4 
2.  Getting  support from others       0       1      2     3      4 
3.  Having enough energy for social activities       0       1      2     3      4 
 
COGNITIVE FUNCTIONING  (problems with...)  Never  Almost  
Never  Some - 
times  Often  Almost  
Always  
1.  Keeping attention  on things       0       1      2     3      4 
2.  Remembering what people tell you       0       1      2     3      4 
3.  Remembering what you just heard or read       0       1      2     3      4 
4.  Thinking quickly       0       1      2     3      4 
5.  Solving math problems       0       1      2     3      4 
6.  Writing school papers or reports       0       1      2     3      4 
7.  Remembering what you were just thinking       0       1      2     3      4 
    
NF Protocol #105   Version 2.1 
05/01/2019  
105 
QOL INSTRUMENT (TEEN REPORT) : 16 to 20 years old  
 Participant’s Study ID:     Course Number:    
Protocol:      Visit Date:     
 
 
COMMUNICATION  (problems with...)  Never  Almost  
Never  Some - 
times  Often  Almost  
Always  
1.  Telling the doctors and nurses how you feel  0 1 2 3 4 
2.  Asking the doctors and nurses questions  0 1 2 3 4 
3.  Talking with others about your disorder  0 1 2 3 4 
 
WORRY  (problems with...)  Never  Almost  
Never  Some - 
times  Often  Almost  
Always  
1.  Worrying about neurofibromas  0 1 2 3 4 
2.  Worrying about side effects from medical 
treatments  0 1 2 3 4 
3.  Worrying about whether or not medical treatments 
are working  0 1 2 3 4 
4.  Worrying that neurofibromas will grow bigger or 
reoccur  0 1 2 3 4 
5.  Worrying about my future or the risk of having 
children  with Neurofibromatosis Type 1  0 1 2 3 4 
6.  Worrying about the risk of other health related 
issues associated with Neurofibromatosis Type 1  0 1 2 3 4 
 
PERCEIVED PHYSICAL APPEARANCE  
 (problems with...) Never  Almost  
Never  Some - 
times  Often  Almost  
Always  
1.  Feeling that I am not good looking  0 1 2 3 4 
2.  Not wanting other people to see my neurofibromas  0 1 2 3 4 
3.  Being embarrassed about others seeing my body  0 1 2 3 4 
 
PAIN AND HURT (problems with...)  Never  Almost  
Never  Some - 
times  Often  Almost  
Always  
1.  Aching or hurting  0 1 2 3 4 
2.  Aching or hurting a lot  0 1 2 3 4 
3.  Not sleeping because of pain  0 1 2 3 4 
 
PARESTHESIAS (problems with...)  Never  Almost  
Never  Some - 
times  Often  Almost  
Always  
1.  A burning sensation in some part of my body  0 1 2 3 4 
2.  A tingling sensation in some part of my body  0 1 2 3 4 
 
 
 
  
NF Protocol #105   Version 2.1 
05/01/2019  
106 
QOL INSTRUMENT (TEEN REPORT) : 16 to 20 years old  
 Participant’s Study ID:     Course Number:    
Protocol:      Visit Date:     
 
SKIN IRRITATION (problems with...)  Never  Almost  
Never  Some - 
times  Often  Almost  
Always  
1.  Itching  0 1 2 3 4 
2.  Itching a lot  0 1 2 3 4 
3.  Getting a  skin rash when exposed to sun  0 1 2 3 4 
4.  Tolerating temperature changes  0 1 2 3 4 
5.  Rough skin  0 1 2 3 4 
 
SENSATION (problems with...)  Never  Almost  
Never  Some - 
times  Often  Almost  
Always  
1.  Vision in one or both eyes  0 1 2 3 4 
2.  Seeing  well enough with glasses or contact  lenses   0 1 2 3 4 
3.  Hearing in one or both ears  0 1 2 3 4 
4. Speech  0 1 2 3 4 
 
MOVEMENT AND BALANCE  (problems with...)  Never  Almost  
Never  Some - 
times  Often  Almost  
Always  
1.  Bending my body  0 1 2 3 4 
2.  Moving  one or both legs  0 1 2 3 4 
3.  Using or moving one or both arms  0 1 2 3 4 
4.  Keeping balance when sitting/standing  0 1 2 3 4 
 
SCHOOL ACTVITIES  (problems with...)  Never  Almost  
Never  Some - 
times  Often  Almost  
Always  
1.  Writing or drawing with a pen or  pencil  0 1 2 3 4 
2.  Carrying school books  0 1 2 3 4 
3.  Using a mouse or keyboard on the computer  0 1 2 3 4 
 
DAILY ACTVITIES (problems with...)  Never  Almost  
Never  Some - 
times  Often  Almost  
Always  
1.  Putting on shoes  0 1 2 3 4 
2.  Buttoning my shirt  0 1 2 3 4 
3.  Combing my hair  0 1 2 3 4 
4.  Getting into the bathroom to use the toilet  0 1 2 3 4 
5.  Undressing to use the toilet  0 1 2 3 4 
6.  Getting in and out of bathtub or shower  0 1 2 3 4 
7.  Brushing my teeth  0 1 2 3 4 
8.  Eating with a fork  and knife  0 1 2 3 4 
9.  Using a phone  0 1 2 3 4 
10. Shopping  0 1 2 3 4 
11. Managing money  0 1 2 3 4 
12. Driving  0 1 2 3 4 
NF Protocol #105   Version 2.1 
05/01/2019  
107 
QOL INSTRUMENT (TEEN REPORT) : 16 to 20 years old  
 Participant’s Study ID:     Course Number:    
Protocol:      Visit Date:     
 
 
FATIGUE  (problems with...)  Never  Almost  
Never  Some - 
times  Often  Almost  
Always  
1.  Feeling tired  0 1 2 3 4 
2.  Resting a lot  0 1 2 3 4 
3.  Having enough energy to do things that I like to do  0 1 2 3 4 
 
TREATMENT  ANXIETY (problems with...)  Never  Almost  
Never  Some - 
times  Often  Almost  
Always  
1.  Getting scared about going to the doctor  0 1 2 3 4 
2.  Getting scared about going to the hospital  0 1 2 3 4 
3.  Being responsible for my medicines or  therapy  0 1 2 3 4 
4.  Managing my Neurofibromatosis Type 1  0 1 2 3 4 
 
Please write any comments that you have about how NF -1 affects your health and well -being. 
Please write any comments about the survey and whether or not it captures how NF -1 affects 
people’s health and well-being.
NF Protocol #105   Version 2.1 
05/01/2019  
108 
QOL INSTRUMENT (ADULT  REPORT) : > 21 years old  
 QOL INSTRUMENT  (ADULT SURVEY ) 
For adults (> 21 years old) with NF-1 
 
 
                                                    DIRECTIONS  
This survey is for ADULTS with NF 1.  Neurofibr omatosis type 1 sometimes causes special problems. 
Please tell us how much of a problem each one has been for you during the  past ONE month  by circling:  
 
0 if it is never  a problem 
1 if it is almost never  a problem  
2 if it is sometimes a problem 
3 if it is often  a problem  
4 if it is almost always  a problem  
 
There are no right or wrong answers. 
If you do not know an answer, take your best guess. 
Thank you for your help! 
                                                                                                                                                      
 
 
  
NF Protocol #105   Version 2.1 
05/01/2019  
109 
QOL INSTRUMENT (ADULT  REPORT) : > 21 years old  
 Participant’s Study ID:     Course Number:    
Protocol:      Visit Date:     
 
 
Please select which of the following describes you the best (you can choose more than one):  
o I am an adult with Neurofibromatosis Type 1 (NF-1)  
o I am a professional who treats people with NF-1 
o I am a friend or family member of a person with NF-1 
o Other, please specify ___________________ 
 
How old are you? (in years)  ________________ 
 
Do you have plexiform neurofibromas?  
o Yes  
o No 
o Don’t know 
If yes, on a scale of 0 to 10 (where 0 is plexiform neurofibromas have no impact to 10 where plexiform neurofibromas have a huge impact), please rate the impact of your plexiform neurofibromas on your 
day-to-day life. ___________ 
 
In general, how would you rate your health? 
o Excellent  
o Very good  
o Good 
o Fair 
o Poor 
 
How many times did you visit the doctor for your NF-1 in the past ONE year? _____________ 
 
On average, how many different medications do you take for your NF-1 in a day? _________ 
 
  
NF Protocol #105   Version 2.1 
05/01/2019  
110 
QOL INSTRUMENT (ADULT  REPORT) : > 21 years old  
 Participant’s Study ID:     Course Number:    
Protocol:      Visit Date:     
 
 
In the past ONE month , how much of a problem  has this been for you...  
PHYSICAL FUNCTIONING  (problems with...)  Never  Almost  
Never  Some - 
times  Often  Almost  
Always  
1.  Feeling physically weak  0 1 2 3 4 
2.  Walking more than one block  0 1 2 3 4 
3.  Climbing stairs  0 1 2 3 4 
4.  Running  0 1 2 3 4 
5.  Doing a sports activity  or exercise  0 1 2 3 4 
6.  Lifting something heavy  0 1 2 3 4 
7.  Doing chores around the house  0 1 2 3 4 
 
EMOTIONAL FUNCTIONING  (problems with...)  Never  Almost  
Never  Some - 
times  Often  Almost  
Always  
1.  Feeling anxious       0       1      2     3      4 
2.  Feeling sad       0       1      2     3      4 
3.  Feeling angry       0       1      2     3      4 
4.  Feeling frustrated       0       1      2     3      4 
5.  Feeling helpless or hopeless       0       1      2     3      4 
 
SOCIAL FUNCTIONING  (problems with...)  Never  Almost  
Never  Some - 
times  Often  Almost  
Always  
1.  Getting support from others       0       1      2     3      4 
2.  Having enough energy for social activities       0       1      2     3      4 
 
COGNITIVE FUNCTIONING  (problems with...)  Never  Almost  
Never  Some - 
times  Often  Almost  
Always  
1.  Keeping attention on things       0       1      2     3      4 
2.  Remembering what people tell you       0       1      2     3      4 
3.  Remembering what you just heard/read       0       1      2     3      4 
4.  Thinking quickly       0       1      2     3      4 
5.  Remembering what you were just thinking       0       1      2     3      4 
 
COMMUNICATION  (problems with...)  Never  Almost  
Never  Some - 
times  Often  Almost  
Always  
1.  Telling the doctors and nurses how you feel  0 1 2 3 4 
2.  Asking the doctors and nurses questions  0 1 2 3 4 
3.  Talking with others about your disorder  0 1 2 3 4 
Participant’s Study ID:     Course Number:    
NF Protocol #105   Version 2.1 
05/01/2019  
111 
QOL INSTRUMENT (ADULT  REPORT) : > 21 years old  
 Protocol:      Visit Date:     
 
 
WORRY  (problems with...)  Never  Almost  
Never  Some - 
times  Often  Almost  
Always  
1.  Worrying about my neurofibromas  0 1 2 3 4 
2.  Worrying about side effects from medical treatments  0 1 2 3 4 
3.  Worrying about whether or not medical treatments are 
working  0 1 2 3 4 
4.  Worrying that neurofibromas will grow bigger or reoccur  0 1 2 3 4 
5.  Worrying about my future or the risk of having children  
with Neurofibromatosis Type 1  0 1 2 3 4 
6.  Worrying about the risk of other health related issues 
associated with Neurofibromatosis Type 1  0 1 2 3 4 
 
PERCEIVED PHYSICAL APPEARANCE  
                               (problems with...) Never  Almost  
Never  Some - 
times  Often  Almost  
Always  
1.  Feeling that I am not good looking  0 1 2 3 4 
2.  Not wanting other people to see my neurofibromas  0 1 2 3 4 
3.  Being embarrassed about others seeing my body  0 1 2 3 4 
 
PAIN AND HURT (problems with...)  Never  Almost  
Never  Some - 
times  Often  Almost  
Always  
1.  Aching or hurting  0 1 2 3 4 
2.  Aching or hurting a lot  0 1 2 3 4 
3.  Not sleeping because of pain  0 1 2 3 4 
 
PARESTHESIAS (problems with...)  Never  Almost  
Never  Some - 
times  Often  Almost  
Always  
1.  A burning sensation in some part of my body  0 1 2 3 4 
2.  A tingling sensation in some part of my body  0 1 2 3 4 
 
SKIN IRRITATION (problems with...)  Never  Almost  
Never  Some - 
times  Often  Almost  
Always  
1.  Itching  0 1 2 3 4 
2.  Itching a lot  0 1 2 3 4 
3.  Getting a skin rash when exposed to sun  0 1 2 3 4 
4.  Tolerating temperature changes  0 1 2 3 4 
5.  Rough skin  0 1 2 3 4 
 
  
NF Protocol #105   Version 2.1 
05/01/2019  
112 
QOL INSTRUMENT (ADULT  REPORT) : > 21 years old  
  
Participant’s Study ID:     Course Number:    
Protocol:      Visit Date:     
 
 
SENSATION (problems with...)  Never  Almost  
Never  Some - 
times  Often  Almost  
Always  
1.  Vision in one or both eyes  0 1 2 3 4 
2.  Seeing  well enough with glasses or contact  lenses   0 1 2 3 4 
3.  Hearing in one or both ears  0 1 2 3 4 
4. Speech  0 1 2 3 4 
 
MOVEMENT AND BALANCE  (problems with...)  Never  Almost  
Never  Some - 
times  Often  Almost  
Always  
1.  Bending my body  0 1 2 3 4 
2.  Moving  one or both legs  0 1 2 3 4 
3.  Using or moving one or both arms  0 1 2 3 4 
4.  Keeping balance when sitting or standing  0 1 2 3 4 
 
DAILY ACTVITIES (problems with...)  Never  Almost  
Never  Some - 
times  Often  Almost  
Always  
1.  Putting on shoes  0 1 2 3 4 
2.  Buttoning my shirt  0 1 2 3 4 
3.  Combing my hair  0 1 2 3 4 
4.  Getting into the bathroom to use the toilet  0 1 2 3 4 
5.  Undressing to use the toilet  0 1 2 3 4 
6.  Getting in and out of bathtub or shower  0 1 2 3 4 
7.  Brushing my teeth  0 1 2 3 4 
8.  Eating with a fork and knife  0 1 2 3 4 
9.  Using a phone  0 1 2 3 4 
10. Shopping  0 1 2 3 4 
11. Managing money  0 1 2 3 4 
12. Driving  0 1 2 3 4 
 
FATIGUE  (problems with...)  Never  Almost  
Never  Some - 
times  Often  Almost  
Always  
1.  Feeling tired  0 1 2 3 4 
2.  Resting a lot  0 1 2 3 4 
3.  Having enough energy to do things that I like to do  0 1 2 3 4 
 
TREATMENT  ANXIETY (problems with...)  Never  Almost  
Never  Some - 
times  Often  Almost  
Always  
1.  Getting scared about going to the doctor  0 1 2 3 4 
NF Protocol #105   Version 2.1 
05/01/2019  
113 
QOL INSTRUMENT (ADULT  REPORT) : > 21 years old  
 2.  Getting scared about going to the hospital  0 1 2 3 4 
3.  Being responsible for my medicines or  therapy  0 1 2 3 4 
Participant’s Study ID:     Course Number:    
Protocol:      Visit Date:     
 
 
SEXUAL FUNCTIONING (problems 
with...) Never  Almost  
Never  Some - 
times  Often  Almost  
Always  Not 
Applicable  
1.  Fatigue or lack of energy affecting your 
satisfaction with your sex life  0 1 2 3 4         5 
2.  Pain affecting your satisfaction with your 
sex life  0 1 2 3 4 5 
3.  Ability to have children with a fertile 
partner  0 1 2 3 4 5 
 
 
Please write any comments that you have about how NF- 1 affects your health and well -being. Please write 
any comments about the survey and whether or not it captures how NF -1 affects people’s health and well -
being.  
 
  
NF Protocol #105   Version 2.1 
05/01/2019  
114 
 SUBJECTS 3 - 15 YEAR S: 
 
I. QOL and Pain Measures  for Subjects 3 – 15 years  
 
In participants with plexiform neurofibromas  (PN)  in all locations , this study will assess general health -
related qualify of life (QOL) and pain (pain intensity and pain interference) using patient- reported outcomes 
(PROs) as well as global impression of change as described below.  
 
Description of QOL and Pain Measures  
 
General Health -Related Quality of Life  
Pediatric Quality of Life Inventory (PedsQL; Varni, 2001):  The PedsQL 4.0 Generic Core Scales (Acute 
Form assessing the past 7 days) are multidimensional chi ld self-report  and parent proxy report  scales to 
assess heal th-related quality of life (QOL) in children, adol escents, and young adults ages 2  – 25 years.  It 
is a brief standardized pediatric QOL scale with good reliability and validity, which includes both generic 
and disease specific modules.  It consists of a 2 3-item core measure of global QOL that has four subscales:  
physical functioning, emotional functioning, social functioning, and school functioning.  The domain of physical functioning will be used as a specific secondary outcome measure for this study , especially the 
parent proxy for younger children as it assesses children under 6 years of age.  
There are different forms for parents of patient ’s ages 2 – 18 years (toddler: 2 – 4; young child: 5 – 7; child: 
8 – 12; adolescent:  13 – 18) and parallel self-r eport forms for patient’s ages 5 – 25 years (young child: 5 – 
7; child: 8 – 12; adolescent: 13 – 18; young adult:  18 – 25).  It takes approximately  5 - 10 minutes to 
complete.  For  this study, children from 8 to 15 years of age will complete self-report  measures of the 
PedsQL, and parents or  legal guardians of children from 3 to 15 years of age  will complete the parent proxy 
report  measures of the PedsQL.   
 
Pain Intensity  
The Numerical Rating Scale- 11 (NRS -11) is a self-report  segmented 11 -point numeric  scale that assesses 
pain severity (Hawker et al., 2011).  It consists of a horizontal line with 0 representing “no pain” at the right 
end of the line and 10 representing “worst pain you can imagine” at the left end.  Patients are asked to circle the one number from 0 to 10 that best describes  their worst pain over the past week for the following:  1) 
most important tumor pain chosen by the participant, 2 ) target tumor pain  and 2) other pain.  It takes less 
than 5 minute to complete.  The NRS- 11 is recommended as a core outcome self-report  measure of pain 
intensity for clinical trials (Dworkin et al., 2005) in children with NF1 (Wolters, et al., 2013).  Children, 
ages 8 to 15  years, will complete self -report measures of the NRS -11 for this study .   
 
Pain Interference  
The Pain Interference Index (PII) is a 6 -item measure that assesses the degree to which pain has interfered 
with daily activities in the past week. This measure was developed in Sweden and validated in Swedish 
with a group of children and adolescents with longstanding idiopathic pain (Wicksell, Melin, Lekander, & Olsson, 2009). The author (R. Wicksell) translated the measure into English, and members of the 
Neurobehavioral Group (S. Peron and P. Wolters) worked with the Swedish group to modify the wording 
to make it more readable and to shorten the time frame to one week, and we adapted it to create a parallel 
parent version. Dr. Wicksell and the Swedish research group are supportive of our efforts to validate the 
self-report and parent versions  of the PII in NF1. Results of our validation studies in children with NF1 and 
their parents indicate that the internal consistency and construct validity of the PII are good.  These data 
support the use of the PII to assess pain interference in youth with  NF1 and PNs  (Martin et al., submitted) .  
NF Protocol #105   Version 2.1 
05/01/2019  
115 
 For this study, children from 8 to 15 years of age will compl ete self-report  PII, and parents or  the legal 
guardian of children from 5 to 15 years of age  will complete the parent proxy report  PII.   
 
Global Impress ion of Change  
The p atient Global Impression of Change (GIC) Scale  evaluate s the clinical significance of changes in pain 
intensity or other PN morbidities. W e will administer an adapted version of the self-report  GIC Scale at the 
follow -up PRO evaluations  only (it should not be given pre -study because it assesses change from 
baseline) .  A parallel parent proxy report  form also was developed.  On the adapted GIC, patients (and their 
parents separately) will give their overall impression of change in level o f the child’s 1) tumor pain, 2) other  
pain, and 3) PN morbidity  from before initiation of the study drug  to the current evaluation point.  This 
global measure of change will be administered to children >8 years and for parents of children > 5 years of 
age at each PRO assessment.  The GIC Scale has been used in several research studies on chronic pain  in 
adults and more recently children (Arnold et al., 2011; Mohammad et al., 2014). It has been recommended 
by the Initiative on Methods, Measurement, and Pain A ssessment in Clinical Trials (IMMPACT) for 
clinical trials involving chronic pain  (Dworkin et al., 2005; McGrath et al., 2008) .  
 
Global Impression of Change (in PN morbidities)  
We also adapted the GIC for clinicians to rate change in PN morbidities for each participant from before 
the initiation of cabozantinib to the current evaluation point based on their history and physical examination.  
This global measure of change will be completed for participants of all ages by a clinician (familiar with the part icipant).   
 Pediatric Background Information  
The Pediatric QOL B ackground Form  should be completed by the parents/primary caregivers of all patients 
ages from 3 -15 years at each evaluation  to document information about demographics, use of pain 
medication, and NF1 disease severity.  These data will be used to better interpret the PRO data.   
 
Administration of QOL and Pain Measures  
• Participants will complete the PRO measures at baseline ( prior to starting treatment) and then after cycle 
4 +2 weeks, 8 +2 weeks, 12 +2 weeks, 18 +2 weeks, and 24 +2 weeks, except  for the Global Impression of 
Change scale that will only be administered at the follow -up evaluations because it assesses change fro m 
baseline.    
 
Self-report  
• Children, 8 to 15 years of age, will complete the self-report measures of the PedsQL, NRS-11, and PII at 
baseline and all follow-up evaluations.  The GIC scale will be done only at the follow-up evaluations after  
the other measures have been completed.   
 Parent Proxy  Report  
• Parents (or the legal guardian ) of children, 3 to 15 years of age,  will complete the parent p roxy measures 
of the PedsQL  and a background form.   
 
• Parents (or the legal guardian ) of children, 5 to 15  years of age,  also will complete the parent p roxy 
measures of the PII.  At the follow -up evaluations only, they will be administered the GIC scale, which is 
to be completed after  the other measures have been done.   
 
 
 
NF Protocol #105   Version 2.1 
05/01/2019  
116 
 Clinician Report  
• Clinicians  will complete the Global Impression of Change of the morbidities at the follow -up evaluations 
only for pediatric participants of all ages (3- 15 years).   
 
References:  
Arnold LM, Zlateva G, Sadosky A, Emir B, Whalen E. Correlations between fibromyalgia symptom and 
function domains and patient global impression of change: a pooled analysis of three randomized, placebo-
controlled trials of pregabalin. Pain Med. Feb 2011;12(2):260-267. 
Dworkin, RH, Turk, DC, Farrar, JT et al., (2005).  Core outcome measures for chronic pain clinical trials: IMMPACT recommendations.  Pain, 113, 9 – 19.   
Hawker, G.A., Mian, S., Kendzerska, T., & French, M.  (2011).  Measures of Adult Pain.  Arthritis Care & 
Research , 63 (S11), S240-S252. 
Martin, S., Nelson Schmitt, S., Wolters, P., Abel, B., Toledo- Tamula, M., Baldwin, A., Wicksell, R.K., 
Merchant, M., and Widemann, B.  Development and Validation of the English Pain Interference Index and Pain Interference Index – Parent Report.  Manuscript submitted. 
McGrath PJ, Walco GA, Turk DC, et al. Core outcome domains and measures for pediatric acute and chronic/recurrent pain clinical trials: PedIMMPACT recommendations. J Pain. Sep 2008;9(9):771-783. 
Mohammad S, Di Lorenzo C, Youssef NN, et al. Assessment of abdominal pain through global outcomes 
and recent FDA recommendations in children: are we ready for change? J Pediatr Gastroenterol Nutr. Jan 
2014;58(1):46-50. 
Varni JW, Seid M, Kurtin PS.  (2001).  PedsQL 4.0: Reliability and validity of the pediatric quality of life 
inventory version 4.0 generic core scales in healthy and patient populations. Med Care, 39, 800–812. 
Varni JW, Burwinkle TM, Seid M. (2005). The PedsQL as a pediatric patient -reported o utcome: Reliability 
and validity of the PedsQL measurement model in 25,000 children. Expert Rev Pharmacoecon Outcomes 
Res, 5:705–719. 
Wicksell RK, Melin L, Lekander M, Olsson GL. (2009).  Evaluating the effectiveness of exposure and 
acceptance strategies to improve functioning and quality of life in longstanding pediatric pain - A 
randomi zed controlled trial. Pain, 141:248-257. 
Wolters, P.L.,  Martin, S., Merker, V.L., Gardner, K.L., Hingtgen, C.M., Tonsgard, J.H., Schorry, E.K., 
Baldwin, A. for the REiNS International Collaboration. (2013).  Patient -reported outcomes in 
neurofibromatosis and schwannomatosis clinical trials.  Neurology, 81, (Suppl 1), S6-S14.  
 
   
 
NF Protocol #105   Version 2.1 
05/01/2019  
117 
 
  
NF Protocol #105   Version 2.1 
05/01/2019  
118 
 
  
NF Protocol #105   Version 2.1 
05/01/2019  
119 
 
 
  
NF Protocol #105   Version 2.1 
05/01/2019  
120 
 
 
 
NF Protocol #105   Version 2.1 
05/01/2019  
121 
 
 
 
NF Protocol #105   Version 2.1 
05/01/2019  
122 
 
 
 
NF Protocol #105   Version 2.1 
05/01/2019  
123 
 
 
NF Protocol #105   Version 2.1 
05/01/2019  
124 
 
 
NF Protocol #105   Version 2.1 
05/01/2019  
125 
 
 
 
NF Protocol #105   Version 2.1 
05/01/2019  
126 
  
  
NF Protocol #105   Version 2.1 
05/01/2019  
127 
 
  
NF Protocol #105   Version 2.1 
05/01/2019  
128 
 
  
NF Protocol #105   Version 2.1 
05/01/2019  
129 
 
  
NF Protocol #105   Version 2.1 
05/01/2019  
130 
 
  
NF Protocol #105   Version 2.1 
05/01/2019  
131 
  
  
NF Protocol #105   Version 2.1 
05/01/2019  
132 
 
  
NF Protocol #105   Version 2.1 
05/01/2019  
133 
 
  
NF Protocol #105   Version 2.1 
05/01/2019  
134 
 
  
NF Protocol #105   Version 2.1 
05/01/2019  
135 
 
  
NF Protocol #105   Version 2.1 
05/01/2019  
136 
 
  
NF Protocol #105   Version 2.1 
05/01/2019  
137 
 
  
NF Protocol #105   Version 2.1 
05/01/2019  
138 
 
 
  
NF Protocol #105   Version 2.1 
05/01/2019  
139 
 APPENDIX VIII: BLOOD PRESSURE  NORMS  
 
  
 
Blood press ure (BP)  levels for MALES  
 
 Systolic Blood Pressu re, mm Hg Diastolic Blood Pressu re, mm Hg 
Age BP Perce ntile of Height Perce ntile of Height 
(years)  Perce ntile 5th 10th 25th 50th 75th 90th 95th 5th 10th 25th 50th 75th 90th 95th 
16 95th 129 130 132 134 135 137 137 82 83 83 84 85 86 87 
≥17 95th 131 132 134 136 138 139 140 84 85 86 87 87 88 89 
 
 
Blood press ure (BP)  levels for FEMALES  
 
 Systolic Blood Pressu re, mm Hg Diastolic Blood Pressu re, mm Hg 
Age BP Perce ntile of Height Perce ntile of Height 
(years)  Perce ntile 5th 10th 25th 50th 75th 90th 95th 5th 10th 25th 50th 75th 90th 95th 
16 95th 125 126 127 128 130 131 132 82 82 83 84 85 85 86 
≥17 95th 125 126 127 129 130 131 132 82 83 83 84 85 85 86 
 
  
NF Protocol #105   Version 2.1 
05/01/2019  
140 
  
 
Blood pressure  (BP)  levels for BOYS  
 
 Systolic  Blood  Pressure,  mm Hg Diastolic  Blood  Pressure,  mm Hg 
Age BP Percentile  of Height  Percentile  of Height  
(years)  Percentile  5th 10th 25th 50th 75th 90th 95th 5th 10th 25th 50th 75th 90th 95th 
1 95th 98 99 101 103 104 106 106 54 54 55 56 57 58 58 
2 95th 101 102 104 106 108 109 110 59 59 60 61 62 63 63 
3 95th 104 105 107 109 110 112 113 63 63 64 65 66 67 67 
4 95th 106 107 109 111 112 114 115 66 67 68 69 70 71 71 
5 95th 108 109 110 112 114 115 116 69 70 71 72 73 74 74 
6 95th 109 110 112 114 115 117 117 72 72 73 74 75 76 76 
7 95th 110 111 113 115 117 118 119 74 74 75 76 77 78 78 
8 95th 111 112 114 116 118 119 120 75 76 77 78 79 79 80 
9 95th 113 114 116 118 119 121 121 76 77 78 79 80 81 81 
10 95th 115 116 117 119 121 122 123 77 78 79 80 81 81 82 
11 95th 117 118 119 121 123 124 125 78 78 79 80 81 82 82 
12 95th 119 120 122 123 125 127 127 78 79 80 81 82 82 83 
13 95th 121 122 124 126 128 129 130 79 79 80 81 82 83 83 
14 95th 124 125 127 128 130 132 132 80 80 81 82 83 84 84 
15 95th 126 127 129 131 133 134 135 81 81 82 83 84 85 85 
16 95th 129 130 132 134 135 137 137 82 83 83 84 85 86 87 
≥17 95th 131 132 134 136 138 139 140 84 85 86 87 87 88 89 
Instructions  for using this BP Chart:  
1. Measure the patient’s  blood  pressure using  an appropriate size cuff.  
2. Select  appropriate chart  for a female or male patient.  
3. Using the “age” row and “height” column  determine if the BP is within the  ULN.  
  
This table was taken from “The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents” 
PEDIATRICS Vol. 114 No. 2 August 2004, pp. 555 -576. 
 
    
NF Protocol #105   Version 2.1 
05/01/2019  
141 
 Blood pressure  (BP) levels for GIRLS  
 
 Systolic  Blood  Pressure,  mm Hg Diastolic  Blood  Pressure,  mm Hg 
   
Age BP Percentile  of Height  Percentile  of Height  
(years)  Percentile  5th 10th 25th 50th 75th 90th 95th 5th 10t
 25th 50th 75th 90th 95th 
1 95th 100 101 102 104 105 106 107 56 57 57 58 59 59 60 
2 95th 102 103 104 105 107 108 109 61 62 62 63 64 65 65 
3 95th 104 104 105 107 108 109 110 65 66 66 67 68 68 69 
4 95th 105 106 107 108 110 111 112 68 68 69 70 71 71 72 
5 95th 107 107 108 110 111 112 113 70 71 71 72 73 73 74 
6 95th 108 109 110 111 113 114 115 72 72 73 74 74 75 76 
7 95th 110 111 112 113 115 116 116 73 74 74 75 76 76 77 
8 95th 112 112 114 115 116 118 118 75 75 75 76 77 78 78 
9 95th 114 114 115 117 118 119 120 76 76 76 77 78 79 79 
10 95th 116 116 117 119 120 121 122 77 77 77 78 79 80 80 
11 95th 118 118 119 121 122 123 124 78 78 78 79 80 81 81 
12 95th 119 120 121 123 124 125 126 79 79 79 80 81 82 82 
13 95th 121 122 123 124 126 127 128 80 80 80 81 82 83 83 
14 95th 123 123 125 126 127 129 129 81 81 81 82 83 84 84 
15 95th 124 125 126 127 129 130 131 82 82 82 83 84 85 85 
16 95th 125 126 127 128 130 131 132 82 82 83 84 85 85 86 
≥17 95th 125 126 127 129 130 131 132 82 83 83 84 85 85 86 
Instructions  for using this BP Chart:  
1. Measure the patient’s  blood  pressure using  an appropriate size cuff.  
2. Select  appropriate chart  for a female or male patient.  
3. Using the “age” row and “height” column  determine if the BP is within the  ULN.  
 
This table  was taken  from  “The  Fourth  Report  on the Diagnosis,  Evaluation,  and Treatment  of High  Blood 
Pressure  in Children and Adolescents”  PEDIATRICS Vol. 114 No. 2 August  2004,  pp. 555-576.  
 
            
NF Protocol #105   Version 2.1 
05/01/2019  
142 
 APPENDIX IX: MRI ELIGIBILITY FORM   
 
This form must accompany all MRI studies sent to the NCI POB for review of target plexiform 
neurofibroma eligibility (i.e. whether it is measurable and amenable to volumetric analysis).  Please mail the MRI on a CD along with this form to: 
 
 Eva Dombi, MD  NCI,  POB  
 10 Center Drive  
Building 10 CRC, Room 1-5750 
 Bethesda, MD 20892  
 Phone: 301-451-7023 
 E- mail: dombie@mail.nih.gov
  
  
 PID#1 : ________   Date of MRI:  ___________ 
 
 
 
Location of target plexiform:  _______________________________________________ 
 
 
 
From:  
Name of Investigator:  _______________________________________________ 
 
Study Center:   _______________________________________________ 
 Phone #:  _______________________________________________ 
 
Email Address:   _______________________________________________ 
   
 
 
 
_____________________________________________________________________________________ From Eva Dombi, MD:  
 
The target PN is measurable and amenable to volumetric analysis:   
 Yes:_____________ No: ____________ 
 
Comments: _______________________________________________
  
NF Protocol #105   Version 2.1 
05/01/2019  
143 
 APPENDIX X : SUGGESTED PROPHYLAXIS AND TREATMENT FOR PALMAR -
PLANTAR ERYTHODYSESTHESIA SYNDROME (PPE)  
 
These guidelines were developed by the company  (Exelixis ) based on their experience treating over 1000 
patients. These guidelines are helpful in prevention and treatment.  
 
Prophylaxis:  
Ammonium lactate 12% cream BID to palms of hands and soles of feet. 
 
Treatment: (to begin as soon as mild symptoms begin)  
1. Urea 20% cream twice daily and  
2. Clobetasol 0.05% cream once to twice daily  
 
  
 Management of Treatment -Emergent Hand -Foot Syndrome (PPES)  
CTCAE v.4.0 Grade  Action To Be Taken  
Grade 1  Study treatment may be continued at the current dose if PPES is clinically 
insignificant and tolerable. Otherwise, study treatment should be reduced to the 
next lower dose level.a Start urea 20% cream twice daily AND clobetasol  0.05% 
cream once daily. Reassess at least weekly; if PPES worsens at any time or does 
not improve after 2 weeks, proceed to the intervention guidelines for Grade  2. 
Grade 2  Study treatment may be continued if PPES is tolerated. Study treatment should be  
dose reduced or interrupted if PPES is intolerable. Continue urea 20% cream 
twice daily AND clobetasol 0.05% cream once daily and add analgesics 
(eg, NSAIDs/gamma -aminobutyric acid agonists) for pain control if needed. 
Reassess at least weekly; if PPES worsens or affects self -care, proceed to the 
intervention guidelines for Grade  3. 
Grade 3  Interrupt study treatment until severity decreases to Grade 1 or 0. Continue treatment of skin reaction with clobetasol 0.05% cream twice daily AND analgesics. Resume study drug at a reduced dose if PPES recovers to Grade ≤  1. 
Discontinue subject from study treatment if PPES does not improve within 
6 weeks.  
CTCAE, Common Terminology Criteria for Adverse Events; NSAID,  non-steroidal anti -inflammatory drug; PPES,  palmar 
plantar erythrodysesthesia syndrome.  
a Permitted dose levels are defined by individual protocols.  
NF Protocol #105   Version 2.1 
05/01/2019  
144 
 APPENDIX XI: CABOZANTINIB DOSING NOMOGRA M 
 
 
23 mg/m2,  
Level -1 30 mg/m2,  
Level 1  40 mg/m2,  
Level 2  Dose/Schedule  Weekly Dose  
0.34 – 0.43   20 mg M, W, F  60 mg  
0.44 – 0.55 0.35 – 0.42  20 mg M, W, F, Sun  80 mg  
0.56 – 0.68 0.43 – 0.52 0.33 – 0.39 20 mg M, W, H, Sat, Sun  100 mg  
0.69 – 0.79 0.53 – 0.60 0.40 – 0.45 20 mg M, T, W, F, Sat, Sun  120 mg  
0.80 - 0.96  0.61 – 0.73 0.46 – 0.55 20 mg Daily  140 mg  
0.97 – 1.11 0.74 – 0.85 0.56 – 0.64 40 mg M, W, F, Sun  160 mg  
1.12 – 1.36 0.86 – 1.04 0.65 – 0.78 40 mg M, W, H, Sat, Sun  200 mg  
≥ 1.37  1.05 – 1.21 0.79 – 0.90 40 mg M, T, W, F, Sat, Sun  240 mg  
 ≥ 1.20  0.91 – 1.09 40 mg Daily  280 mg  
  1.10 – 1.17 60 mg M, W, H, Sat, Sun  300 mg  
  1.18 – 1.36 60 mg M, T, W, F, Sat, Sun  360 mg  
  ≥ 1.37  60 mg Daily  420 mg  
  
 
  
NF Protocol #105   Version 2.1 
05/01/2019  
145 
 Yes dose 
limiting 
toxicity23mg/m230 mg/m2
Cycle 1-2
Off studyYes dose 
limiting 
toxicity
No dose 
limiting 
toxicityNo dose 
limiting 
toxicity
40 mg/m2
Cycle 3 +No dose 
change
No Dose 
limiting 
toxicityYes dose 
limiting 
toxicity
30 mg/m2 No dose 
change
No Dose 
limiting 
toxicityNo dose 
changeDosing Flow Chart Cohort B (3 – 15 years)
NF Protocol #105   Version 2.1 
05/01/2019  
146 
 APPENDIX XII: PLEXIFORM NEUROFIBROMA SYM PTOM CHECKLIST  
To be completed by Patient if able, otherwise completed by the Parent/Guardian. To be completed by the 
same individual at each timepoint.  
 Testing should be performed pre- treatment, and then post cycles 4, 8, 12, 18, 24. 
 
Select one:  
Pre-treatment  ☐  Post  cycle 4  ☐  Post cycle 8  ☐   Post cycle 12  ☐  
 
Post cycle 18  ☐       Post cycle 24  ☐  Other (Please specify): _________________________  
 
For each item below, please check one box (unless otherwise indicated) to describe how much each of these 
has been a problem for you in the past two weeks: 
 
1) Fatigue/feeling tired  
   Not at all   A little  Some  Pretty much           A lot  
   
2) Sleep problems  
   Not at all   A little  Some  Pretty much           A lot  
3) Less appetite  
    (eating less)  
  Not at all   A little  Some  Pretty much           A lot  
4) More appetite  
    (eating more)    Not at all   A little  Some  Pretty much           A lot  
 
5) Headaches  
   Not at all   A little  Some  Pretty much           A lot  
   
6) Vision changes  
   Not at all   A little  Some  Pretty much           A lot  
7) Decreased hearing  
   Not at all   A little  Some  Pretty much           A lot  
8) Mouth Sores  
  Not at all   A little  Some  Pretty much           A lot  
9) Trouble swallowing  
      Not at all   A little  Some  Pretty much           A lot  
10) Choking  
   Not at all   A little  Some  Pretty much           A lot 
11) Snoring  
  Not at all   A little  Some  Pretty much           A lot  
12)Frequent awakenings 
at night   Not at all   A little  Some  Pretty much           A lot 
 
 
 
13) Cough  
   Not at all   A little  Some  Pretty much           A lot  
NF Protocol #105   Version 2.1 
05/01/2019  
147 
    
14) Wheezing  
   Not at all   A little  Some  Pretty much           A lot  
15) Difficulty breathing    Not at all   A little  Some  Pretty much           A lot  
 
16) Chest pain  
   Not at all   A little  Some  Pretty much           A lot  
   
17) Palpitations/fluttering  
   Not at all   A little  Some  Pretty much           A lot  
18) Shortness of breath    
with activity  
   Not at all   A little  Some  Pretty much           A lot  
19) Shortness of breath at 
rest 
  Not at all   A little  Some  Pretty much           A lot  
20) Swelling in hands/feet      Not at all   A little  Some  Pretty much           A lot  
 
21) Abdominal pain  
   Not at all   A little  Some  Pretty much           A lot  
   
22) Heartburn  
   Not at all   A little  Some  Pretty much           A lot  
23) Nausea  
   Not at all   A little  Some  Pretty much           A lot  
24) Vomiting  
  Not at all   A little  Some  Pretty much           A lot  
25) Diarrhea  
      Not at all   A little  Some  Pretty much           A lot  
26) Constipation  
   Not at all   A little  Some  Pretty much           A lot 
27) Stool incontinence   Not at all   A little  Some  Pretty much           A lot  
 
28) Pain with urination  
   Not at all   A little  Some  Pretty much           A lot  
   
29) Increased urinary 
frequency/urgency  
   Not at all   A little  Some  Pretty much           A lot  
30)Difficulty beginning    
urination 
   Not at all   A little  Some  Pretty much           A lot  
31)Urinary incontinence   Not at all   A little  Some  Pretty much           A lot  
 
32) Weakness  
  Not at all   A little  Some  Pretty much           A lot  
NF Protocol #105   Version 2.1 
05/01/2019  
148 
 If yes, where?   
   
33) Muscle pain  
 
If yes, where?   Not at all   A little  Some  Pretty much           A lot  
 
34) Dizziness  
   Not at all   A little  Some  Pretty much           A lot  
   
35) Numbness  
  Not at all   A little  Some  Pretty much           A lot  
36) Tingling      Not at all   A little  Some  Pretty much           A lot  
 
 
 
COMPL ETED BY:       DATE  
 
 
NF Protocol #105   Version 2.1 
05/01/2019  
149 
 APPENDIX XIII: PN LOCATION AND ASSOCIATED MORBIDITIES  
INSTRUCTIONS :  
 To be completed by the Site PI prior to starting treatment 
- Assess PN location (s) by clinical exam and imaging studies  (target PN and up to 2 non target PN ; fill out a separate form for each PN )  
- List morbidities present using numbers below (see list)  
- If no morbidity present, list potential morbidities based on PN site (s) 
 
PN Location   PN Associated Morbidities  
 R L B/L Pain 
(Y/N)  Present PN Morbidities  (using numbers listed below)/ 
Comments  Potential Morbidities  
Orbit        
Face        
Ear canal        
Tongue        
       
Anterior neck/upper airway        
Posterior neck  
(cervical paraspinal)        
       
Mediastinum        
Intra -thoracic        
Thoracic/paraspinal/chest wall        
       
Liver        
Abdominal        
Mesentery        
Posterior abdomen/pelvis  
(Lumbo -sacral plexus)        
Perineum/peri -rectal/bladder        
       
NF Protocol #105   Version 2.1 
05/01/2019  
150 
 Upper arm  
(Brachial plexus)        
Forearm        
Hand        
       
Thigh/upper leg        
Lower leg        
Foot       
       
Other (please specify):        
 
 
Morbidities :  
1- Vision loss  
2- Facial motor dysfunction 
3- Auditory loss 4- Difficulty swallowing  
5- Abnormal speech 
6- Airway obstruction 
7- Respiratory compromise 8- Bladder dysfunction  
9- Bowel dysfunction 
10- Motor weakness  
11- Decreased range of motion  12- Sensory deficit   
13- PN related Disfigurement/ appearance  
 
14- Other (please describe) : 
 
 
 
***Instruction to site PI:  Please place asterisk  next to target lesion morbidity.   
 
    
NF Protocol #105   Version 2.1 
05/01/2019  
151 
  
APPENDIX  XIV:  PLEXIFORM NEUROFIBROMA CLINICIAN MORBIDI TY ASSESSMENT  
 
Instructions 
• To be completed by the treating physician.  
• At baseline, please identify morbidities.   
• Please fill out a separate form for each PN identified in Appendix X III) 
• At follow -up, for each morbidity identified at baseline, please document whether the noted morbidity is: 
o worse  
o stable  
o improved but still present 
o resolved  
• Please include comments (ex. previously was using 2 pain medications and now using one; previously on Bipap setting of 8, 
now on Bipap setting of 4).  If available, please provide any objective applicable testing results related to morbidities (in the 
comments box). 
 Please document the Baseline Morbidi ties. 
 
Baseline Morbidity 1:  Baseline Morbidity 2:  Baseline Morbidity 3:  Baseline Morbidity 4:   
 
  
COMPLETED BY:  ___________________________________ DATE:  __________________________
NF Protocol #105   Version 2.1 
05/01/2019  
152 
 Follow- up assessments should be performed post cycles 4, 8, 12, 18, 24.  
 
Select one:  
Post  cycle 4  ☐  Post cycle 8  ☐   Post cycle 12  ☐  
 
Post cycle 18  ☐       Post cycle 24  ☐  Other (Please specify): _________________________  
 
Evaluation Date :     
 
For each baseline morbidity, please document whether the morbidity is:  1) worse; 2) stable; 3) improved but still present; or 4) resolved  
 Select One  Comments  
Baseline Morbidity #1 - Worse  
- Stable  
- Improved but still present - Resolved   
Baseline Morbidity #2 - Worse  
- Stable  
- Improved but still present - Resolved   
Baseline Morbidity #3 - Worse  
- Stable  
- Improved but still present - Resolved   
Baseline Morbidity #4 - Worse  
- Stable  
- Improved but still present - Resolved   
 
COMPLETED BY:  ___________________________________ DATE:  __________________________ 
NF Protocol #105   Version 2.1 
05/01/2019  
153 
 APPENDIX XV:  BIOLOGICAL SPECIMEN FOR BANKING  – COLLECTION AND 
SHIPPING  
 
1) Blood  
Prior to the day of blood draw, the site will have arranged for a sample collection kit supplied by the 
biorepository to be shipped to the site.  The Center for Data Driven Discovery in Biomedicine (D3b) at CHOP will be providing kits and labels. The kit will contain tubes and bar -coded labels (which include a 
specimen number) for blood co llection.  It will also contain shipping materials and instructions for sending 
collected blood samples to the biorepository, as well as a pre-paid shipping label. 
 
Samples 
• Streck tube (for plasma):  ~ 2 mL.   
• EDTA tube (for DNA):  ~ 5 mL.   
• PAXGene tube (for RNA) ~ 2.5 mL.  
Tubes should be inverted at least 10 times after being drawn.  
 
The samples will only be obtained if the total blood volume does not exceed 5 mL/kg.  If not enough blood 
can be drawn for all tubes, the priority order for obtaining the specimens is: 1) Streck tube, 2) EDTA tube, 3) PAXGene tube.  
 Label the specimens with the specimen labels provided with the specimen kit.  
 Blood samples must be shipped (unprocessed) same day at ambient temperature to the biorepository by 
overnight delivery using shipping container provided by the biorepository.  Samples must be shipped 
Monday through Thursday. 
 
Enter the specimen numbers into the NF Consortium Operations Center eDES. 
 
For questions about shipping, kits, tubes, etc., and to confirm the shipping address prior to sending samples, 
please contact:  Elizabeth Appert (apperte@email.chop.edu) and BioRc (biorc@email.chop.edu).  
2) Tumor Tissue  
Prior to the day of surgery, the site will have arranged for a tissue sample collection kit supplied by the  
biorepository to be shipped to the site.  The Center for Data Driven Discovery in Biomedicine (D3b) at 
CHOP will be providing kits and labels. The kit will contain bar -coded cryovials (which include a specimen 
number) for tissue collection.  It will also contain shipping materials and instructions for sending collected 
tissue samples to the biorepository, as well as a pre-paid shipping label.  
Samples 
• Fresh frozen tissue:  1 -2 pea sized aliquots (~ 0.3 cm
3, equivalent to 0.8 cm in diameter) of excess 
(left over) tumor tissue.  Place each aliquot in a separate cryovial and label the specimen with 
subject’s study number. Snap freeze the aliquots in liquid nitrogen (preferred) or dry ice and then store in a freezer at -80°C or below until they can be sent to t he biorepository.  
• 1 H&E stained slide cut from each submitted piece to confirm tumor is present.  
• If fresh frozen tissue is unavailable, please submit processed DNA (at least 3 micrograms) and 
RNA (at least 400 nanograms with optimal RIN > 7) if available.  
 Label the specimen manifest with the subject’s study number.  
Fresh frozen tissue or DNA/RNA must be shipped on dry ice via overnight delivery using shipping 
NF Protocol #105   Version 2.1 
05/01/2019  
154 
 materials provided by the biorepository. The H&E slide should be shipped at ambient temperature.  Samples 
must be shipped Monday through Thursday. 
 
Enter the specimen numbers into the NF Consort ium Operations Center eDES.  
 For questions about shipping, kits, tubes, etc., and to confirm the shipping address prior to sending samples, please contact:  Elizabeth Appert (apperte@email.chop.edu) and BioRc 
(biorc@email.chop.edu). 